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resumo 
 
 
A presente dissertação teve como foco principal o desenvolvimento de 
estruturas 3D porosas (scaffolds) para regeneração óssea por robocasting. 
Esta técnica de fabrico aditivo permite a produção de scaffolds com morfologia 
e estrutura predefinidas e sem a necessidade de maquinagem subsequente, 
podendo ser usada para o fabrico de implantes personalizados com estrutura 
interna semelhante à do osso que se pretende substituir.  
Como materiais de partida, foram utilizados pós de fosfatos de cálcio bifásicos 
(hidroxiapatite + β-fosfato tricálcico) não dopados, e dopados com diferentes 
iões (Sr, Ag, Cu, Mg e Zn), obtidos por precipitação em meio aquoso. A 
substituição parcial de iões Ca pelos iões dopantes induziu alterações na 
composição de fases cristalinas e resultou em partículas com características 
morfológicas distintas e em materiais com desempenhos biológicos diferentes. 
Os pós foram dispersos em meio aquoso com a ajuda de aditivos de 
processamento adequados (um dispersante e um ligante) de modo a obter 
suspensões com elevada concentração de sólidos, requisito essencial para o 
fabrico de componentes por robocasting. O tamanho e a morfologia das 
partículas e a concentração dos aditivos de processamento desempenharam 
os papéis cruciais no comportamento reológico das suspensões. A adição de 
agente floculante modificou drasticamente as propriedades reológicas do 
sistema e permitiu a obtenção de pastas com comportamento viscoelástico 
adequado para o processo de extrusão. Os scaffolds com diferentes tamanhos 
de poro foram produzidos pela deposição de um filamento com 410 μm de 
diâmetro. A resistência à compressão dos scaffolds sinterizados a 1100°C foi 
comparável ou mesmo superior à do osso esponjoso.  
Scaffolds com diferentes tamanhos de poro (120-500 μm) foram testados 
in vitro usando células estaminais mesenquimais humanas (hMSCs). 
Pretendeu-se avaliar a influência do tamanho dos poros na adesão celular 
inicial, na atividade metabólica e no potencial osteogénico. Os resultados 
obtidos mostraram que os poros com maior dimensão proporcionam condições 
favoráveis para a diferenciação osteogénica das hMSCs. Além disso, os 
fosfatos de cálcio co-dopados com Sr e Zn melhoraram o desempenho 
biológico, incluindo adesão, atividade metabólica e proliferação das hMSC. 
A última parte da tese foi dedicada à preparação de scaffolds não sinterizados 
incorporando um fármaco (levofloxacina) de forma a obter componentes com 
capacidade de regeneração óssea e de tratamento local de infeções. A pasta 
utilizada foi obtida através da dispersão dos pós de CaP numa solução de 
quitosano na presença do fármaco e de um agente de reticulação (genipin).  
Os scaffolds 3D à base de fosfatos de cálcio produzidos por robocasting no 
âmbito desta tese revelaram-se muito promissores para aplicações na 
engenharia de tecidos, particularmente regeneração de tecido ósseo e 
administração de fármacos. 
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abstract 
 
The main focus of this thesis was the development of novel 3D porous 
scaffolds for bone regeneration by robocasting. This additive manufacturing 
technique allows the production of scaffolds with predefined morphology and 
structure without the need for subsequent machining and can be used for the 
manufacture of customized implants with an internal structure similar to that of 
the bone to be replaced. 
Biphasic calcium phosphates (hydroxyapatite + β-tricalcium phosphate), 
undoped and doped (with Sr, Ag, Cu, Mg and Zn), obtained through aqueous 
precipitation process were used as starting powders. The partial substitution of 
Ca ions by doping ions induced changes in the crystalline phase assemblages 
and resulted in particles with distinct morphological characteristics and in 
materials with different biological outcomes. 
The powders were dispersed in aqueous medium with the aid of suitable 
processing additives (a dispersant and a binder) in order to obtain suspensions 
with high solids loading, an essential requirement for the manufacture of 
components by robocasting. The size and morphology of the particles and the 
concentration of the processing additives played crucial roles in the rheological 
behaviour of the suspensions. The addition of a flocculating agent drastically 
modified the rheological properties of the systems and allowed obtaining pastes 
with viscoelastic behaviour suitable for the extrusion process. The scaffolds 
with different pore sizes were produced by the controlled deposition of filaments 
with 410 μm in diameter. The compressive strength of scaffolds sintered at 
1100 ° C was comparable or even superior to that that of spongy bone.  
Scaffolds with different pore sizes (120-500 μm) were tested in vitro using 
human mesenchymal stem cells (hMSCs). The aim was to evaluate the 
influence of pore size on initial cell adhesion, metabolic activity and osteogenic 
potential. The results showed that larger pores provide favourable conditions 
for osteogenic differentiation of hMSCs. In addition, calcium phosphates co-
doped with Sr and Zn improved the biological performance, including adhesion, 
metabolic activity and proliferation of hMSC. 
The last part of the thesis was devoted to the preparation of sintering-free 
scaffolds incorporating a drug (levofloxacin) in order to obtain components with 
capacity for bone regeneration and local treatment of infections. The paste 
used was obtained by dispersing the CaP powders in a solution of chitosan in 
the presence of the drug and a crosslinking agent (genipin). 
The 3D scaffolds produced by robocasting in the frame of this thesis program 
revealed to be very promising for tissue engineering applications, particularly 
bone tissue regeneration and drug delivery. 
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AIM AND STRUCTURE OF THE THESIS 
With the increase of the average life expectancy, tissue engineering became an area of 
great interest. Every year, there are millions of people who need some kind of 
prostheses, and the need for all kind of implants became very well known in our 
society. In recent years, particular attention was paid to the synthesis of bioceramics 
with porous morphology since most strategies to regenerate bone depend on 3D 
porous structures (scaffolds) to support cell attachment, proliferation, and 
differentiation. Diverse conventional techniques, such as the polymeric sponge 
method, starch consolidation, the use of porogens and foaming agents, have been used 
to build porous ceramic scaffolds. However, a precise control of pore size, geometry 
and spatial distribution is essential to satisfy the greatest challenges in this area. Such 
a target can be properly achieved by using additive manufacturing (AM) techniques 
that enable producing customized scaffolds with predefined shape and internal 
architecture according to a computer design, without the need for subsequent 
machining. Robocasting, as one of these techniques, combines the extrusion of a 
continuous filament with a computer-guided positioning system in a layer by layer 
fashion to build 3D structures.  
The main target of this PhD thesis was developing novel 3D porous scaffolds similar 
to the human cancelous bone for bone regeneration by robocasting technique. 
Porosity was tailor-made in order to evaluate the influence of porous structure in the 
formation of bone tissue in a cellular environment, enabling the prediction of 
scaffolds behaviour after implantation. Thereby, all the relevant properties (chemical, 
structural, mechanical and biological) were considered and balanced in order to get 
the best compromise for the proposed aim.   
For this purpose, firstly calcium phosphate powders with co-substituted elements 
were developed in order to find a material holding anti-microbial or/and osteoblastic 
stimulation properties. These properties could enable them acting in specific 
situations, as excellent alternatives to traditional un-doped calcium phosphate 
powders. Lastly, a hybrid system that allows the release of an antibiotic for bone 
regeneration by diffusion was also developed.  
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Accordingly, the first chapter of this thesis consists in a brief overview of bone tissue 
and calcium phosphate as bone regeneration materials, and a description of the state 
of the art, specifically results compilation presented in literature related to the 
scaffolds production and their performance in tissue engineering. 
Chapter 2 and Chapter 3 present studies related to synthesis and characterization of 
calcium phosphate powders, undoped and co-substituted with ions that have important 
roles in biological processes. The first study, Chapter 2, introduces the results of ionic 
substitution in the HA lattice, which are crucial for understanding the importance of 
dopant ions in obtaining biphasic calcium phosphate powders. Subsequently, Chapter 
3 presents the assessment of substitution elements that could confer anti-microbial 
properties and/or osteoblast proliferation in the biphasic calcium phosphate powders. 
Rietveld refinement was used to determine composition and structural parameters of 
the phases formed. Evaluation of the anti-microbial and/or osteoblast proliferation 
properties of the synthesized powders was also studied.  
Chapter 4 describes 3D porous scaffolds fabrication using robocasting as direct write 
assembly technique. The powders were thoroughly characterized and their in vitro 
biocompatibility and antibacterial activities were evaluated. Colloidal inks with high 
solids loading and appropriate rheological properties were prepared, enabling the 
successful production of 3-D structures with improved mechanical properties, suitable 
for bone tissue engineering. 
In Chapter 5, the effect of varying internal architectural scaffold designs on the 
mechanical and biological performance was investigated, in an attempt to devise an 
“ideal scaffold”, with ability for inducing bone formation. In vitro osteogenic 
potential of human mesenchymal stem cells (hMSCs) in the scaffolds was studied and 
the best compromise between scaffolds macroporosity and in vitro performance was 
evaluated by different cell parameters, such as morphology, viability, adhesion and 
proliferation 
The preparation and characterization of the macroporous hybrid scaffold 
(chitosan/biphasic calcium phosphate) is described in Chapter 6.  In an attempt to 
produce a scaffold with a practical application, the ability of porous scaffolds to be 
used as controlled drug delivery systems for osteomyelitis treatment was studied. 
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In Chapter 7 are presented the general conclusions that could be drawn from the 
discussions of all the results presented throughout the thesis, and future work 
perspectives. 
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BONE – OVERVIEW  
Bone is a highly specialized form of connective tissue whose primary functions are to 
provide a mechanical support system for muscular activity, provide for the physical 
protection of organs and soft tissues, and act as a storage facility for systemic mineral 
homeostasis [1]. It is a complex living tissue in which the extracellular matrix is 
mineralized, conferring marked rigidity and strength to the skeleton while still 
maintaining some degree of elasticity. In addition to its supportive and protective 
functions, bone is a major source of inorganic ions, actively participating in calcium 
homeostasis in the body. There is increasing evidence that the central control of 
development and renewal of the skeleton is more sophisticated than previously 
appreciated [2]. Bone extracellular matrix is composed of approximately 70% 
inorganic phase, in the form of crystals of a calcium phosphate (hydroxyapatite 
[Ca10(PO4)6(OH)2)], for structural reinforcement and stiffness, 25% organic phase 
(~90% type I collagen, ~5% noncollagenous proteins (NCPs), ~2% lipids by weight), 
that provides flexibility and toughness, and 5% of water [3,4]. 
The structural-functional unit of the bone is an osteon, a microscopic system of 
osseous tubes inserted in one another (Fig. 1). In the centre of the system, there is a 
nutrient canal 10 to 100 µm in diameter, containing a blood capillary. The number of 
osseous tubes constituting an osteon may vary from 4 to 20. Bone is covered with a 
thin layer of connective tissue (periosteum), containing vessels and nerves. The inner 
layer of periosteum contains a large amount of osteoblasts [5,6].  
Morphologically, the bone of the mature skeleton consists of cortical (or compact) 
bone (80%) and cancellous (or trabecular) bone (20%) (Fig.1). In cortical bone, 
densely packed collagen fibrils form concentric lamellae, and the fibrils in adjacent 
lamellae run in perpendicular planes as in plywood. Cancellous bone has a loosely 
organized, porous matrix. Differences between cortical and cancellous bone are both 
structural and functional, related to their primary functions cortical bone provides 
mechanical and protective functions and cancellous bone provides metabolic 
functions [1]. 
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Fig. 1. Structure organization of bone: cortical (compact) bone and cancellous (or trabecular) 
bone [Adapted from 7].  
 
The mechanical strength of the two architectures varies depending on the type of bone 
and its porosity [8]. The apparent density of cancellous bone varies from 0.1 to 1 
gcm−3 according to the porosity that changes from 50%−90% resulting in its modulus 
and ultimate compressive strength being around 20 times less than that of cortical 
bone [9,10]. Table 1 shows the summary differences between the two types of bone.  
 
Table 1- Differences between cortical bone and cancellous bone [1,11]. 
Properties Cortical Bone Cancellous Bone 
Bone mass (%) 80 20 
Main functions Mechanical support and physical 
protection 
Mineral homeostasis 
Porosity (%) 5−10 75−90 
Elastic modulus (GPa) 17 0.1−2 
Stiffness modulus (GPa) 8.7−14.1 0.02−0.5 
Compressive strength (MPa) 131−224 2−12 
Flexural strength (MPa) 135−195 − 
Tensile strength (MPa) 50−151 1−5 
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Bone is a highly dynamic organ composed by four types of cells: osteoblasts, 
osteoclasts, bone lining cells presented on bone surfaces and bone lining permeating 
the mineralized interior (osteocytes) [1]. 
Osteoblasts are cuboidal differentiated cells found on the surface of new bone 
responsible for the production of the extracellular matrix (ECM) of bone, and its 
subsequent mineralization process [12,13]. Osteoblasts produce the organic matrix of 
bone, called osteoid. Some of the osteoblasts become trapped in the lacunae within 
the matrix of bone and differentiate into osteocytes [14]. Old osteoblasts become 
inactive, thin and elongated lining cells which lies on the bone surface [15]. The 
repair process and formation of new bone requires the differentiation and the 
proliferation of osteoblasts. Genes must be activated in the osteoblasts in order to 
signal cell division and ECM production that is capable of mineralizing to become 
bone [16]. 
The osteocyte is a mature osteoblast inside the bone matrix and is responsible for its 
maintenance, through the growth of new arms on the cell and the packing of 
osteoblasts and osteoclasts [14,15]. They become responsible for communication 
between other analogous cells and bone lining cells by developing long branches, 
forming a wide network of intercellular communication. Osteocytes are mature bone 
cells, uniform in shape and size, smaller than osteoblasts and greater in number; they 
form more than 90% of bone cells in the skeleton of an adult human.  
Bone lining cells are flat, elongated, inactive cells that cover bone surfaces that are 
undergoing neither bone formation nor resorption. Little is known regarding the 
function of these cells; however, it has been speculated that bone lining cells can be 
precursors for osteoblasts [1].  
Osteoclasts originate from hematopoietic stem cells, they are large multinucleated 
cells, responsible for resorbing the mineralized bone matrix and they move from 
different locations on the bone surface dissolving the bone [17]. Osteoclasts contain a 
stockpile of lysosomal enzymes, which are secreted and are able to resorb 
200,000 µm3/day during 15−20 days of lifetime [14]. 
Bone remodelling is a dynamic process of bone formation and bone destruction, 
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accounts for its growth during the development stages of the body, preserving its 
shape and consistency, and enabling its regeneration in case of fracture, however, for 
larger defects, human intervention is required to aid or stimulate the healing. Bone 
remodelling is linked to bone growth and is influenced by genetic factors, nutrition 
and hormones and is composed of four consecutive phases: activation, resorption, 
reversal and formation [18]. An unbalanced ratio between the formation of new bone 
and resorption of old bone, can lead to several osseous diseases.  
 
 
Fig. 2. Bone remodelling process that consists of four consecutive steps: activation, 
resorption, reversal, and formation [18]. 
 
BONE GRAFTS  
Bone graft is the second most commonly transplanted tissue [19], approximately 2.2 
million bone grafting procedures are performed annually worldwide [20]. Bone tissue 
regeneration remains an important challenge in the field of orthopaedic and 
craniofacial surgery. Bone grafts are crucial for the treatment of a number of 
conditions, including segmental bone defects caused by trauma or by pathological 
diseases as tumour excision, chronic osteomyelitis, osteoarthritis, osteogenesis 
imperfecta and Paget's disease, non-unions, avascular necrosis and spinal fusions 
[21,22]. Current clinical treatments found for large defects are challenging, and 
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despite the natural capacity of bone for healing, if an injury is beyond a critical limit 
(critical size defect), it cannot heal by regeneration. Traditional tissue engineering 
treatment options in reconstructive surgery include autologous bone grafts and 
allografts bone grafts (tissue from another patient) to repair large bone defects [23]. 
Autologous bone grafting remains the gold standard to fill a bone defect with the 
highest success rates for bone regeneration [24,25] but autografting may be restricted 
by donor site morbidity, bone availability, secondary surgery cost and burden and 
potential risk of disease transmission [26,27]. Using the allografts, which accounts for 
34% of the current bone grafts, appears as an alternative to autografts, but also has 
drawbacks including availability, disease transmission and risks of infection and 
rejection by the immune system [28,29]. Xenografts are another option for bone 
grafts. In this case, animal bone is supplied as a powder, granules or blocks, but 
disease transmission and immune rejection are major risks [30]. The limitations with 
conventional grafting approaches can be overcome by the use of synthetic bone 
substitutes/scaffolds. A large number of synthetic bones have been developed, which 
can vary in composition, mechanical of action, and special characteristics. Althoutgh 
they should be biocompatible, they are still unable to provide an osteogenic capacity 
as good as the autografts [31,32]. 
Along the last years the bone graft biomaterials have evolved and can be categorized, 
according Hench, into three different generations [16]. The first generation bone graft 
require the biomaterial to match the physical properties of the tissue to be replaced, 
these include metals and alloys which have excellent mechanical properties but are 
neither bioresorbable nor bioactive and because their limited lifetime it needs to be 
removed and replaced surgically. The second generation of bone grafts include 
bioactive ceramics and bioresorbable polymers that were developed with bioactive 
interfaces which would elicit a specific biological response. The third generation bone 
grafts try to get closer to the autograft, made up of polymer–ceramic composite 
scaffolds, with the incorporation of osteogenic cells, growth factors or bone 
morphogenetic proteins, capable of inducing specific cellular responses at the 
molecular level. 
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BONE TISSUE ENGINEERING  
Tissue engineering has emerged as a promising approach for the repair and 
regeneration of tissues and organs lost or damaged as a result of trauma, injury, 
disease or aging [33,34]. Tissue engineering has been defined as an interdisciplinary 
field that incorporates principles of engineering and the life sciences to produce 
biological substitutes that restore, maintain or improve tissue function [35]. This 
innovative technology has attracted increasing attention as an alternative strategy to 
treat damaged organs and tissues that cannot be self-regenerated, such as full-
thickness skin burn, over critical-sized bone defects, and chronic cartilage disease.  In 
contrast to classic biomaterials approach, it is based on the understanding of tissue 
formation and regeneration, and aims to induce new functional tissues, rather than just 
to implant new spare parts [9]. Tissue engineering aims to eliminate the disadvantages 
of the conventional clinical treatments associated with donor-site morbidity and 
scarcity in autografting and allografting. Developed as an artificial bone matrix, a 
tissue engineering scaffold plays an essential role in regenerating bone tissue. Bone 
tissue engineering (BTE) has emerged to regenerate damaged bone and therefore to 
recover its malfunctions rather than replacing it. There are three basic elements 
required for bone tissue engineering: osteogenic cells, growth factors and an 
osteoconductive scaffold matrix [36-38]. The main principle of BTE strategy is to 
cultivate cells in a designed artificial 3D porous matrix, working as a scaffold to 
sustain cell proliferation, differentiation and to provide guidance for tissue 
regeneration and growth. The culture of these cells, under controlled stimulation with 
growth factors in vitro, leads to new extracellular matrix (ECM) generated by the 
cells that may be implanted into the body when matured. After implantation the 
natural tissue regeneration processes will ideally take place, integrating the implant, 
leading to blood vessel formation. The structure of the scaffold dissolves while new 
tissue is formed in its place [39].  
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BIOMATERIALS FOR BONE TISSUE ENGINEERING 
According to the American National Institute of Health, Biomaterial can be defined as 
“any substance or combination of substances, other than drugs, synthetic or natural in 
origin, which can be used for any period of time, which augments or replaces partially 
or totally any tissue, organ or function, in order to maintain or improve the quality of 
life of the individual” [40].  
In general, these can be classified according two aspects: chemical composition and 
biological behaviour. The first subdivided biomaterials in four main classes of 
materials as ceramics, metals, polymers, and composites, with varied degree of 
bioactivity. Therefore, biomaterials can be classified into four categories according to 
the nature of their interaction with the surrounding tissue; these are: bioinert, when 
introduced to the body do not cause any reaction or interact with the biological tissue, 
meaning that the host won´t recognized them as a strange body (ex: titanium, zirconia 
and alumina); biotolerant, not necessarily rejected by the host but rather moderately 
accepted by the recipient tissue which encapsulates the implant with a fibrous 
interface (ex: stainless steel, glass, chromium-cobalt fibres and 
polymethylmethacrylate (PMMA)); bioactive, may cause a reaction or have an effect 
on the living environment, also due to their composition are capable of forming a 
direct link with the tissue (ex: hydroxiapatite, bioactive glasses);  
biodegradable/reabsorbable, those that suffer of slow degradation and gradual 
substitution of the host tissue (ex: tricalcium phosphate and bioactive glass) [40]. 
The basic requirements of a scaffold material are high cell/tissue biocompatibility, 
non-toxicity, capability of promoting cell proliferation and differentiation, and 
sufficient mechanical properties [41,42]. However, in order to achieve an excellent 
restoration of a bone implant, three different processes must take place, 
osteoinduction, osteoconduction and osseointegration [43]. Osteoinduction is the 
ability of a material to recruit and induce progenitor or undifferentiated cells to 
differentiate towards the osteoblastic lineage, thus, is the process by which 
osteogenesis is induced. Osteoconduction means that bone grows on a surface, for 
this, the materials allowing the bone cells adhere, proliferate and form extracellular 
matrix on its surface or down into pores and channels. Osseointegration is the stable 
anchorage of an implant achieved by direct bone-to-implant contact, materials bonded 
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with surrounding bone without growth fibrous tissue at the bone-implant interface.  
 
CALCIUM PHOSPHATES  
Among several synthetic bone substitutes options, there are ceramics, glasses and 
glass ceramics that have been used to produce are synthetic scaffolds for applications 
in dentistry and orthopaedics since 1980s [44,45]. Being a major constituent of bone, 
calcium phosphates (CaPs) have been extensively studied as scaffold materials for 
bone tissue engineering. Among different CaPs, the majority of research has been 
focused on hydroxyapatite (HA, Ca10(PO4)6(OH)2), β-tricalcium phosphate (β-TCP, 
Ca3(PO4)2) or  biphasic calcium phosphate (BCP, a mixture of HA and β-TCP) [32]. 
Among the various monophasic calcium phosphate ceramics, HA (Ca10(PO4)6(OH)2) 
is the most stable, the most dense and the most insoluble, possessing a Ksp value of 
around 2.9 × 10−58 over a pH range of ∼4.5 to ∼9.7 [46-48]. From a chemical and 
structural point of view it is the material most similar to the mineralized constituents 
of hard tissue (bones and teeth). Moreover, stoichiometric HAP has a Ca/P ratio of 
1.67 and is considered to be osteoconductive but not osteoinductive [49]. HA can be 
easily prepared by different methods, precipitation, thermal treatments at high 
temperature or hydrothermal conversion from coral [50]. 
Of the two known crystal forms of HA—monoclinic, space group P21/b, and 
hexagonal, space group P63/m—only the hexagonal phase is of practical importance 
because the monoclinic form is destabilized by the presence of even small amounts of 
foreign ions [51]. The hexagonal structure contains two different cation sites, Ca(I) 
and Ca(II), but only one phosphate environment (Ca(I), Ca(II) are used for 
stoichiometric apatite; M(I), M(II) are the general symbols for substituted apatites). 
The structure can be roughly described as a phosphate assembly crossed by parallel 
channels filled by OH− ions and parallel to the crystallographic c-axis (Fig. 3 (a)). The 
channel walls are formed of Ca(II) atoms arranged in staggered triangular arrays. 
Ca(I) atoms have a different environment and are positioned in columns parallel to the 
OH− channels [52]. A unit cell accommodates a formula unit Ca10(PO4)6(OH)2. 
Among the 10 cations, the 4 Ca(I)s are tightly bonded to 6 oxygens and less strongly 
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to the other 3 oxygens (mean Ca(I)–O distance 0.255 nm), whereas the 6 Ca(II) atoms 
are surrounded by 7 oxygens (mean Ca(II)–O distance 0.245 nm). Ca(I) atoms are 
strictly aligned in columns and any small change in the metal–oxygen interactions 
affects the entire lattice. However, the Ca(II) atoms belonging to consecutive layers 
are staggered, allowing random local misplacements without compromising the whole 
structure. As a consequence, cations smaller than Ca or also low concentrations of 
slightly larger cations are preferably accommodated in site Ca(I) where stronger 
interactions are present, while larger cations should be accommodated in position 
Ca(II), even at high concentrations. 
 
 
Fig. 3 Crystal structure of hydroxyapatite (a) and β-tricalcium phosphates (b) projected 
perpendicular to c-axis. [Adapted from 53]. 
 
Stoichiometric tricalcium phosphates (TCP) (Ca3(PO4)2) possesses a Ca/P ratio of 1.5 
and occurs in two phases, α and β; these phases possess identical chemistries but 
different crystal structures [54]. The rhombohedral β-TCP, space group R3c (Fig. 3 
(b)), can be obtained only at high temperature, by solid-state reaction or by thermal 
conversion of other phosphates, and is stable up to 1125 ºC. Moreover, β-TCP form 
cannot be obtained by direct precipitation and it results from the calcining at 700-
800 ºC of Ca deficient apatite, with the loss of water, according to the equation [55]: 
Ca9(HPO4)(PO4)5(OH) → 3Ca3(PO4)2 + H2O 
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Above 1125 ºC β-TCP converts into α-TCP, which unit cell is monoclinic, space 
group P21/a. [51]. Both phases are less stable than HAP and hence more soluble in 
aqueous environments [47]: Ksp values of 10−25.5 for α-TCP and 10−28.9 for β-TCP 
at 25 ºC have been reported [56]. The principal disadvantage of the use of HA and 
related calcium phosphates as bone scaffold is that the slow degradation of these 
inorganic ceramics in the body limits their utility for bone-regeneration application. 
Sintered hydroxyapatite can take more than five years to be reabsorbed by the body, 
while tricalcium phosphate can be completely degraded in one or two years [57]. β-
TCP has been used more extensively in bone regeneration than α-TCP and is 
considered to be both osteoconductive and osteoinductive [58].  
 
Biphasic calcium phosphate 
Biphasic calcium phosphate (BCP) ceramics are a mixture of hydroxyapatite and β-
tricalcium phosphate that combines the great biodegradability of β-TCP with the 
strong mechanical properties of HA [59] and were developed to better control the 
process of biomaterials resorption and bone substitution. BCPs are considered better 
when compared to either single phase HA or β-TCP components because of their 
unique dissolution characteristics which promote new bone formation at the implant 
site [60]. 
Increasing the β-TCP/HA ratio will give a more biodegradable material since β-TCP 
dissolves preferentially from its matrix, releasing calcium and phosphate ions to the 
media, enhancing the in vivo activity and decreasing the resorption time. 
Simultaneously, a higher β-TCP/HA ratio will diminish the mechanical strength in the 
BCP material. However, it has been proved that the mixture of calcium phosphates 
turns out to be the ideal choice [59]. 
Daculsi found an optimum balance of the more stable phase of HA and more soluble 
TCP, enabling to gradually control the dissolution in the body, seeding new bone 
formation as it releases calcium (Ca2+) and phosphate (PO43−) ions into the biological 
medium [61].   
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Some authors have defended the superior properties of the BCP materials directly 
prepared over those obtained by mixing two single phases [62]. Therefore, there are 
several synthesis routes that can be employed in preparation of BCPs, being the most 
widely used the precipitation [63]. 
 
Dopant ions of calcium phosphates 
Bone is not a homogenous material. Besides Ca and P, it also incorporates various 
trace elements playing vital roles in the formation, growth, and repair of bone. In 
recent years various studies demonstrated that adding trace elements to CaP materials, 
such as strontium, magnesium, zinc, copper and even silver, can lead to controlled 
degradation, increase the mechanical strength of the materials, and positively 
influence the biological response, improving the performance process after 
implantation [50,64].  
Orthopaedic implants can cause post-operative infections owing to the adhesion of 
bacteria on their surface, being a serious problem with awful consequences [65]. 
Open fractures, in particular, involving large segmental bone defects filled with 
artificial bone grafts are prone to such infections [66-68]. The infection rate on 
orthopaedic implants restoration was reported to be 72.9% [69]. Such infections 
significantly increase the treatment costs due to additional surgery required and 
extended recovery of the patient [70,71]. It has been reported that incorporation of 
trace ions such as Ag, Zn, and Cu into synthetic materials improves their 
antimicrobial properties, preventing the adhesion of bacteria at the site of 
implantation [72,73]. There are three main mechanisms for the antimicrobial activity 
of these ions [74-77]. Firstly, metal ions bind to proteins deactivating them. Secondly, 
metal ions can interact with microbial membrane and induce structural and 
permeability changes. Finally, metal ions interact with microbial nucleic acids, 
preventing microbial replication. 
Small quantities of copper and zinc ions are essential for various metabolic processes 
in most of the living organisms, while higher amounts are potentially toxic. Besides 
its antimicrobial activity, copper, is an essential trace element for mammalian life, 
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with its highest abundance in the liver tissue [78], playing a cross-linking role for 
collagen and elastin of bone [79-81]. It also induces a stimulatory effect on 
endothelial cells towards angiogenesis, probably caused by upregulation of VEGF 
expression [82,83]. On the other hand, zinc is present in all biological tissues, 
especially in bone, which accounts for 28% of the total Zn content in the body. Zn 
also plays a vital role in the maintenance of membrane structure, function, protein 
synthesis, DNA synthesis, mitosis, and cell proliferation [84,85]. Several important 
metalloenzymes utilize zinc for structure, catalytic, or regulatory actions, including 
alkaline phosphatase (ALP) that is absolutely vital for the maturation of new bone 
formation. Zinc stimulates bone formation and mineralization [86,87] having a direct 
specific proliferative effect on osteoblastic cells in vitro and it is thought to possess a 
potent and selective inhibitory effect on osteoclastic bone resorption in vivo  [88,89]. 
Zinc-doped CaP materials have shown increased osteoblastic response in vitro as well 
as new bone formation in vivo [88,90]. Zinc phosphate cements are some of the oldest 
and most widely used cements in dental industry [91]. 
Strontium is a non-essential element, present in mineral phase of bone, especially at 
regions of high metabolic turnover [92]. Sr has bone-seeking behaviour and favours 
bone growth [93]. Low Sr doses are beneficial in the treatment of osteoporosis [94] 
and its administration as Sr ranelate showed significant reduction of fractures in 
osteoporotic patients [95]. In addition, Sr decreases bone resorption by inhibition of 
osteoclast-resorbing activity and osteoclastic differentiation, and it promotes bone 
formation by enhancing pre-osteoblastic cell replication and osteoblastic 
differentiation [92,93]. The evidences of the beneficial effects of strontium on bone 
regeneration justify the increasing interest in addition it into calcium phosphate 
bioceramics [96-98]. 
Magnesium (Mg2+) has been often associated with the mineralization of calcified 
tissues and indirectly influences mineral metabolism [99,100]. Its ability to stimulate 
the formation of biphasic HA-TCP mixtures upon heating [101] by enhancing the 
thermal stability of TCP is an added benefit from Mg-doping HA, making the 
resulting bone grafts more biodegradable. 
The use of multiple ionic doping has been attempted to get further biological benefits 
from synthetic CaP bone grafts, but their physical properties can also be 
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altered [102-104]. The changes in mechanical properties and biological responses 
reflect the effects of doping on the physicochemical properties of CaPs such as phase, 
crystallinity, microstructure, solubility, grain size, mechanical strength, and strength 
degradation kinetics caused by cation substitution [102]. 
Most of the ion doping reported on literature was accomplished through methods of 
chemical precipitation, sol-gel, and ion-exchange process [105-107]. The 
physicochemical properties of CaP might vary depending on whether the dopant is 
substituting ‘Ca’ or ‘P’ site in the crystal lattice and/or staying in its respective salt 
form. Depending on the ionic radius, the substitution of the added dopant can either 
stabilize or destabilize the crystal structure of CaPs [108]. 
SCAFFOLDS IN TISSUE ENGINEERING 
In bone tissue engineering scaffolds play a fundamental role; they can provide a 
temporary three-dimensional (3D) system for initial cell proliferation, differentiation 
and extracellular matrix production and, in addition, providing a template for new 
tissue regeneration [35,109]. Both the scaffold material and its architectural design 
(pore size, porosity and interconnectivity) play a significant role in governing tissue 
regeneration and define the ultimate shape of newly grown soft or hard tissue 
[39,110]. The ideal scaffold must have certain properties and characteristics to occur 
effective bone formation, such as:  
(i) Be biocompatible (non-toxic), described as its ability to support normal cellular 
activity, including molecular signalling systems without any local and systematic 
toxic effects to the host tissue [111]. An ideal bone scaffold must be osteoconductive 
where the scaffold allows the bone cells to adhere, proliferate, and form ECM on its 
surface and pores. The scaffold should also be able to induce new bone formation 
through biomolecular signalling and recruiting progenitor cells, a property known as 
osteoinduction. Furthermore, an ideal scaffold needs to form blood vessels in or 
around the implant within few weeks of implantation to actively support nutrient, 
oxygen, and waste transport [112]; 
(ii) Exhibit, after in vitro tissue culture, mechanical properties comparable to those of 
the tissue to be replaced. Mechanical properties of bone vary widely from cancellous 
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to cortical bone. Young's modulus of cortical bone is between 15 and 20 GPa and that 
of cancellous bone is between 0.1 and 2 GPa. Compressive strength varies between 
100 and 200 MPa for cortical bone, and between 2 and 20 MPa for cancellous bone. 
Therefore, the large variation in mechanical property and geometry makes it difficult 
to design an ‘ideal bone scaffold’ [112]; 
(iii) Have a porous three-dimensional (3D) architecture and interconnected open 
porosity to allow cell proliferation, vascularization and diffusion of nutrients between 
the cells seeded within the matrix and the surroundings. A must have property for 
scaffolds is interconnected porosity where the pore size should be at least 100 µm in 
diameter for successful diffusion of essential nutrients and oxygen for cell survival 
[113]. The optimum pore size range for bone tissue in-growth is within 200–350 µm 
[114]. Recent studies indicated that multi-scale porous scaffolds involving both micro 
(pore size <20 µm) and macro porosities (pore size >100 µm) can perform better than 
only macro porous scaffolds [115]; 
(iv) Bioresorbability is another fundamental factor for scaffolds in bone tissue 
regeneration, to degrade at a rate that matches the production of new tissue, into 
nontoxic products that can be easily resorbed or excreted by the body;  
(v) Capable of being processed economically into anatomically relevant shapes and 
dimensions, and be sterilized for clinical use [116]. 
 
FABRICATION TECHNIQUES  
In an organ, cells and their ECM are usually organized into 3D tissues. Therefore, in 
tissue engineering, a highly porous 3D matrix (scaffold) is often necessary to 
accommodate cells and to guide their growth and tissue regeneration in three 
dimensions. A variety of techniques, conventional or advanced processing methods, 
have been used to fabricate 3D porous ceramics scaffolds for tissue engineering and 
regenerative medicine. 
Conventional techniques are relatively simple methods, including solvent casting and 
particulate leaching, gas foaming, fibre meshes and fibre bonding, phase separation, 
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melt molding, emulsion freeze drying, solution casting and freeze drying [109,117]. 
However, there are inherent limitations in these processing methods, most of them are 
incapable of producing fully continuous interconnectivity and uniform pore 
morphology within a scaffold, it is difficult to accurately control the pore geometry, 
pore size, spatial distribution cannot be controlled, and overall porosity of the 
scaffolds [118]. In addition, the use of organic solvents may cause toxic effects on 
cells during subsequent culture [119,120]. Recently, to overcome these obstacles, 
advanced additive manufacture (AM) techniques, also known as Rapid Prototyping 
(RP) or Solid Free-form Fabrication (SFF), have been successfully used to fabricate 
porous 3D structures with customized external shapes and predesigned internal 
microarchitecture. Additive manufacturing is a fabrication method using 3D multi-
layered constructs to build porous biocompatible scaffolds of pre-defined shapes with 
excellent mechanical and osteoconductive properties [121]. AM techniques used to 
fabricate 3D ceramic structures can be classified as [122]: (1) laser assisted sintering 
(e.g., SLS and LENS), (2) extrusion (e.g., fused deposition of ceramics, FDC), (3) 
polymerization (e.g., SLA), and (4) direct writing-based processes (e.g., ink-jet 3DP). 
In all AM techniques, a 3D model is created by computer-aided design (CAD) 
program and then is converted to an STL (standard tessellation language) file. The 3D 
object is then sliced to two-dimensional (2D) cross sections and fabrication of the part 
is started from the base in alternating layers. Manufacturing is continued layer by 
layer until the entire part is fabricated. Compared to traditional manufacturing 
processes, the primary advantage of AM is its ability to create complex designs with 
high accuracy in dimensions and structural features without the need for specific 
tooling or dies. In addition, almost all AM techniques are faster than traditional 
processes without the need for further surface finishing. However, not all the AM 
techniques are useful for fabrication of similar ceramic structure due to the limitations 
of each technique [122].  
A brief overview of the most important AM techniques including 3D printing (3DP), 
stereolithography (SLA), fused deposition modelling (FDM), and selective laser 
sintering (SLS) is presented below. 
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3D printing 
3D printing technology was developed at the Massachusetts Institute of Technology 
in 1995 by Sachs et al. [123] and it is considered one of the most attractive AM 
system. With a high application potential for bone tissue engineering, 3D printing can 
be adapted to produce porous ceramic-based bone scaffolds with well-defined inner 
and external structures [124]. 3DP is a power-based freeform fabrication method in 
which using a regular ink-jet printed-head, binders are printed on to loose powders in 
a powder bed. Fig. 4 shows a schematic representation of the 3DP process. A first 
layer of powder is laid on the building platform and a liquid binder is sprayed on the 
surface of the powder layer bonding together the powder granules. Once the layer is 
completed, the platform is lowered the height of one layer and a new one is laid over 
the precedent one. This process is repeated until all of the layers have been printed. 
The printed structure, embedded in the loose powder, must be extracted from the 
powder bed after it has been printed, and the unbound powder must be removed from 
its pores and cavities, a crucial step in the printing process that is referred to as 
depowdering. The scaffold can then be sintered [125-128]. In general, a large variety 
of ceramic, metallic, polymeric, and composite materials can be processed using 3DP, 
being binder selection and process parameter optimization the keys to successful part 
fabrication.  
 
Fig. 4. (a) Schematic drawing representing the 3D printing process [128]. Examples of 
bioceramic scaffolds produced by 3DP: (b) TCP and HA photograph and (c) SEM image of 
HA [124]. 
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Stereolithography 
The manufacturing of 3D objects by stereolithography (SLA) is based on the spatially 
controlled solidification of a liquid resin by photo-polymerisation. This technique was 
developed, at the same time, by Kodama (1981) and Nakai and Marutani (1986), in 
two different laboratories [129,130]. SLA uses a computer-controlled laser beam or a 
digital light projector with a computer-driven building stage, where a pattern is 
illuminated on the surface of a resin. As a result of this, the resin in the pattern is 
solidified to a defined depth, causing the adherence to a support platform. After 
photo-polymerisation of the first layer, the platform is moved away from the surface 
and the built layer is recoated with liquid resin. A pattern is then cured in this second 
layer [129]. Figure 5 shows a schematic representation of the stereolithography 
process. 
The possibility to fabricate flexible, submicron/decimetre-sized accurate structures as 
well as components with different geometries with high efficiency level is the main 
advantage of SLA [122]. 
The limited number of resins that are commercially available for processing by 
stereolithography has often been considered the main limitation of the technique. The 
resin should be a liquid that rapidly solidifies upon illumination with light [140].  
 
Fig.  5. (a) Schematic drawing representing of an SLA system. [131] (b) Photograph of 
PDLLA scaffolds built by SLA and SEM micrograph (c). Bar: 500 µm [132]. 
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Fused deposition modeling 
Fused deposition modelling (FDM) is an AM technique that utilizes thermoplastic 
fibre that is heated and selectively extruded out of nozzles, moving within the x- and 
y-axes layer-by-layer, Figure 6. The semi-molten polymer is extruded onto a base 
plate following a path predetermined by CAD specifications. When a layer is 
completed, the base platform is lowered vertically on the z-axis and another layer of 
thermoplastic polymer is delivered. This process is repeated until the structure has 
been completed [125,133,134]. Fused deposition modelling was used to produce 
novel scaffolds with honeycomb-like pattern, fully interconnected channel network, 
and controllable porosity and channel size. In comparison with other AM techniques, 
the FDM method does not require any solvent and offers great ease and flexibility in 
material handling and processing. However, the resolution of FDM is relatively low, 
at 250 µm [120,133]. 
 
Fig. 6. (a) A schematic diagram of the FDM extrusion and deposition process [135], (b) SEM 
images of PCL/TCP composite scaffolds obtained from FDM [136]. 
 
Selective laser sintering  
Selective laser sintering (SLS) is one of the most established and widely used additive 
manufacturing techniques. This technique was developed and patented by Deckard 
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and Beaman from the University of Texas at Austin. In this process, an object is 
created layer-by-layer from heat-fusible powdered material with heat generated from 
a scanning laser beam [127].  
The laser beam selectively fuses powders following the cross-sectional information 
carried by the CAD data. During sintering, the laser beam-powder interaction 
increases the temperature inducing fusion of adjacent particles. After a layer is 
created, the powder bed is lowered and another layer of powder is rolled over it; the 
process is repeated layer after layer until the scaffold is completed. Unlike what 
happens with SLA, temporary support structures are not needed during the process, as 
support is provided by the unbound powder and, just as in 3DP, all remaining powder 
is removed after the scaffold has been completed [125,137].   
Although the potential of scaffolds fabricated via SLS for bone tissue engineering has 
been recognized from a relatively wide range of powder materials such as poly(lactic 
acid), PCL and bioceramics, this technique needs high operating temperatures during 
manufacturing process, being the main disadvantage [137].   
 
 
 
Fig. 7. (a) Schematic representation of the SLS system [131]. (b) Photograph of PHBV/TCP 
composite scaffolds built by SLS, and (c) a SEM morphology [138]. 
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Robocasting 
Robocasting, also called direct-write assembly, is a versatile AM technique 
[139-145]. This new AM technique was developed at Sandia National Laboratories, 
Albuquerque, New Mexico. It consists of a computer controlled robotic deposition of 
highly concentrated pastes (containing water, trace amounts of chemical modifiers, 
and ceramic powder), capable of fully supporting their own weight during assembly, 
allowing precise control of pore size (100 µm to 2 mm), shape and alignment 
[122,141,146]. Scaffold designs are created in a computer-aided design (CAD) 
program, which is then used to control the movements of the robocaster.  A colloidal 
paste is loaded into a syringe mounted on a z -axis motion control stage and extruded 
through fine nozzles onto a moving x–y stage. Complex 3D parts are built in a layer-
by-layer sequence. Figure 8 shows a schematic representation of the robocasting 
process. Compared with other AM technologies for ceramic materials, the most 
obvious advantage of robocasting is that the entire process, including fabrication, 
drying and sintering, can be complete in less than 24 hours [122,147]. 
 
 
 
Fig. 8. (a) Schematic of robocasting process [141]. Examples of scaffolds produced by 
robocasting: (b) low magnification picture showing HA/PLA scaffold [148] and SEM 
micrographs showing the morphology of HA (c, d) and β -TCP (e) scaffolds after sintering 
[149,150]. 
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Robocasting requires careful characterization and control of viscoelastic properties of 
the paste being deposited, commonly denominated as inks [141,146]. Colloidal inks 
must satisfy two important criteria: (i) exhibit a well-controlled viscoelastic response, 
i.e., they must be able to flow through a deposition nozzle and then “set” immediately 
to facilitate shape retention of the deposited features even as they span gaps in the 
underlying layer(s), and (ii) contain high solids volume fractions to minimize drying-
induced shrinkage after assembly, meaning that particle network must be able to resist 
compressive stresses arising from capillary tension [145,151-153]. These criteria 
require careful control of colloidal forces to generate a highly concentrated, stable 
dispersion. These conditions are usually achieved by selecting an appropriate 
dispersant and exerting some mechanical action (stirring, milling), or ultrasonic 
agitation, to break down the agglomerates. Additionally, particle size and particle size 
distribution are also relevant factors that determine the rheological properties of the 
suspensions [146,154,155]. After the preparation of high solids loading suspensions, a 
system change is induced by several ways (e.g., ∆pH, ionic strength, or solvent 
quality) that promotes a fluid-to-gel transition [146]. Until now, several ink proposals 
have been explored, however, since the main challenge in robocasting is developing 
ceramic slurries with suitable viscoelastic properties for the deposition process, the 
research for new ceramic inks has never stopped.  
Porosity in robocast scaffolds can be tailored on three length scales: macro- (greater 
than 100 µm), micro- (1–30 µm), and submicron (less than 1 µm). Macroscale 
porosity is introduced directly by the robocasting process as it draws successive 
layers. Robocast rods, arranged in latticed patterns, create macroporous pathways in 
three dimensions. Varying the rod spacing and size, pathways can be precisely 
constructed to produce highly uniform macropores. This technique has been used to 
produce porous ceramic and composite scaffolds with different architectures 
[149,156-158]. The size and fraction of submicron porosity can be controlled by 
sintering conditions [159-162].  
The appearance of robocasting as AM technology opened the opportunity to construct 
medical devices and scaffolds for tissue engineering, particularly, orthopaedic 
applications by using bioceramic powders.  Porous bioceramic scaffolds are widely 
regarded as promising candidates for bone tissue regeneration, since the pore 
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architecture in such materials must exhibit an appropriate level of interconnectivity 
[163-165] to allow vascularization and diffusion of nutrients in order to promote cell 
ingrowth. This requirement implies the fabrication of scaffolds with large and higher 
total porosity when compared to ones fabricated by conventional techniques 
[166-168]. In recent years, different studies have been done in the fabrication of 
calcium phosphate scaffolds [59,148,149,156,169,170], remaining the possibility to 
explore new compositions such as HA, β-TCP and BCP.  
Using the robocasting technique, Dellinger et al. [170] produced model HA scaffolds 
of various architectures, including periodic, radial, and superlattice structures with 
macropores (100–600 µm), micropores (1–30 µm), and submicron pores (< l µm). 
This study indicates that by precise control of scaffold features, these model scaffolds 
may be used to systematically study the effects of scaffold porosity on bone ingrowth 
processes both in vitro and in vivo.  
Russias et al. also reported the preparation of tissue engineering scaffolds by 
robocasting with HA or bioglass/polylactide or polycaprolactone. The mechanical 
property was characterized before and after submerging in simulated body fluid for 20 
days. It was strongly dependent on the ratio of the organic and inorganic phase, and 
could be controlled based on different applications [148]. All these scaffolds showed 
encouraging biological response in in vitro evaluations. 
Miranda and co-workers optimized the particle size and morphology of TCP powders, 
in order to prepare suitable inks for robocasting. Reducing particle size and increasing 
specific surface area of the TCP powders could be appropriate procedures for 
successful slurry preparation [156]. Therefore, through the analysis of microstructure 
and heat treatment, scaffolds fabrication via robocasting with tailored performance 
could be achieved for bone tissue engineering applications as well [156]. 
Heo et al. [171] produced HA/PCL composite scaffolds using the robocasting 
process. The macropores in the scaffolds were well interconnected, with a porosity of 
73 % and a pore size of 500 µm. The compressive modulus of the nano-HA/PCL and 
micro-HA/PCL scaffolds was 3.2 and 1.3 MPa, respectively. The higher modulus of 
nano-HA/PCL was to be likely caused by the well-dispersed nanosized HA particles. 
In addition, the more hydrophilic surface of nano-HA/PCL, which resulted from the 
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greater surface area of HA of nano size, could promote cell attachment and 
proliferation compared with micro-HA/ PCL. Martinez-Vazquez et al. [158] reported 
the infiltration of PCL or PLA into β-TCP porous scaffolds fabricated by robocasting 
increased their compressive strength compared with pure calcium phosphate 
scaffolds.  
The incorporation of biomolecules in the scaffolds, such as growth factors, antibiotic 
or anti-inflammatory drug with the aim to accelerate local bone healing, is promising 
and currently under extensive research. The usage of the robocasting offers 
opportunities for fabricating scaffolds a broad range of materials, however, the green 
bioceramics should be submitted to a sintering step at high temperatures to obtain the 
desired mechanical properties of the scaffolds, barring the incorporation of 
temperature sensitive bioactive molecules in the extrudable ink, hence before 
sintering. Martinez-Vazquez et al. [172] studied the processing conditions to 
fabricate, by robocasting, composite scaffolds with a high content of ceramic, and 
with no sort of additive (dispersant, binder, etc.), in order to obtain ideal synthetic 
scaffolds of gelatin and silicon-doped hydroxyapatite (HASi) for bone regeneration 
and drug release, in a single step, without the need for sintering.  
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Abstract 
Several types of biodegradable materials have been investigated for the treatment of 
osteomyelitis. Calcium phosphate (CaP) ceramics are among the most performing 
materials due to their resemblance to human hard tissues in terms of mineralogical 
composition, and proven ability to adsorb and deliver a number of drugs. This 
research work was intended to study the suitability of modified calcium phosphate 
powders loaded with a fluoroquinolone as drug delivery systems for osteomyelitis 
treatment. Levofloxacin (LEV) was chosen due to the well-recognized anti-
staphylococcal activity and adequate penetration into osteoarticular tissues. 
Substituted calcium phosphate powders (5 mol% Sr2+ or 5 mol% Mg2+) were 
synthesised through aqueous precipitation. The obtained powders were characterised 
by X-ray diffraction, SEM and FTIR analysis. The X-ray diffraction patterns 
confirmed the presence of HA and β-tricalcium phosphates (β-TCP) phases in doped 
compositions, especially in the case of Mg-doped system. The fixation of LEV at the 
surface of the particles occurred only by physisorption. Both the in vitro 
microbiological susceptibility, against Staphylococcus spp, and biocompatibility of 
LEV-loaded CaP powders have not been compromised.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: osteomyelitis, calcium phosphate, fluoroquinolone, drug delivery 
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1. Introduction 
Osteomyelitis is a difficult-to-treat progressive infection of the bone, caused by 
bacteria or sometimes by fungus, characterized by bone destruction, bone necrosis, 
and may progress to a chronic and persistent state [1,2]. The traditional treatment of 
chronic osteomyelitis involves operative debridement of the dead infected tissue, 
obliteration of dead space, osseous repair, adequate soft tissue coverage and long-term 
systemic antibiotic therapy [3]. However, the inability to maintain high antibiotic 
concentrations at the site of infection for an extended period of time is considered as 
the major reason for failure in the treatment of this disease [4,5]. Thus, it has been 
recognized that antibiotic local delivery offers several advantages compared to oral or 
systemic treatment, including higher concentrations of drug at the target site while 
avoiding systemic toxicity [6]. Antibiotic-impregnated implants are particularly 
attractive because they not only deliver high levels of drug but also help to obliterate 
the dead space that follows bone debridement [7, 8]. 
Polymethylmethacrylate (PMMA) beads loaded with gentamicin are the most widely 
studied material for osteomyelitis treatment. But the surgical removal of the beads 
after antibiotic release is a drawback [9,10]. Coping with this limitation, a number of 
recent research works focused on biodegradable bone filler systems for local delivery 
of antibiotics [8, 11-13]. Besides not requiring surgical removal, such systems also act 
as guides for bone repair as the implant is gradually resorbed and replaced by the 
newly formed bone. 
Antibiotic-loaded resorbable CaP ceramics have been suggested as potential materials 
for the treatment of osteomyelitis [14-16]. HA deserved a particular attention because 
of its chemical and structural similarities with the inorganic phase of human bone and 
its biocompatibility, osteoconductive and osteophilic nature [17,18]. Moreover, the 
crystalline lattice of HA is able to easily incorporate foreign substituting ions that 
enhance osteointegration and mechanical properties of the grafts [19-23]. Magnesium 
(Mg2+) has been often associated with the mineralization of calcified tissues and 
indirectly influences mineral metabolism [24,25]. Its ability to stimulate the formation 
of biphasic HA-TCP mixtures upon heating [26] by enhancing the thermal stability of 
TCP is an added benefit from Mg-doping HA, making the resulting bone grafts more 
biodegradable. Strontium (Sr2+) is another interesting doping ion since it increases 
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osteoclast apoptosis and enhances preosteoblastic cell proliferation and collagen 
synthesis, with consequent depression in bone resorption and maintained bone 
formation [23].  
Considering the importance of LEV in osteomyelitis treatment due to its broad 
antibacterial spectrum and excellent bone penetration properties [27,28], the present 
aims at studying the adsorption and release kinetics of this drug by CaP powders 
doped with Mg2+ and Sr2+. The interactions between levofloxacin and CaP powders 
were studied by X-ray diffraction and FTIR spectroscopy. The adsorption efficiency 
of LEV and its in vitro releasing kinetics from the different doped powders were 
determined by high-performance liquid chromatography-UV (HPLC-UV). The LEV 
minimum inhibitory concentration (MIC) from different powders was evaluated for 
Staphylococcus aureus, Staphylococcus epidermidis and Escherichia coli cultures. 
The in vitro biocompatibility was evaluated using MG63 and L929 cell lines. 
 
2. Materials and Methods 
2.1. Preparation of CaP powders  
Powders of pure and HA-doped (with Mg2+ and Sr2+) were synthesized via aqueous 
precipitation. Diammonium hydrogen phosphate [(NH4)2HPO4, Quality Chemicals, 
Spain], calcium nitrate tetrahydrate [Ca(NO3)2·4H2O, Quality Chemicals, Spain], 
magnesium nitrate hexahydrate [Mg(NO3)2·6H2O, Sigma-Aldrich, Darmstadt, 
Germany] and strontium nitrate [Sr(NO3)2, Sigma-Aldrich, Darmstadt, Germany] 
were used as reagents. The concentrations of the starting precursor solutions were set 
in order to have total (Ca + M)/P molar ratio = 1.67 (M = Sr or Mg) for all the 
compositions, as reported in Table 1. For each composition, the (NH4)2HPO4 solution 
was slowly added to the continuously stirred (1000 rpm) cationic solution and the pH 
of the system was then increased to 9 and maintained at this value by adding the 
required amounts of 8 M ammonium hydroxide [NH4OH, Sigma-Aldrich, Darmstadt, 
Germany] solution. After the completion of addition, the reaction was performed at 
90 ºC for 2 h under constant stirring conditions (1000 rpm). In parallel, a standard 
material of Ca/P molar ratio of 1.67 (pure HA) was also prepared under similar 
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conditions and used as control. After the completion of the reaction, the suspension 
was poured out from the reactor and the precipitate was separated through vacuum 
filtration and dried at 100 ºC overnight. The dried powders were calcined at 800 ºC 
temperature in a Thermolab furnace (Pt30%Rh/Pt6%Rh thermocouple) using a 
heating rate of 5 ºC⋅min–1 followed by a dwelling time of 1 h at that temperature, and 
then cooled to room temperature (RT). The calcined powders were then dry milled for 
30 min in a high energetic ball milling up to achieving mean particle sizes <500 nm 
and labelled according to the compositions as HA, Sr-HA and Mg-HA. 
 
Table 1. Planned concentrations of the Ca, P and Sr and Mg precursors used in the synthesis, 
and experimental compositions as determined from ICP analysis.  
 
Sample 
Code 
Planned compositions 
Experimental compositions 
(from ICP analysis (± 0.02) 
(Ca+M)/P 
molar ratio 
Molar concentrations 
of the percursors 
M (mol%) (Ca+M)/P 
molar ratio 
M (mol%) 
Ca P Sr Mg Sr Mg Sr Mg 
[HA] 1.67 2 1.2 0 0 0 0 1.67 0 0 
[Sr-HA] 1.67 1.9 1.2 0.1 0 5 0 1.66 5.04 0 
[Mg-HA] 1.67 1.9 1.2 0 0.1 0 5 1.65 0 4.83 
 
2.2. Calcium phosphate powders characterization 
The characteristics of the CaP powders prior to LEV adsorption were assessed by 
different complementary techniques. Dynamic light scattering (DLS) (Zetasizer Nano 
ZS, Malvern Instruments, UK) was used to determine particle size. The specific 
surface area was measured through the gas adsorption BET method using a 
Micromeritis Gemini 2370 V5.00 (Norcross, USA) after degassing the powders in a 
Micromeritis Flow prep 060 (Norcross, USA). The morphological features were 
observed by scanning electronic microscopy (SEM − Hitachi SU-70, Hitachi High-
Technologies Europe, GmbH, Germany) using 25 kV acceleration voltage and beam 
current of 10 µA. The mineral phases formed upon heat-treating at 800 ºC were 
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identified by X-ray diffraction using a High Resolution X-ray Diffractometer 
(PANalytical X'Pert PRO) with Cu Kα radiation (λ = 1.5406 Å) produced at 45 kV 
and 40 mA, which scanned the diffraction angles (2θ) between 20º and 80º with a step 
size of 0.01º, time per step 198,6450 s. Spectra-fitting software called HighScorePlus 
was utilised to quantify the percentages of crystalline phases for the calcined powders. 
This software requires crystallographic information files to fit and quantify each 
specific phase within a XRD spectrum. The database utilized was PDF-47 2015 RDB, 
and the files utilised in the evaluation of the powders were; HA (# 04-015-7245) [29], 
β–TCP (# 04-006-9376) [30].   
Zeta-potential measurements (Malvern Zeta sizer, Nano ZS, Malvern, Worcestershire, 
UK) were performed before and after LEV adsorption at the surface of CaP powders 
heat treated at 800 ºC at several pH values. The aim was obtaining information about 
the effects of LEV adsorption on the solid/liquid interface. The powders were firstly 
dispersed ultrasonically, and allowed to stand for 30 min to let larger particles to 
settle. An aliquot taken from the supernatant was used to measure the zeta potentials. 
The pH of the suspensions was adjusted with 0.1 M HCl and 0.1 M NaOH. For 
comparison purposes, the measurements were also performed for solid LEV particles. 
Elemental analyses for Ca, P and doped ions (Sr and Mg) were determined for all 
powders using inductively coupled plasma (ICP) spectrometry (ICP-OES Jobin Yvon 
Activa M., USA). For this purpose, nitric acid with double-distilled water was used to 
dissolve the powders prior to ICP analysis.  
 
2.3. Drug loading, adsorption efficiency, in vitro release 
 
2.3.1. Drug loading (DL) and adsorption efficiency (AE)  
Aqueous LEV solutions were prepared in distilled water with suitable antibiotic 
concentrations (determined through preliminary tests) to allow the incorporation of an 
approximate amount of ~2.5 w% of drug into the powders. The impregnation process 
consisted in immersing 3 g of each kind of CaP powders into 5 mL solutions 
containing 400 mg of LEV, meaning a theoretical DL of 13.3 %. The mixtures were 
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kept under stirring in the absence of light for 24 h. The LEV-loaded CaP powders 
were then centrifuged, frozen at −80 ºC (Hettich, Germany) for 4 h, and freeze-dried 
at −51 ºC under a pressure of 1.5 Pa (Labconco, USA) for 48 h. According to the 
compositions, the LEV-loaded powders are hereafter labelled as LEV[HA], LEV[Sr-
HA] and LEV[Mg-HA]. 
Drug loading efficiency (DL, or AE) was determined as the percentage of LEV 
incorporated relative to dry mass of CaP [(wLEV/wparticles)*100]. For this, 6.0 mg (±5 
%) of each LEV-loaded powder was completely dissolved in 2 mL HCL (0.1 N). 
After adequate dilution, the drug content was determined by HPLC-UV (Shimadzu 
LC-6A and SPD-6A, Kyoto Japan), using an adjusted method described in literature 
[31]. Briefly, the chromatographic analysis was performed using a 125-4, 5 µm 
LiChrosphere® 100 RP-18 (Merck, Darmstadt, Germany) column, a degassed mobile 
phase of water:acetonitrile and triethylamine (85:15(V/V); 0.6%(V/V)), and adjusted to 
pH 3 using ortho-phosphoric acid, a 1.2 mL⋅min–1 flow rate and UV detection at 294 
nm (at 25 ºC). All chromatographic separations were carried out in triplicate for each 
independent batch. 
 
2.3.2. Drug release studies 
Levofloxacin release was determined after a previous dispersion of the different 
LEV[HA], LEV[Sr-HA] and LEV[Mg-HA] powders in the release medium during a 
predefined time period. Briefly, 6.0 mg (±5%) of particles were dispersed in 
propylene tubes containing 2 mL of a solution of NaCl 0.9%(w/V) with 0.05%(V/V) 
Tween20® (hereinafter release medium) in a shaking water-bath at 37 ºC. At pre-
determined time points throughout a 1-week period (0 h, 0.5 h, 1 h, 2 h, 6 h, 24 h, 48 
h and 168 h) samples were collected and analysed for LEV content by the HPLC-UV 
method as described earlier. Between collections, and throughout that release period, 
the withdrawn aliquots were replaced with equal volume of fresh release medium 
solution and sink conditions were guaranteed. 
Furthermore, to determine the LEV kinetic mechanism of release of either LEV[Mg-
HA] and LEV[Sr-HA], experimental data was fitted to a first order model equation 
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presented on Equation (1). 
𝑀! = 1− 𝑒!!"   Eq. (1) 
 
where Mt denotes the fraction of drug released up to time t, and k is the constant of the 
mathematical model. 
 
2.4. Antimicrobial susceptibility testing  
The antimicrobial susceptibilities of selected strains to LEV standard solution and to 
48 h release medium supernatants, were obtained by the Broth Microdilution Method 
described by the Clinical and Laboratory Standards Institute (CLSI) [32]. All assayed 
samples were two-fold diluted in Müeller-Hinton broth (Biokar Diagnostics, France) 
and final LEV concentration ranged from 2 µg⋅mL–1 to 0.015 µg⋅mL–1. The medium 
supernatants recovered by centrifugation after 48 h of LEV release (LEV[HA], 
LEV[HA-Sr] and LEV[HA-Mg]), were also tested for antimicrobial susceptibility. 
Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 12228) 
and Escherichia coli (ATCC 25922) obtained from American Type Culture 
Collection (ATCC) were first cultured in Tryptic Soy Agar (TSA) (Liofilchem, Italy) 
and the inoculum was prepared according to CLSI (CLSI, 2012) in Müeller-Hinton 
broth. Minimum inhibitory concentration (MIC) results were obtained by 
measurement of absorbance at 595 nm in a spectrofluorometer (Anthos, Zenyth 3100) 
after 24 h of incubation at 37 ºC. All assays were performed with negative controls 
(not inoculated media) and positive controls (inoculated media). E coli ATCC®25922 
was used as a quality control strain to guarantee that the test system performed as 
expected [34]. Assays were carried out in three independent experiments.  
 
2.5. Cytotoxicity evaluation of the CaP powders 
The cytotoxicity of the LEV loaded CaP powders was assessed using a general cell 
viability endpoint MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
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bromide) [35, 36]. MTT is a yellow, water-soluble tetrazolium dye that is converted 
by viable cells to a water-insoluble, purple formazan. Two cell lines were chosen for 
cytotoxicity evaluation, L929 (Mouse fibroblast cell line, ATCC® CCL-1™) and 
MG63 (human osteoblast cell line, ATCC CRL-1427™). 
Cell viability was assessed after 24 h of incubation of the two cell lines with a 
powders concentration at 300 µg⋅mL–1. The day before experiment, cells were seeded 
in sterile flat bottom 96 well tissue culture plates (Greiner, Germany), in RPMI 1640 
culture medium, supplemented with 10% (V/V) fetal serum bovine, 100 units⋅mL–1 of 
penicillin G (sodium salt), 100 µg⋅mL–1 of streptomycin sulphate, and 2 mM L-
glutamine, at a cell density of 2×105 cells⋅mL–1 (L929) and 1×105 cells⋅mL–1 (MG63) 
100 µL per well. All the mentioned products were purchased from Life Technologies 
(UK). Cells were incubated at 37 ºC and 5% CO2.  
On the next day, culture medium was replaced by fresh medium containing the 
different samples to be analysed. Each sample was tested in six wells per plate. 
Culture medium was used as negative control and sodium dodecyl sulphate (SDS) at 1 
mg⋅mL–1 as positive control. After 24 h the culture medium was removed and 
replaced by medium containing 0.5 mg⋅mL–1 of MTT. The cells were further 
incubated for 3 h. Medium was removed from the plates containing reduced MTT, 
and the intracellular formazan crystals were solubilized and extracted with 100 µL 
dimethylsulfoxide. After 15 min at room temperature the absorbance was measured at 
570 nm in Microplate Reader (FLUOstar Omega, BMGLabtech, Germany).  
The relative cell viability (%), compared to control cells, was calculated by 
[Absorvance570 nm]sample/[Absorvance570 nm]control*100. 
Data was expressed as mean and standard deviation (mean ± SD) of six independent 
experiments (n=6). Statistical evaluation of data was performed using one-way 
analysis of variance (ANOVA). Tukey–Kramer multiple comparison test (GraphPad 
PRISM 5 software, USA), was used to compare the significance difference between 
groups, a p < 0.05 was accepted as significant. 
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3. Results 
3.1. Characterisation of CaP powders  
The morphological features of all CaP powders are shown in the SEM images of 
Figure 1. The powders consist of small and tightly agglomerated regular shaped 
particles. No significant morphological differences could be perceived among the 
three compositions. The physical properties of the calcined CaP powders, namely the 
specific surface area (SSA) and medium particle size (D50), are presented in Table 2. 
The [Mg-HA] powder presents the smallest medium particle size (D50 = 281 nm) and 
the highest SSA (27.4 m²⋅g-1). The D50 and SSA values measured for [HA] and [Sr-
HA] powders are not much dissimilar, with the last one being slightly coarser and 
consequently presenting the lowest SSA. From the nanometre size of the primary 
particles observed by SEM (Fig. 1) one can easily conclude that the D50 values 
measured by DLS analysis (Table 2) respect to clusters of CaP particles.  
 
 
Fig. 1. SEM micrographs of CaP powders calcined at 800 ºC, (a) [HA], (b) [Mg-HA], (c) [Sr-
HA]. 
 
Table 2. Physical properties, namely specific surface area and particle size, of [HA], [Mg-
HA] and [Sr-HA] 
CaP Powders Specific Surface Area (m²⋅g–1) Particle Size (D50)  (nm) 
[HA] 20.4 320 
[Mg-HA] 27.4 281 
[Sr-HA] 19.7 325 
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Table 1 compares the planed compositions with the results of elemental ICP analysis 
performed to the synthesized powders. A fair agreement between the planned and the 
experimentally obtained values is observed.  
The XRD patterns of the CaP powders calcined at 800 ºC (Fig. 2) reveal that they 
consist essentially of well-crystallized HA and β-TCP phases in different proportions. 
Pure HA phase (# 04-015-7245 [29]) was apparently formed in the stoichiometric 
[HA] composition, while the [Mg-HA] and [Sr-HA] compositions present both HA 
and β-TCP phases. The intensity of β-TCP peaks is higher in the case of [Mg-HA] in 
comparison to [Sr-HA] and appear slightly shifted to higher 2θ (smaller lattice 
parameters) relatively to the standard (# 04-006-9376) [30] card. The relative 
percentages of crystalline phases formed upon calcination were: 100% HA for [HA], 
65% HA+ 35% β−TCP for [HA-Mg] and 92% HA+ 8% β−TCP for [HA-Sr]. Such 
crystalline phase assemblages can be understood considering that both doping 
elements are preferentially incorporated in the β−TCP lattice (especially Mg), 
enhancing its thermal stability [37]. 
Figure 3 compares the FTIR spectra of all the powders calcined at 800 ºC before and 
after LEV adsorption. The presence of vibrational modes of PO4 groups at 475, 574, 
609, 966 and 1020–1120 cm−1 and OH groups (630 and 3570 cm−1) confirm the 
formation of an apatite phase in all the compositions [38], in good agreement with 
XRD results (Fig. 2). The intensity of the FTIR peaks relative to OH groups observed 
at 630 cm−1 (vibrational mode) and at 3570 cm−1 (stretching frequency) for the doped 
samples decreased in comparison to the stoichiometric HA (Fig. 3). The FTIR 
spectrum of LEV within 1100−1400 cm−1 exhibits some characteristic peaks, namely 
carbonyl C=O at 1724 cm−1, aromatic C−H at 2935 cm−1, O−H group of carboxyl 
group at 3265 cm−1, C-N group at 1294 cm−1 due to stretching of amines and halogen 
group [39,40]. The presence of LEV in the LEV-adsorbed CaP powders is confirmed 
by the enhanced noisy appearance of the FTIR spectra between 1200 to 1600 cm−1. 
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Fig. 2. XRD patterns of [HA], [Mg-HA] and [Sr-HA] calcined powders. 
 
 
Fig. 3. FTIR spectra of [HA], [Mg-HA] and [Sr-HA] powders heat treated at 800 ºC before 
and after levofloxacin adsorption. 
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Fig. 4. Zeta potential of the [HA], [Mg-HA] and [Sr-HA] powders before (full bullets) and 
after levofloxacin adsorption (open bullets). The curve for LEV solid particles is also 
presented for comparison purposes.  
 
The results of zeta potential (ZP) presented in Fig. 4 show that the apparent isoelectric 
points (IEPs) are roughly withing the pH gange of 4.8-6.8 and that the entire 
electrophoretic curves of LEV adsorbed samples appear slightly shifted towards the 
basic region and more positive ZP values. There is a good coincidence between the 
electrophoretic curves of LEV sample and LEV-loaded CaP powders. Significant 
diffferences among a given set of ZP curves (before, or after LEV adsorption) can 
hardly be noticed, but in both situations the pure and Mg-doped powders tend to 
exhibit slightly higher absolute ZP values at a given pH in comparison to Sr-doped 
one. The electrical conductivity (µS⋅m−1) values of the diluted suspensions used to 
measure ZP at pH ~7.4 were: 1.75, 2.34, 2.94, for [HA], [Sr-HA], and [Mg-HA], 
respectively.  
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3.2. In vitro levofloxacin release 
 The percentages of drug loading (DL) and corresponding adsorption efficiency (AE) 
of the different CaP powders are presented in Table 3. The DL for pure HA coincided 
well with the planned value of 2.5 wt.%. But the CaP-doped powders were able to 
retain higher doses, with the highest value being observed for LEV[Sr-HA].  
 
Table 3.  DL and AE values (%, w/wparticles) for CaP powders. 
 
 
 
 
Concerning the release kinetics, there was a sudden burst at the first contact with the 
liquid medium in the case of LEV[HA] particles that hindered to establish any reliable 
time dependent relationship. The release data for LEV[Mg-HA] and LEV[Sr-HA] 
could be fitted to a first order model equation to determine the LEV release kinetics 
mechanism. The results presented in Table 4 reveal that the best fitting parameters 
were obtained for LEV[Mg-HA].  
 
Table 4. Fitted parameter values and r2 for the first order equation model used to fit the 
release mechanism of LEV from CaP powders. 
 
The LEV release profiles for all CaP powders are displayed in Fig. 5. Fig. 5a 
highlights the changes occurring within the first hours of contact up to 6 h, while 
Fig. 5b shows the entire picture along the maximum testing period of 168 h. From 
 
CaP Powders %DL (wLEV/wparticles) %AE (wLEV/winitial LEV) 
LEV[HA] 2.51 ± 0.33 18.9 ± 2.5 
LEV[Mg-HA] 2.97 ± 0.33 22.3 ± 2.5 
LEV[Sr-HA] 3.43 ± 0.22 25.8 ± 2.9 
  CaP powders 
Equation Models Models Parameters LEV[Sr-HA] LEV[Mg-HA] 𝑀! = 1 − 𝑒!!" r2 0.626 0.952 
k1st (h-1) 0.644 0.771 
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both plots, it is apparent that for LEV[HA] 100% release occurred  immediately after 
the contact with the medium. Significant amounts (73-84%) of LEV were also 
released from doped CaP powders within the first 30 min. At the 6 h time point, 
complete release was achieved for LEV[Sr-HA], while a plateau at about 94% was 
reached in the case of LEV[Mg-HA], suggesting that about 6% remained adsorbed at 
the surface of the particles even after one week. This apparently enhanced affinity of 
LEV towards the surface of Mg-doped powder is consistent with its smaller particle 
size and consequently its higher specific surface area, as reported in Table 2. It is also 
noteworthy that some of the most significant differences between ZP curves (before, 
or after LEV adsorption) were observed for Mg-doped powder. The fast and complete 
release from LEV[HA] (100% HA) and the slowest kinetics observed for LEV[Mg-
HA] (65% HA+ 35% β−TCP) also suggest a stronger adsorption of LEV at the 
surface of β−TCP particles in comparison to HA phase. This hypothesis needs to be 
further investigated in future works.  
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Fig. 5. Levofloxacin release profiles up to different time periods: (a) 6 h; (b) 168 h. Results 
are expressed as percentages of LEV released in relation to adsorbed antibiotic. Markers and 
error bars represent the means ± SD (n=3). 
 
3.3. Biological properties 
Safety issues must be always considered when developing materials for biomedical 
applications. Here, the antimicrobial susceptibility to LEV and the cytotoxicity of 
LEV-adsorbed CaP powders in L929 (mouse fibroblast cell line) and MG63 (human 
osteoblast cell line) cells were evaluated. 
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3.3.1. Antimicrobial susceptibility 
The results of antimicrobial susceptibility to LEV released from CaP powders after 
48 h are shown on Table 5. The results of antimicrobial susceptibility to LEV released 
from the powders are in agreement to the MIC values of a free LEV solution, 
meaning that powders formulation have not affected LEV antimicrobial effectiveness 
against the studied strains.  
 
Table 5.  Microbiological study related to LEV released from doped CaP powders after 48 h. 
Microorganism 
Strain 
MIC (µg⋅mL−1) 
Levofloxacin LEV[HA] LEV[Mg-HA] LEV[Sr-HA] 
S. aureus  ≥ 0.25 ≥ 0.25 ≥ 0.25 ≥ 0.25 
S. epidermidis  ≥ 2 ≥ 1 ≥ 1 ≥ 1 
E. coli  ≥ 0.03 ≥ 0.03 ≥ 0.03 ≥ 0.03 
 
 
3.3.2. Cytotoxicity evaluation of the CaP powders 
The results of the in vitro biocompatibility of MG63 and L929 cells cultured for 24 h 
in the presence CaP powders with and without adsorbed LEV, and of the cell viability 
assessed by MTT assay, are presented in Fig. 6 and Fig. 7 respectively. No significant 
changes in cell viability were induced by the presence of LEV. Microscopic 
observations of cells in contact with LEV-loaded CaP powders before adding 
MTT showed no morphological changes in both osteoblasts and fibroblasts cells in 
comparison to those exhibited by the same cells in contact with culture medium 
(control) (Fig. 8). This is a clear evidence of the material biocompatibility.  
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Fig. 6. Cell viability MTT assays of MG63 osteoblastic-like cells exposed to [HA], 
LEV[HA], [Mg-HA], LEV[Mg-HA], [Sr-HA], LEV[Sr-HA] powders, culture medium as 
negative control and sodium dodecyl sulphate (SDS) as positive control. Data are expressed 
as mean % of control ± SD of at least three independent experiments. Statistically significant 
difference are marked as * (p < 0.05). 
 
Fig. 7. Cell viability MTT assays of L929 mouse fibroblast cells exposed to [HA], LEV[HA], 
[Mg-HA], LEV[Mg-HA], [Sr-HA], LEV[Sr-HA] powders, culture medium as negative 
control and sodium dodecyl sulphate (SDS) as positive control. Data are expressed as mean % 
of control ± SD of at least three independent experiments. Statistically significant difference 
are marked as * (p < 0.05). 
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Fig. 8. Representative phase contrast microphotographs of MG63 and L929 cells exposed to 
[HA], LEV[HA], [Mg-HA], LEV[Mg-HA], [Sr-HA] and LEV[Sr-HA] powders after 24 h in 
culture. 
 
4. Discussion  
Being a well-known bioceramic, HA can be considered as a convenient drug delivery 
carrier. Doping HA with Mg and Sr ions is likely to further enhance the physico-
chemical and especially the biological properties of the resulting materials [23-25]. 
While pure HA phase was obtained for the stoichiometric composition heat treated for 
1 h at 800 ºC, doping with Mg and Sr ions resulted in the formation of β-TCP as 
secondary phase, which is more abundant in [Mg-HA], Fig. 2.  This is not surprising 
considering the thermal stabilizing effect of Mg towards the β-TCP phase. Mg also 
influences the crystallinity, morphology, crystal size and thermal stability of biphasic 
CaP mixtures [25]. This is due to the preferential replacement of Ca in the β-TCP 
lattice [41,42]. This replacement causes a reduction in the lattice parameters of β-TCP 
induced by the smaller ionic radius of six-fold coordinated Mg2+ (0.65 Ǻ) in 
comparison to that of Ca (0.99 Ǻ) at Ca(5) site of β-TCP structure [43]. This explains 
why the XRD peaks of this phase appear shifted to higher 2θ angles relatively to the 
standard file ( # 04-006-9376) in Fig. 2.   
Despite having a larger ionic radius (1.13 Ǻ), Sr can also replace Ca in both the HA 
and β-TCP structures over the whole range of compositions causing a linear 
expansion of lattice constants and a decreasing trend of crystallite size [44]. It was 
also concluded that Sr tends to preferentially occupy the Ca(1,2,3,4) sites of β-TCP 
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structure [45]. This stabilizing role of Sr towards β-TCP structure justifies the 
formation of trace amount of β−TCP in the [Sr-HA] powder as identified by XRD, 
and further confirmed by FTIR, namely, the decrease in intensity of peaks relative to 
OH groups observed at 630 cm−1 and at 3570 cm−1 for the Mg- and Sr-doped powders 
in comparison to the stoichiometric HA (Fig. 3) [44,46]. The formation of biphasic 
(HA + β−TCP) mixtures are usually preferred for bone graft applications because 
their resorption rate can be tuned to match the bone healing rate allowing to obtain a 
suitable balance between implant degradation and bone regeneration [47].  
The different extents of LEV adsorption at the surface of CaP powders and of its in 
vitro release kinetics are likely to derive from the chemical changes and the lattice 
strains induced by doping. The adsorption capacity of a carrier is known to depend on 
several parameters such as its chemical composition, surface charge density [48], 
porosity [49,50] and specific surface area [51]. The results of XRD and FTIR gathered 
for the synthesized CaP powders did not reveal any changes in crystallinity and phase 
assemblage induced by LEV-loading. The FTIR spectra also confirmed the individual 
features of both powders and LEV, meaning the absence of any chemical interaction. 
These results suggest that LEV has been attached at the surface of CaP powder 
particles by physisorption.  
The use  of particles as drug carriers in drug delivery systems is usually driven by 
criteria that include bioavailability, predictable therapeutic response, greater efficacy, 
safety, and more controlled and prolonged release of drugs over time. HA powders as 
drug carriers aroused greater interest due to its biocompatibility and osteoconductive 
ability [52]. Doping HA with Mg and Sr noticeably affected DL and AE. The three 
different adsorption extents (Table 3) and release profiles (Fig. 5) observed for the 
[HA], [Mg-HA] and [Sr-HA] powders over 1-week period are probably related to 
variations in the contents of HA and β−TCP phases and to some lattice strains derived 
from the ionic substitutions. According to Sasikumar [53], the size and morphology of 
the particles are the most relevant parameters that control the adsorption and release 
kinetics of the drug, as they determine the exposed surface area, the packing 
efficiency and the diffusivity. A more extensive adsorption should be expected for the 
[Mg-HA] powder that presents the smallest particle size and the highest SSA (Table 
2). But the adsorption data reported in Table 3 reveals that the highest LEV dose was 
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retained by LEV[Sr-HA], which exhibits the smallest SSA (close to that of [HA]). 
This means that besides size and morphology, the lattice strains induced doping and 
the variation in crystalline phase contents of the CaP powders also play some role. 
These would help explaining why doped powders were able to adsorb higher LEV 
doses. Moreover, electrostatic interactions constitute an important component of the 
driving forces that lead to adsorption. The small right shifting trend observed in ZP 
curves of CaP particles with adsorbed LEV means that drug species possess a slightly 
cationic character, fostering its electrostatic attraction to the surface. The extent of 
LEV adsorption at the surface of CaP powders is also likely to depend on the surface 
charge density and its distribution, which might vary with the polarity of doping ions. 
The field strength, defined as the charge of an ion divided by the square of its ionic 
radius, is a measure of the strength of the electrostatic field created by the ion. 
Accordingly, the electrical charge around Mg2+ is more locally concentrated than 
around larger alkaline earth cations, enabling a less localized and more uniform 
surface charge distribution in case of Sr-doped powder. This might help explaining 
why the extent of LEV adsorption was highest for LEV[Sr-HA] (Table 3).  
The same ionic field strength considerations were recently suggested to govern the 
non-stoichiometric leaching of alkaline earth ions [54-56]. In those cases, the lower 
field strength associated to the larger size cation revealed a good consistency with the 
enhanced leaching easiness of larger Ba2+ ions to the solution. However, in the present 
case the electrical conductivity values (µS⋅m−1) of the diluted suspensions used to 
measure ZP (Fig. 4) at pH ~7.4 were: 1.75, 2.34, 2.94, for [HA], [Sr-HA], and [Mg-
HA], respectively. These results indicate that the leaching easiness of alkaline earth 
ions in the present case could be ordered as follows: Mg2+ > Sr2+ > Ca2+. This finding 
suggests that factors other than field strength (size of ionic cages in crystalline 
structure, and lattice strains associated to size fittingness) seem to prevail in dictating 
the dissolution behaviour and diffusivity of alkaline earth ions from pure and doped 
HA.  
The same factors, together with the ionic polarity related issues, seem to play also 
important roles in determining the drug adsorption extent and release profiles. The 
non-distorted pure HA lattice adsorbed less and facilitated the LEV desorption 
through a burst type release. The lattice strains derived from the replacement of Ca2+ 
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(0.99 Ǻ) in HA and β-TCP lattices by ions with smaller (Mg2+ = 0.65 Ǻ) and larger 
(Sr2+ = 1.13 Ǻ) sizes are expected to be higher in the case of [Mg-HA]. Forming a 
higher fraction of β-TCP and decreasing the lattice parameters was the 
thermodynamic response of the system to mitigate lattice distortions. The slowest 
release kinetics of LEV[Mg-HA] and the remnant of ~6% LEV in this powder after 
one week are likely related to a higher adsorption strength due to a more localised 
surface charge and the higher specific surface area of this powder. Oppositely, the 
lattice strains combined with a more uniform surface charge distribution seem to be 
the main factors determining the most extensive LEV adsorption by [Sr-HA] (Table 
3), and its release profile from LEV[Sr-HA] (Fig. 5).  
The relatively fast release rates mean that CaP powders alone do not exhibit the 
required features desired for controlled drug delivery systems. Indeed, the ultimate 
target of the present work was to prepare suitable drug carriers. The assessment of the 
drug release and in vitro behaviors aimed at gathering data to support the selection of 
the most promising CaP composition to further develop more complex biomedical 
devices cumulating the two functions: an antibiotic-loaded bone graft, and a drug 
carrier able to deliver it under controlled rates when incorporated into an adequate 
polymer matrix. This will hinder the burst release type profile [57]. The data gathered 
represent an important step towards this goal and to find out suitable solutions for 
chronic osteomyelitis, which is still very difficult to treat and presents a challenge to 
clinicians. For this reason, the bacteria strains that are major causative agents of 
orthopaedic infections (S. aureus, S. epidermidis and E.coli) were selected for the 
microbiological studies. The minimal inhibitory concentration (MIC) of the LEV was 
not affected for the presence of CaP powders. Additionally, the levels of drug released 
from LEV[Sr-HA] (89 µg⋅mL−1), LEV[Mg-HA]  (69 µg⋅mL−1) and LEV[HA] (78 
µg⋅mL−1), are well above for the  LEV MIC values for these strains (Table 5). 
Furthermore, the systems reveal an initial burst release, which is one of the 
requirements for local antibiotic delivery systems (Fig. 5). After 48 h, the 
concentrations of LEV released increased to ~107 µg⋅mL−1, ~84 µg⋅mL−1 and 
~80 µg⋅mL−1 for LEV[Sr-HA], LEV[Mg-HA] and LEV[HA] systems, respectively, 
discarding the possibility of sub-therapeutic or sub-inhibitory concentrations that 
could induce resistance in wound-site bacteria [58]. 
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Biocompatibility is an important aspect to consider regarding the development of any 
antibiotic-loaded material as drug delivery systems. Cytotoxicity assay regarding the 
MG63 (osteoblasts) and L929 (fibroblasts) cells incubated in direct contact with the 
calcium phosphates powders, revealed no significant increase when compared with 
the correspondent plain calcium phosphates (Figs. 6 and 7). Considering the final 
values of LEV released, the biocompatibility evaluation was of utmost importance in 
spite of LEV being referred as a low-toxicity fluoroquinolone [28]. Moreover, all the 
obtained values for CaP powders cell viability where above 70%, when compared to 
medium, which reveals no cytotoxic potential [59].  
 
5. Conclusions 
The results presented and discussed along this work enable to draw the following 
conclusions: 
1. Doping pure hydroxyapatite with elements having smaller (Mg2+ = 0.65 Ǻ) 
and larger (Sr2+ = 1.13 Ǻ) ionic radius than calcium (Ca2+ = 0.99 Ǻ) while 
keeping constant the molar ratio (Ca+M/P = 1.67) favoured the formation of 
β-TCP as secondary phase, but with a contraction and an expansion of the 
lattice parameters, respectively. The greater the difference between the 
exchanged ionic radius the larger was the amount of β-TCP formed and the 
extent of lattice distortions. 
2. The resulting lattice strains, the polarity and diffusivity of the alkaline earth 
ions dictate the extents of physical adsorption of Levofloxacin (LEV) at the 
surface of CaP powders and the easiness of its release through a complex 
interplay. All the CaP powders exhibited burst type release profile, but the 
non-distorted pure HA lattice adsorbed less and facilitated the release in 
comparison to the doped systems. 
3. The in vitro antimicrobial activity of the antibiotic and the biocompatibility of 
all synthesized and LEV-loaded CaP powders were demonstrated. Considering 
the overall release results, the doped powders constitute promising candidate 
filler materials for biopolymer matrices for applications as controlled drug 
release systems.  
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4. The present results constitute a first step of a more extended research program 
aiming at developing an appropriate system for the controlled release of 
antibiotic in the treatment of chronic osteomyelitis.  
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Abstract 
Biphasic [hydroxyapatite (HA) + β-tricalcium phosphate (β-TCP)] calcium phosphate 
powders with partial substitutions of Ca2+ by silver, copper, zinc and strontium ions 
were synthesized by precipitation. The aim was to improve the overall biological 
performance (antimicrobial effect and stimulated osteoblasts proliferation) of the bone 
graft materials made thereof. The prepared powders were calcined and characterized 
by different techniques including X-ray diffraction (XRD), elemental analysis, thermo 
gravimetric and differential thermal analysis (TG-DTA), Fourier Transform Infrared 
Spectroscopy (FT-IR) and Scanning Electron Microscopy (SEM). Rietveld refinement 
was used for quantitative phase analysis. The in vitro biocompatibility and the 
antibacterial activity of the powders were evaluated through the resazurin viability 
test with MG63 cells, and against Escherichia coli and Staphylococcus aureus, 
respectively. The quantitative elemental analysis revealed that only strontium ions 
have been fully incorporated into both HA and β-TCP phases. The in vitro 
biocompatibility with pre-osteoblasic cells was proved for all synthesized powders, 
while only the silver-doped powders exhibited antimicrobial activity against S. 
aureus. The information gathered is of high relevance for designing improved 
calcium phosphate bioceramics. 
 
 
 
 
 
 
 
 
 
Keywords: Biphasic calcium phosphates, ionic substitution, antimicrobial, 
biocompatibility  
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1. Introduction 
The use of synthetic bone substitutes for reconstructive surgery, orthopaedics, 
dentistry, spinal arthrodesis, oral, and maxillofacial surgery is increasing. This is 
particularly true for calcium phosphates (CaPs) due to their similar chemical 
composition to bone mineral [1], and their properties of biocompatibility and 
osteoconductivity [2,3]. These features make them suitable alternative materials to 
autologous bone grafts. The most widely used calcium phosphate-based materials are 
hydroxyapatite [HA, Ca10(PO4)6(OH)2] and β-tricalcium phosphate [β-TCP, 
Ca3(PO4)2]. Both are bioactive but exhibit different biological resorption capacities, 
with HA being virtually non-resorbable, whereas β-TCP is a fully resorbable material 
[4]. Biphasic calcium phosphates (BCP) are mixtures of these phases that combine the 
biodegradability of β-TCP with the strong mechanical properties of HA [5], enabling 
the control of the resorption rate of CaP biomaterials [6] and leading to more complex 
biological and chemical events [7]. An optimal balance (β-TCP/HA) between the 
more stable phase of HA and more soluble TCP favours the gradual dissolution of 
calcium (Ca2+) and phosphate (PO43-) ions in the biological medium and seeding of 
new bone [8]. The superior properties of the BCP materials directly prepared [9] over 
those obtained by mixing two single phases have been also highlighted [10]. 
Bone is not a homogenous material, and besides Ca and P it also incorporates various 
trace elements that play vital roles in its formation, growth, and repair. In recent 
years, various studies demonstrated that adding trace elements to CaP materials can 
lead to controlled degradation, increase of the material’s mechanical strength and 
positively influence the biological response [11,12]. This includes the promotion of 
bone apposition, improving the performance process after implantation [13,14]. 
Among the ionic groups within HA or TCP structure, Ca2+ can be replaced by various 
ions and, in the last decades, particular attention has been given to the strontium ion 
(Sr2+) as it increases osteoclast apoptosis and enhances pre-osteoblast cell 
proliferation and collagen synthesis; consequently, it depresses bone resorption, while 
maintaining bone formation [15]. Ions that have antimicrobial properties, such as Ag+, 
Cu2+ or Zn2+ [16,17], have also been widely studied, since one of the most common 
problems when using implants is the risk of developing post-operatory infections 
and/or rejection. Silver and silver ions are long known to have strong inhibitory and 
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bactericidal effects, as well as a broad spectrum of anti-microbial activities [18]. On 
the other hand, zinc and cooper are important trace elements in human development, 
essential for various metabolic processes: copper plays a role in the cross-linking of 
collagen and elastin of bone [19,20], whereas zinc stimulates the bone formation and 
mineralization [21,22], having a direct specific proliferative effect on osteoblastic 
cells in vitro and it is thought to possess a potent and selective inhibitory effect on 
osteoclastic bone resorption in vivo [23,24].  
Different approaches have been reported in literature for doping CaP powders: 
hydrothermal synthesis [25], sol-gel process [26], neutralization method [17], wet-
chemical method [16], ion exchange method [27] and microwave synthesis [28]. In 
this study, aqueous precipitation was adopted to synthesize ionic (silver, copper, zinc 
and strontium) substituted calcium phosphate powders in order to improve their 
overall biological performance. The effects of doping ions (Sr2+, Ag+, Zn2+ and Cu2+) 
on the crystalline phase assemblage, and on the antimicrobial activity and 
biocompatibility of the powders, were investigated.  
 
2. Materials and Methods 
2.1. Powders preparation  
Calcium nitrate tetrahydrate [Ca(NO3)2.4H2O, Panreac], diammonium hydrogen 
phosphate [(NH4)2HPO4, Panreac], silver nitrate [AgNO3, Alfa Saesar], copper (II) 
nitrate trihydratate [Cu(NO3)2.3H2O, Ridel-de Haën], zinc nitrate hexahydrate 
[Zn(NO3)2.6H2O, Sigma-Aldrich] and strontium nitrate [Sr(NO3)2, Sigma-Aldrich] 
were used as chemical precursors for Ca2+, P5+, Ag+, Cu2+, Zn2+  and Sr2+, 
respectively. The planned doping levels were 3 mol% for Ag+, Cu2+ and Zn2+ ions, 
and 7 and 10 mol% for Sr2+. For all compositions, the concentration of Ca precursor 
was conveniently adjusted to keep a constant molar ratio of (Ca+M)/P = 1.62 (M=Ag, 
Cu or Sr), including a non-doped one used as control. For the Zn-doped composition, 
a total ratio (Ca+Zn)/P = 2.5 was required to grant the formation of a biphasic 
powder. Ionic zinc is described as one of the most effective HA crystal growth 
inhibitors, decreasing its crystallite size and thermal stability [29-32]. Doping with 3 
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mol% zinc and adopting the same conditions (pH, temperature, ripening time), a 
preliminary revealed that β-TCP was the single formed from a solution with a Ca/P 
ratio of 1.62, instead of phase (β-TCP+HA) composition as shown in the XRD pattern 
of the resulting powder (not shown in the manuscript). 
The concentration of P precursor was maintained constant (1.2 M) for all synthises.  
Precipitation took place by slowly adding the P precursor solution to a mixed solution 
of cationic precursors under mechanical stirring (1000 rpm). The pH of the mixed 
solution/suspension was increased and maintained at 9 by adding 8 M NH4OH 
solution (Sigma-Aldrich). The reaction was performed at 90ºC for 2 h under constant 
stirring conditions (1000 rpm). The slurries were poured out from the reactor and the 
precipitated particles were separated through vacuum filtration and dried at 80ºC 
overnight.  
The powders were calcined at 1000ºC in a Thermolab furnace using a heating rate of 
5ºC⋅min–1 followed by a dwelling time of 2 h and then cooled to room temperature 
(RT) at the rate of 5ºC⋅min–1, being hereafter designated just as powders.  The doped 
compositions were labelled as 3Ag, 3Cu, 3Zn, 7Sr, 10Sr, and the non-doped (control) 
as BCP.  
2.2. Powders characterization  
The thermal behaviour of the dried powders was assessed by thermal analysis (TG-
DTA, (DTA, Netzsch STA 409 EP, Germany), using a heating rate of 10 ºC⋅min−1 
between 30 and 1300 ºC in air atmosphere.  
Qualitative crystalline phase analysis of calcined powders was performed using a 
high-resolution Bruker D8 Advance DaVinci diffractometer with Cu Kα radiation (λ 
= 1.5406 Å) produced at 40 kV and 40 mA. Data sets were recorded in the 2θ range 
of 20–80º with a step size of 0.015º 2θ s−1. Collection of XRD pattern data for 
Rietveld refinement studies was performed using a conventional Bragg–Brentano 
diffractometer (Bruker D8 Advance DaVinci, Karlsruhe, Germany) with Ni-filtered 
Cu-Kα radiation, with a linear detector (Lynxeye 1-D) by recording X-ray diffraction 
data within the 2θ range = 20−80º (step size 0.015º and 0.5 s for each step). The 
software TOPAS version 4.2 (Bruker AXS, Karlsruhe, Germany) with the 
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fundamental parameter approach, and the ICDD card numbers of # 04-015-7245 for 
HA [33] and # 04-006-9376 for β-TCP [34] were used for Rietveld refinements.  
The specific surface areas of the powders were obtained according to the Brunauer–
Emmett–Teller method (BET) using a Micromeritics Gemini 2370 V5.00 (Norcross, 
USA) through the gas adsorption measurements, after degassing the powders in a 
Micromeritics Flow Prep 060 (Norcross, USA). Particle size distributions of the 
powders were determined using a light scattering instrument (Coulter LS 230, UK, 
Fraunhofer optical model). The morphology and microstructure of the particles was 
observed by scanning electron microscopy (SEM, Hitachi SU-70, Tokyo, Japan). 
Elemental analyses of doped ions (Sr2+, Ag+, Cu2+ and Zn2+) were determined for all 
powders using inductively coupled plasma (ICP) spectrometry (ICP-OES Jobin Yvon 
Activa M., USA). For this purpose, nitric acid with double-distilled water was used to 
dissolve the powders.  
Infrared spectra were obtained by FT-IR spectroscopy (model MattsonGalaxy S-7000, 
USA). Each starting powder was mixed with KBr in the proportion of 1/150 (by 
weight) for 15 min and pressed into a pellet. Each infrared spectrum was the average 
of 32 scans collected at 2 cm−1 resolution at room temperature (RT). 
2.3. Antimicrobial activity assay 
An antimicrobial activity assay was carried out using pure culture colonies of two 
bacterial strains - E. coli (ATCC 25922) and S. aureus (ATCC 25923) – using an agar 
diffusion method on sterile Mueller-Hinton agar (MHA) plates (BioMerieux, France). 
The strains were grown overnight in PVX plates (BioMerieux, France), and a 
suspension of 0.5 MacFarland was achieved using 0.9% NaCl saline solution. The 
suspension was transferred to the surface of the plate using a sterile swab, and the 
entire surface was swabbed. The compacted powders (0.12 g of sample, 10 mm in 
diameter, pressed by 1200 kg for 20 s) (60 Pa⋅s) were placed on the agar surface and 
incubated for 24 h at 37 ºC. Antimicrobial activity was determined by measuring the 
width of the inhibition zone (mm).   
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2.4. Osteoblastic cytotoxicity and cell proliferation assay  
2.4.1. MG-63 pre-osteoblasts cell culture 
The human osteosarcoma-derived MG-63 cell line (ATCC CRL-1427) was 
maintained at 37ºC in a humidified atmosphere of 5% CO2 in air, in Eagle’s 
Minimum Medium in EBSS (Eagle’s Balanced Salt Solution) supplemented with 1% 
non-essential amino acids (NEAA) and 2 mM L-Glutamine (Gibco BRL, Invitrogen), 
10% (v/v) foetal bovine serum (FBS, Gibco BRL, Invitrogen), 1% (v/v) of a 100 
U×mL-1 penicillin and 100 mg×mL-1 streptomycin solution (Gibco BRL, Invitrogen), 
and 2.2 g×L-1 NaHCO3. Sub-confluent cultures (at 80-90% confluence) were split 1:5 
using a 0.05% trypsin/EDTA solution (Gibco BRL, Invitrogen) at 5% CO2, 37ºC. 
2.4.2. Powders preparation and sterilization  
Each powder formulation was weighted (≈800 µg) and sterilized by autoclave (121ºC, 
20 min) before dissolution in 500 µL MG-63 cell culture medium. Solutions of cell 
culture media supplemented with powder at 1.6 mg×mL-1 were in this way prepared 
for each condition. 
2.4.3. Cytotoxicity and cell proliferation assays  
The resazurin metabolic and colorimetric assay was used to determine the powder’s 
cytotoxicity and their effect on MG-63 pre-osteoblastic cells proliferation. Cells were 
seeded at 2x104 cells×cm−2 in 24-well plates containing the medium with powders, 
and kept at 37ºC in a humidified 5% CO2 and 95% air atmosphere for 14 days. At the 
indicated time points (days in vitro, DIV), cells were incubated for 4 h with fresh 
medium containing 10% of a resazurin solution [0.1 mg×mL−1 resazurin (Sigma 
Aldrich) in phosphate-buffered saline (PBS; Pierce, Perbio)]. Following, resazurin 
reduction to resofurin was spectrophotometrically measured (Infinite M200 PRO, 
Tecan) at 570 and 600 nm. For each time period, the resazurin conversion rate was 
calculated as the O.D. 570/O.D. 600 nm ratio minus the O.D. 570/O.D. 600 nm ratio 
of a negative control (resazurin media incubated for 4 h in the absence of cells). The 
resazurin/resofurin ratio was plotted against incubation time. The experiments were 
carried out in triplicate and data expressed as mean ± standard error.  
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2.4.4. Statistical analysis 
The SPSS package v22 (IBM SPSS Statistics) was used to conduct all statistical 
analysis. All data is expressed as mean ± standard error of the mean. Mixed design 
factorial ANOVA was used to compare variability between and within (along 3DIV, 
7DIV and 14DIV) groups in the metabolic activity assay. Post-hoc analysis 
(Bonferroni) was subsequently performed to compare differences between groups. All 
the requirements were previously verified using the following tests: Kolmogorov-
Smirnov test and Shapiro-Wilk test for normal distribution assessment; Levene’s test 
and Sphericity analysis to assess homogeneity of variances and/or covariances. Partial 
Eta squared (ƞ2p) is described as a measure of size effect.  
 
3. Results and Discussion  
3.1. Powders thermal behaviour 
The effectiveness of ions doping in biphasic calcium phosphate powders, namely ion 
amount incorporation in the lattice structure as well as ion preference for HA or 
β-TCP is the first studying step in order to go further for their biological performance.  
FT-IR spectra of the as dried doped and non-doped powders are displayed in Fig. 1. 
All the powders exhibit similar spectra with the vibrational modes of −PO4 groups 
appearing at 475, 574, 609, 966 and 1020–1120 cm−1 and those of −OH groups of 
apatite phase at 630 and 3570 cm−1. The broad band extending from about 2500 cm−1 
to about 3700 cm−1 corresponds to absorbed water. Other information from the FT-IR 
spectra is the presence of carbonate groups (−CO3) at 1660 cm−1, which are due to the 
adsorption of species remaining from the aqueous precipitation [35]. The bands in the 
1320–1480 cm−1 region and at 875 cm−1 correspond to residual nitrates and ammonia 
(NO3−, NH4+) derived from the reagents used in the synthesis of powders [36]. 
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Fig. 1. FT-IR spectra obtained for as prepared all powders (BCP, 3Ag, 3Cu, 3Zn, 7Sr and 
10Sr). 
 
The thermal behaviour of the powders from 30ºC up to 1300ºC was studied by 
simultaneous thermogravimetric and differential thermal analysis to assess the 
influence of substituting ions on the phase transformation. The results displayed in 
Fig. 2 reveal that doping ions have a great impact on the thermal behaviour of the 
precipitated powders. The mass losses upon heating up to 1300ºC were 25%, 34%, 
38% 23%, 24% and 19% for BCP, 3Ag, 3Cu, 3Zn, 7Sr and 10Sr, respectively. 
Despite these differences, the mass loss occurred in three different consecutive stages 
for all the powders. Within the first stage (30−250ºC), all samples experienced similar 
weight losses of about 5%, attributed to the removal of physically adsorbed water. As 
expected, the corresponding DTA curves reveal endothermic effects peaking at 
~100−120ºC. The second step within the 250−300ºC range is due to the loss of 
chemisorbed residuals, accompanied by a structural reorganization as can be deduced 
from the exothermic peaks in DTA curves [37]. This exothermic effect can be 
attributed to the condensation of hydrogenophosphate ions (HPO4−2), resulting in the 
formation of pyrophosphates (P2O7−4) [38] as given below in equation 1: 
2Ca2+  +  2 HPO42−  → Ca2P2O7  +  H2O    (1). 
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Fig.  2.  TG ( ⎯ ) and DTA ( - - ) plots for different powders. 
 
The release of water as described by Eq. (1) helps explaining the abrupt weight losses 
peaking at ~280–290ºC. These weight losses were higher for 3Ag and 3Cu powders. 
The FT-IR spectra of these two powders (Fig. 1) also confirm the presence of largest 
amounts of absorbed water together with residual species from the synthesis 
(carbonates and nitrates). The incorporation of these dopant ions (Ag+ and Cu2+) in 
the crystalline lattice is more difficult as detailed below (Section 3.3), producing 
vacant positions in the Ca2+ lattice sites. Such structural defects are likely to foster 
water absorption, corroborating the higher weight losses determined by TG analysis 
(Fig. 2). Along the third step (temperatures >300ºC) all the powders experienced 
similar gradual weight losses of ~5%. The thermal curves present inflections centred 
at around 800ºC due to an endothermic event accompanied by a slight weigh loss. 
These effects can be attributed to the formation of β-Ca3(PO4)2 [39] as described by 
equation (2):  
Ca2P2O7 + Ca(OH)2 → Ca3(PO4)2 +  H2O    (2). 
These transformations within the temperature range of 700–800ºC gave raise to 
weight losses of about 1.2% in 7Sr and 10Sr powders, and to smaller variations in the 
other powders. The gradual formation of crystalline HA and β-TCP as temperature 
increases is translated by exothermic effects, which occur earlier in the case of doped 
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powders. The small differences observed are likely due to structural changes 
associated with the incorporation of the various doping ions in the biphasic mixtures. 
The small endothermic peaks appearing at ~1280ºC can be attributed to the α-TCP 
phase transformation. These results reveal that the ions have a great impact on the 
thermal behaviour of apatite powders.  
The FT-IR spectra of doped and non-doped powders after calcination at 1000 ºC are 
displayed in Fig. 3. It can be seen that all the peaks powders corresponding to 
adsorbed water and residual nitrates and carbonates have disappeared and all the 
detected vibrations belong to calcium phosphates (HA and β-TCP). In addition to the 
typical −PO4 and −OH vibrations detected before calcination (Fig. 1), the absorption 
band at 475 cm− 1 is assigned to doubly degenerate ν2 O–P–O bending moment, while 
bands at 575 cm− 1 and 609 cm− 1 are due to −PO43 − vibration modes of HA. The 
absorbance bands at 940 cm− 1 and 970 cm− 1 are due to ν1 non-degenerate P–O 
symmetry stretching mode, 1041 cm− 1 and 1160 cm− 1 denote triply degenerate ν3 
anti-symmetric vibration modes confirming the presence of β-TCP. The comparison 
of the FT-IR spectra from non-doped and doped compositions reveals an attenuation 
of the OH-related bands for doped powders. This intensity attenuation is consistent 
with the lower fraction of HA in doped powers, which is the phase responsible for the 
OH bands. 
 
Fig. 3. FT-IR spectra obtained for all powders (BCP, 3Ag, 3Cu, 3Zn, 7Sr and 10Sr) after 
calcination at 1000ºC. 
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3.2. Physical characteristics  
The values of specific surface area (SSA) measured for all powders, as prepared and 
after calcination at 1000ºC, are displayed in Fig. 4. Significant differences within the 
range of ~27−64 m2⋅g−1 can be observed among the as prepared powders doped with 
different ions. The lower SSA values were observed for 10Sr, followed by BCP, and 
the higher ones were registered for 3Cu and 3Zn. These differences suggest that the 
structural disturbances induced by the incorporation of dopant ions in the lattice are 
strongly dependent on the specific doping ion. On the other hand, calcination at 
1000ºC induced drastic decreases in SSA for all tested powders to values within the 
range ~1−7 m2⋅g−1. Interestingly, the lowest value after calcination was measured for 
3Zn powder that exhibited the highest SSA before calcination. This drastic decrease 
can be attributed to the role of zinc in enhancing mass bulk diffusion and 
densification. Mass diffusion upon calcination is expected to occur especially within 
agglomerates of fine particles as deduced from the relatively high values of SSA [40]. 
Less extensive decreases in SSA were observed for powders doped with other ions. 
 
 
Fig. 4.  Specific surface area of the as prepared and calcined at 1000ºC powders. 
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The SEM micrographs of as prepared powders are shown in Fig. 5, confirming that 
primary particles are sub micrometre and appear strongly agglomerated. This 
agglomeration most probably results from the strong capillary forces among fine 
primary particles upon drying.  
 
 
Fig. 5.  SEM micrographs of the as prepared powders BCP (a), 3Ag (b), 3Zn c), 3Cu (d), 7Sr 
(e) and 10Sr (f) (bar: 5µm). 
 
Particle/agglomerate size distributions (PSD) of calcined powders are presented in 
Table 1. All powder batches exhibit dissimilar size distributions, proving that particle 
agglomeration degree is strongly dependent on the dopant nature. The average 
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particle/agglomerate sizes measured were ~3.9 mm, 7.4 mm, 6.6 mm, 10.0 mm, 2.8 
mm and 4.9 mm for BCP, 3Ag, 3Cu, 3Zn, 7Sr and 10Sr powders, respectively. These 
values confirm that particles are extensively agglomerated in good consistency with 
the morphological features of powders displayed in SEM photographs in Fig. 6.  
 
Table 1. Particle size distributions of BCP, 3Ag, 3Cu, 3Zn, 7Sr and 10Sr powders, after 
calcination at 1000ºC. 
Sample code 
Particle size distribution 
Mean (µm) 
Dxa (µm) (±0.05 µm) 
D10 D50 D90 
BCP 5.8 0.50 3.9 14.3 
3Ag 8.7 0.73 7.4 18.3 
3Cu 7.6 1.0 6.6 15.7 
3Zn 10.2 1.4 10.0 18.7 
7Sr 3.5 0.5 2.8 8.0 
10Sr 4.8 0.6 4.9 9.0 
 
a Dx is the particle diameter at or below which there is the amount x (vol.%) of particles in the 
cumulative (from 0 to 100%) particle size distribution curve. 
 
It is also evident that morphological features of powders strongly depend on the 
specific doping element used, an effect that is likely associated to ion ability for bulk 
diffusion upon calcination, accentuating the neck formation among the primary 
particles. The agglomeration degree is apparently more severe in the case of the 
powder doped with zinc (3Zn), as expected, considering its lowest SSA value after 
calcination and the greater variation upon the heat treatment as referred above. This is 
the reason why zinc oxide is often used as sintering additive in diverse ceramic 
compositions. Silver seems to favour the formation of more elongated particle shapes, 
in contrast to the more rounded morphologies observed for the other compositions. 
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Fig. 6. SEM micrographs of the powders calcined, BCP (a), 3Ag (b), 3Zn c), 3Cu (d), 7Sr (e) 
and 10Sr (f) (bar: 5µm). 
 
3.3. Phases identification and quantitative phases analysis  
The effect of doping ions on crystalline phase assemblage was investigated after heat-
treatment at 1000ºC. The XRD patterns of powders presented in Fig. 7 confirm the 
presence of two phases (HA and β-TCP) in all synthesised powders. The diffraction 
peaks are sharp and well defined. A detailed observation enables detecting slight 
shifts in the peak positions of the doped compositions in comparison to non-doped 
BCP. The shifts are towards the left or the right, when the ionic radius of dopant is 
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larger or smaller, respectively. The XRD data was refined assuming, for HA, the 
space group P63/m and the unit cell and structural parameters reported by 
Arcos et al. [33], and for β-TCP, the space group R3c and the parameters reported by 
S. Nicolopoulos et al. [34]. 
 
Fig. 7. XRD patterns of powders (BCP, 3Ag, 3Cu, 3Zn, 7Sr and 10Sr). 
 
 
Fig. 8 presents the refined XRD for BCP powder as a representative example of all 
powders, being the refined lattice parameters for all compositions studied presented in 
Table 1.  For BCP, the refined cell parameters were a = b = 9.414432 Å, c = 6.876729 
Å, α = β =90º, and γ = 120º in HA phase and a = b =10.43256 Å, c = 37.35914 Å, α = 
β = 90º, and γ = 120º in β-TCP phase.  
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Fig. 8. Rietveld analysis patterns of powder diffraction data of non-doped powder (BCP). 
Blue line: calculated intensities; Red line: observed intensities. The difference between the 
observed and calculated intensities is plotted below the profile. 
 
The refined lattice data for all doped (3Ag, 3Cu, 3Zn, 7Sr, 10Sr) and non-doped 
(BCP) powders are plotted in Fig. 9. As it can be seen, all doped compositions present 
slight changes in lattice parameters in comparison to BCP. The lattice parameters are 
higher for powders containing Ag+ and Sr2+, meaning that the substitution of Ca2+ 
(0.099 nm) in the HA and β–TCP lattices by ions with larger radii, Sr2+ (0.12 nm) and 
Ag+ (0.126 nm) makes the lattices to expand. The effect becomes even more evident 
for the higher strontium content (10Sr). Oppositely, the lattices of powders doped 
with elements of smaller ionic radii, Cu2+ (0.072 nm) and Zn2+ (0.075 nm) underwent 
slight decreases in their cell parameters. These results are in good agreement with 
previous reports, where the authors shown that Zn2+ and Cu2+ substitute Ca2+ sites in 
HA or β–TCP lattice, resulting in a shrinkage of the unit cell parameters due to the 
smaller size of dopant cations when compared to calcium ion [17,41]. Increases in cell 
parameters were observed for HA and β–TCP doped with larger sized ions than 
calcium [41,42]. Moreover, from the results presented in Fig. 9, there seems to be a 
tendency for these doping elements to enter preferentially in the β–TCP lattice rather 
than HA. 
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Fig. 9. Influence of doping ions (Ag, Cu, Zn and Sr) on the lattice a- and c-axis parameters 
and the unit cell volumes of HA (a, b) and β-TCP (c, d). Lattice parameters measured for BCP 
(biphasic calcium phosphate): a = 9.414432 Å, c = 6.876729 Å for HA; a = 10.43256 Å, c = 
37.35914 Å for β-TCP. 
 
 
Table 2 compares the planned and experimentally determined ions content (by ICP 
analysis) in the different powder compositions, which together with changes in the 
unit cell parameters (Fig. 9) confirm the incorporation of dopant ions into the HA and 
β-TCP lattices. The quantitative phase analysis data from Rietveld refinement is also 
reported, confirming the presence of both HA and β-TCP phases in all compositions. 
The amount of HA is highest for the control BCP sample, thus, the amounts of β-TCP 
increase in detriment of HA in doped compositions, but not in the same extent.   
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Table  2. Compositions planned and experimentally obtained from ICP analysis. The amounts 
of HA and β-TCP were determined by Rietveld refinement. 95% repeatability limits of the 
phase quantification should be considered to be close to ±1% [43].  
Sample 
Code 
(Ca+M)/P 
molar 
ratio 
Ca/P 
molar 
ratio 
Compositions (mol%) 
  
Wt. % of phase 
composition (±1) Planned Experimental (± 0.03) 
M  M  
HA β–TCP 
Ag Cu Zn Sr Ag Cu Zn Sr 
BCP 1.62 1.62 0 0 0 0 0 0 0 0 83.8 16.2 
3Ag 1.62 1.57 3 0 0 0 0.8 0 0 0 66.1 33.9 
3Cu 1.62 1.57 0 3 0 0 0 2.6 0 0 50.0 50.0 
3Zn 2.50 2.42 0 0 3 0 0 0 2.9 0 46.7 53.3 
7Sr 1.62 1.50 0 0 0 7 0 0 0 7.0 64.1 35.9 
10Sr 1.62 1.45 0 0 0 10 0 0 0 10.1 66.9 33.1 
 
The unit cell of HA, Ca10(PO4)6(OH)2, contains 10 Ca2+ in two different positions: the 
Ca(1) site, where four cations are connected with nine oxygen atoms (mean Ca(1)–O 
distances 0.255 nm), and the Ca(2) site, where six cations are connected with seven 
oxygen atoms (mean Ca(2)–O distance 0.245 nm) [44-46]. When doping ions are 
added to the structure, Ca(1) atoms (aligned in columns within the HA) are preferably 
substituted by the smaller or slightly larger ones in low concentrations. As stronger 
interactions are present in these sites, any small change in the metal–oxygen 
interactions affects the entire lattice [46]. The Ca(2) atoms, displayed in consecutive 
staggered layers, allow random local substitutions without compromising the whole 
structure, consequently, larger cation, even at high concentrations, tend to substitute 
Ca(2) [46].  
On the other hand, the crystal structure of β-TCP possesses five different Ca sites in 
its structure. According to Ananth et al. [47], Ca(4) and Ca(5) in β-TCP structure are 
distinct from the other three sites and are prone for substitution with smaller cations. 
Ca(4)–O(9) bond length is 0.304 nm, longer than the normal Ca–O bonds length of 
0.240 nm, with Ca(5) sites surrounded by O in six fold distorted octahedral 
coordination. All these structural characteristics make small ionic substitutions 
possible.  
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In the present case, not only dopant amounts are varied as well as their size is 
different. So, the substitution level of Ca2+ in the Ca(I) or Ca(II) position was 
responsible for the difference in the percentage transformation of HA to β-TCP phase. 
Doping elements with ionic radii smaller than Ca tend to preferentially occupy Ca 
lattice places in the structure of β-TCP, stabilizing it and favouring the formation of 
higher percentages of this phase. Oppositely, the substitution of Ca2+ by larger size 
Sr2+ or Ag+ ions leads to denser atomic packings, causing retardation of crystal 
growth. This tends to hinder the formation of β-TCP [48] as confirmed by Rietveld 
refinement results, where higher HA contents were observed in powders doped with 
Sr2+ or Ag+ (Table 2).  
The amounts of reagents were planned by assuming that doping ions (silver, copper, 
zinc and strontium) would substitute equivalent amounts of calcium ions. A good 
matching between planned and experimentally measured values is observed for 
strontium that has an ionic radius ~21% larger in comparison to Ca2+. However, when 
the ionic size mismatch increases to ~27% (Ag+) the degree of substitution becomes 
more difficult. The data reported in Table 2 reveals that only about 27% of the 
planned Ag+ has entered the crystalline lattices. This discrepancy in the incorporation 
hindrance can be caused by silver´s ionic size and its fusion temperature (Tfus = 961.8 
ºC), that can lead the ions to leave the structure during the calcination process [49]. 
The measured concentrations are close than the planned ones for cooper (~87%) and 
zinc (~97%), even though in this last case a total ratio (Ca+Zn)/P = 2.5 had to be used 
to grant the formation of a biphasic powder, as stated in the experimental section 
(2.1.1. Powders preparation). As mentioned in the existing literature, zinc tends to 
inhibit the formation of HA phase, reducing the crystallite size and decreasing thermal 
stability [29,30]. 
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3.4. Biological Properties 
The antimicrobial activity of powders against the two most common bacterial strains 
that frequently cause infection in humans, Gram-negative E. coli (ATCC 25922) and 
Gram-positive S. aureus (ATCC 25923), were qualitatively evaluated. The results of 
the disk diffusion tests showed that only 3Ag powders affect the S. aureus (Fig. 10a), 
being the average inhibition zone around 2 mm. The fact that the antimicrobial 
activity has only been verified against one of the bacterial strains can be explained by 
differences in their cell envelope structures, since S. aureus is Gram-positive and E. 
coli is Gram-negative bacteria. It was difficult to establish any bactericidal effect for 
the powders doped with zinc and copper (results not shown). There are three main 
mechanisms to explain the antimicrobial activity of these ions [50-53]. First, metal 
ions could bind to specific groups of the protein chains deactivating them. Second, 
metal ions can interact with microbial membrane and induce structural and 
permeability changes. Finally, metal ions could interact with microbial nucleic acids, 
preventing microbial replication.  
 
Fig. 10. Biological activities of the sintered powders. (a) Photographs of antimicrobial test for 
3Ag against S. aureus (ATCC 29213). Bar: 1 cm. (b) Influence of BCP, 3Zn, 3Ag, 3Cu, 7Sr 
and 10Sr on the metabolic activity of MG-63 pre-osteoblastic cells. Results are depicted as 
mean final optical density (O.D.f) ± SE (n = 3-4). Statistically significant differences of 
metabolic activity were found throughout cell culture (F(2,18) = 103.097; p = <0.001 ƞ2p = 
0.920; Bonferroni post-hoc analysis: 3 DIV vs 7 DIV and 14 DIV p = <0.001; 7DIV vs 
14DIV p = 0.003). No statistically significant differences between groups (F(6,9) = 3.019; p = 
0.067 ƞ2p = 0.668). 
Chapter 3 
 
 
101 
The alterations in the metabolic activity of pre-osteoblastic cells, assessed through the 
reversible resazurin assay that indirectly measures the number of live cells, is 
displayed in Fig. 10b. Results indicate that doping ions (Ag+, Zn2+, Cu2+ and Sr2+) do 
not exert any cytotoxic effects on MG-63 pre-osteoblastic cells. Similar levels of 
resazurin reduction by cells exposed to the powders or not (control cells) were 
registered on day 3. Differences began to be noticed from day 7 in culture. The most 
severe decrease in the proliferative response occurred for cells grown with the BCP 
and 3Zn at both time points (7 and 14 DIV). In opposition, the 3Ag, 3Cu, 7Sr and 
10Sr present the highest levels of resazurin conversion on day 14. These findings 
demonstrated that doping biphasic calcium phosphate powders with these ions 
stimulate cell growth. Strontium is already known to increase osteoblastic 
proliferation [15,42,54]. According to Caverzasio [55], Sr2+ may directly interact with 
the calcium sensing receptor in osteoblast cells to trigger mitogenic signals, via 
activation of the protein kinases ERK, PKC and PKD signaling pathways, resulting in 
increased cell division. Nevertheless, the mechanisms by which Ag+ and Cu2+ ions 
affect the biological response are still unclear and require further investigation.  
 
4.  Conclusions  
Biphasic calcium phosphates doped with different ions were successfully synthesized 
by precipitation from all compositions, with the crystalline phase assemblages and the 
biological performances were strongly depending on the specific dopant ions. Sr2+ 
was the only one capable to enter totally in the lattice structures of both HA and 
β-TCP phases replacing calcium ions. The results indicate that the ability to substitute 
Ca2+ by other ions in the HA or β–TCP lattice structures is greatly dependent on the 
ionic size, with larger ionic radii mismatches resulting in less extensive substitution 
degrees. Only silver-doped powder exhibited antimicrobial activity against S. aureus, 
while powders doped with copper and zinc did not show any antimicrobial effects. 
Good osteoblastic biocompatibility was demonstrated for Ag, Cu and Sr-substituted 
powders. These findings are important tips for designing better synthetic bone graft 
substitute materials and constitute a first step of a more extended research program 
aiming to develop appropriate powders for biomedical applications including 
osteoregeneration, providing a good environment for osteoblasts.  
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Abstract 
The present work reports on the fabrication of 3-D porous calcium phosphate 
scaffolds by robocasting from biphasic (HA/β-TCP ≈ 1.5) powders, undoped and co-
doped with Sr and Ag. Scaffolds with different pore sizes and rod diameter of 410 μm 
were fabricated and sintered at 1100 ºC. The size and morphology of the powder 
particles, and the concentrations of the processing additives, were shown to play 
major roles in the robocasting process. For all pore sizes tested, the compressive 
strength of scaffolds was comparable to or even higher than that of cancellous bone, 
and mechanical data could be systematically correlated with the porosity fraction. Co-
doping the starting powders with Sr and Ag enhanced the mechanical strength of 
scaffolds, conferred good antimicrobial activity against Staphylococcus aureus and 
Escherichia coli, and did not induce any cytotoxic effects on human MG-63 cells. 
Furthermore, the co-doped powder was more effective in inducing pre-osteoblastic 
proliferation. 
 
 
 
 
 
 
 
 
 
 
Keywords: Robocasting, Biphasic calcium phosphate, Bone scaffolds, Mechanical 
properties.   
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1. Introduction 
Calcium phosphate (CaP) bioceramics, both of natural and synthetic origin, are among 
the biomaterials with higher bone replacement potential [1,2]. In this regard, 
hydroxyapatite (HA) has received particular attention due to its biocompatibility, 
bioactivity, osteoconductivity and osteophilic nature [3,4]. The HA inability to resorb 
is however a weak point [5], and hence, biodegradable systems that do not require 
surgical removal have been emphasized [6-8]. Biphasic calcium phosphates (HA + 
β−TCP) possess a set of attractive characteristics, including: (a) different dissolution 
rates (HA, non-resorbable and β−TCP, resorbable); (b) rapid bone formation around 
the implant site; and (c) similarity to the inorganic component of bones [9-11]. 
In recent years, ionic substitutions in calcium phosphates (CaP) ceramics have been 
subject of massive interest owing to the critical roles these ions play in the biological 
process after implantation. For example, strontium (Sr2+) increases osteoclast 
apoptosis and enhances pre-osteoblastic cell proliferation and collagen synthesis, and 
consequently depresses bone resorption, while maintaining bone formation [12]. 
Therefore, Sr-substituted CaPs are expected to produce enhanced biological and 
chemical responses in the body [13,14]. Since one of the most common problems 
when using implants is the risk of developing post-operatory infections and/or 
rejection, some attention has been turned to silver (Ag+), an element with a long 
history in medicine as an antibacterial agent [15,16]. Accordingly, silver and silver 
ions are known to have strong inhibitory and bactericidal effects, as well as a broad 
spectrum of anti-microbial activities [17]. 
The strategies to regenerate bone tissues include the use of scaffolds with suitable 3D 
porous structures to act as temporary templates for migration, proliferation and 
differentiation of osteoblasts, which are the cells responsible for new bone formation 
[18–20]. Porosity and pore size of biomaterial scaffolds play a critical role in bone 
formation in vitro and in vivo. Porosity is necessary for bone tissue formation since it 
allows migration and proliferation of osteoblasts and mesenchymal stem cells, matrix 
deposition in the empty spaces, as well as vascularization. Several studies investigated 
the effects of pore size on the regeneration efficacy of mineralized bone. Altogether, 
results indicate that a minimum pore size of about 100 µm is required for cell 
migration and transport [21].  
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Current bone regeneration strategies are mainly based on the development of 
scaffolds, but the difficulties of manufacturing porous structures with suitable 
characteristics (geometry and size of pores, their spatial distribution, etc.) have been 
the major obstacles and constitute some of the greatest challenges in this area. Solid-
freeform fabrication (SFF) techniques can overcome these obstacles, producing 
scaffolds with customized shape and predefined internal morphology, by building the 
structure layer-by-layer following a computer design, without the need for subsequent 
machining. Among these, robocasting, also referred to as direct-write assembly 
(DWA), is an additive manufacturing technique based on the extrusion of a 
concentrated colloidal suspension (ink/paste) [22,23]. The extruded continuous 
filament has pseudo-solid behaviour and is able to support its own weight during the 
assembly of the 3-D structures layer-by-layer. This technique has been successfully 
applied to the fabrication of bone tissue engineering scaffolds from both calcium 
phosphates and bioglasses [23-28]. Porosity in robocast scaffolds can be tailored on 
three length scales: macro- (greater than 100 µm), micro- (1–30 µm), and submicron 
(less than 1 µm). Macroscale porosity is introduced directly by the robocasting 
process as it draws successive layers. Robocast rods arranged in latticed patterns 
create macroporous pathways in three dimensions. By varying the rod spacing and 
size, these pathways can be precisely constructed to produce highly uniform 
macropores [29]. 
The main aims of the present study are: (i) the synthesis of CaP powders with 
antimicrobial and osteoblastic stimulation properties; (ii) developing high 
concentrated colloidal paste-like systems from these powders with the appropriate 
viscoelastic properties for scaffolds fabrication by robocasting, with controlled pore 
size (macroporosity) for bone regeneration and tissue engineering applications; (iii) 
correlate the porosity with the mechanical performance of the scaffolds. 
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2. Experimental procedure 
2.1. Synthesis and characterisation of the starting powders 
Calcium nitrate tetrahydrate [Ca(NO3)2·4H2O, Quality Chemicals, Spain], strontium 
nitrate [Sr(NO3)2, Sigma-Aldrich, Germany] and silver nitrate [AgNO3, Alfa Aesar, 
Germany] were used as cationic precursors for Ca, Sr and Ag. Diammonium 
hydrogen phosphate solution [(NH4)2HPO4, Quality Chemicals, Spain], was used as 
the source of phosphate. 
The synthesis of the starting biphasic calcium phosphate powders with a planned total 
cationic/anionic molar ratio of 1.62 was envisaged in this work, one undoped (BCP) 
and the other a co-doped with 7 mol% Sr2+ and 3 mol% Ag+ (BCP-7Sr3Ag). For this, 
solutions of P and cationic species were firstly prepared with molar concentrations of 
1.2 M and 1.94 M, respectively. The precipitation was carried out by slowly adding 
the required volume of P solution to a given volume of each continuously stirred 
(1000 rpm) cationic solution. The pH of the mixed system was increased to 9 and 
maintained at this value by adding the required amounts of 8 M ammonium hydroxide 
[NH4OH, Sigma-Aldrich, Germany] solution. The reaction was performed at 90ºC for 
2 h under constant stirring conditions (1000 rpm). 
The suspensions were poured out from the reactor and the precipitates separated 
through vacuum filtration and dried at 100 ºC overnight. The prepared powders were 
calcined at 1100 ºC in a Thermolab furnace (Pt30%Rh/Pt6%Rh thermocouple) using 
a heating rate of 5 ºC×min–1 followed by a dwelling time of 2 h at that temperature, 
and then cooled to room temperature (RT). The calcined powders were then dry 
milled for 45 min in a high energetic ball milling up to achieving mean particle sizes 
of ~1 µm. 
The phase assemblage of calcined powders was studied using a High Resolution X-
ray Diffractometer (PANalytical X'Pert PRO) with Cu Kα radiation (k = 1.5406 Å) 
produced at 45 kV and 40 mA, which scanned the diffraction angles (2θ) between 20º 
and 80º with a step size of 0.01º, time per step 198,6450 s. A spectra-fitting software 
called HighScorePlus was utilised to quantify the percentages of crystalline phases for 
the calcined powders. This software requires crystallographic information files to fit 
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and quantify each specific phase within a XRD spectrum. The database utilized was 
PDF-47 2015 RDB, and the files utilised in the evaluation of the powders were; HA 
(# 01-079-5683) [30], β–TCP (# 04-014-2292) [31].   
Particle size and particle size distributions of all powders were evaluated using a 
particle size analyser (COULTER LS230, UK) with Fraunhofer optical model. 
 
2.2. Preparation and rheological characterization of the inks 
The CaP inks for robocasting were prepared by dispersing the starting powders in 
aqueous media in the presence of some processing additives (dispersant, viscosifier 
agent and jellifying agent). Initially, high concentrated aqueous suspensions (55 vol.% 
and 60 vol.%, from BCP and BCP-7Sr3Ag powders, respectively) were prepared by 
adding 0.4 wt.% (relative to the dry mass of solids) of ammonium polycarbonate 
dispersant (Targon 1128, BK Ladenburg, Germany). Different amounts (1−2 % based 
on mass of solids) of hydroxypropyl methylcellulose (HPMC, average Mn~10,000, 
Sigma-Aldrich) were also added to increase the intrinsic viscosity of the liquid. The 
subsequent addition of varied amounts (0.1−1 %, based on mass of solids) of 
polyethylenimine (PEI, 50% w/v in water, Sigma-Aldrich) as cationic jellifying agent 
enabled adjusting the viscoelastic behaviour of the suspensions. The most drastic 
changes on the rheological properties occurred in the presence of 0.3 wt.% PEI. The 
resulting inks were suitable for robocasting. Since both HPMC and PEI were added as 
aqueous solutions, the final solid loadings of the inks decreased to 48 vol.% and 53 
vol.% for BCP and BCP-7Sr3Ag, respectively. After each component addition, the 
system was placed in a planetary centrifugal mixer (ARE-250, Thinky Corp., Tokyo, 
Japan) for a few minutes to improve the homogeneity of the mixture.  
Rheological measurements at different steps of ink preparation (after each 
incremental amount of the processing additives), were made using a Kinexus Pro+ 
Rheometer (Malvern, USA). The apparent viscosity of the ink was measured in 
viscometry mode using a cone and plate sensor system (4º/40 mm) and 150 µm gap 
size. The visco-elastic properties were assessed using the same rheometer equipped 
with plate and plate sensor (20 mm), with 1 mm gap size, in the oscillatory mode 
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using a solvent trap (a metal ring with di-ionized water) to prevent water evaporation 
from the samples during the tests.  
In order to understand the specific interactions between the processing additives and 
the surface of calcium phosphate powder particles, zeta-potential measurements were 
evaluated (Malvern Zeta sizer, Nano ZS, Malvern, Worcestershire, UK) at several pH 
values. A dilute suspension was firstly prepared by ultrasonically dispersing the 
testing powder for 10 min, followed by 30 min rest for allowing the larger particles to 
settle. An aliquot taken from the supernatant was then used to measure the zeta 
potentials at different pH values. The pH of the suspensions was adjusted with 0.1 M 
HCl and 0.1 M NaOH, for decreasing and increasing pH runs, respectively. 
 
2.3. Scaffolds printing by robocasting  
3D BCP scaffolds consisting of a mesh of ceramic rods were constructed layer-by-
layer via direct write assembly of the ink using a robotic deposition device (3-D Inks, 
Stillwater, OK) as illustrated in Fig. 1. The ink was deposited through cylindrical 
metallic deposition nozzles (EFD Inc., East Providence, RI) with a diameter d = 410 
μm, at a printing speed of 10 mm⋅s –1 (Fig. 1a). The external dimensions of the 
scaffolds were about 9×9×3 (Fig. 1b) in a total of 12 layers. Each structure consisted 
of 9 individual scaffolds of 3×3×3 mm (Fig. 1c-d), which were produced with six 
different pore sizes of 120, 180, 220, 300, 350 and 500 μm. The deposition was 
performed into a paraffin oil bath to ensure uniform drying during assembly. The 
samples were removed from the bath and dried in air at RT for 24 h, heat treated at 
the heating rate of 1ºC⋅min–1 up to 400ºC, and held at this temperature for 1 h to 
burnout the organics. The samples were subsequently sintered at 1100 ºC for 2 h 
using a heating rate of 5 ºC⋅min–1.  
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Fig. 1. Robocasting fabrication process: the ceramic scaffold is built layer-by-layer from a 
computer design (a). The external dimensions of the scaffolds were about 15×15×3 (b) in a 
total of 12 layers being 9 individual scaffolds of  3×3×3 mm (c) and (d). 
 
2.4. Microstructural and mechanical characterization  
The density of the scaffolds, ρs, was determined from the mass and external 
dimensions of the structures of at least 25 samples with regular shape. The porosity, 
P, was then calculated according to equation 1:  
P = 1 – (ρs /ρth) = 1 − ρrel                                                               (1) 
where ρth is the theoretical density, calculated taking into account the percentage of 
each phase (HA and β−TCP) in each composition, and considering 3.13 g⋅cm−3 and 
3.12 g⋅cm−3 the theoretical density values for pure BCP and BCP-7Sr3Ag, 
respectively.  
The morphological features and the microstructure of the sintered scaffolds were 
analysed by scanning electron microscopy (SEM, Hitachi SU-70, Hitachi High-
Technologies Europe, GmbH, Germany), under an acceleration voltage of 25 kV and 
a beam current of 10 µA. Internal dimensions of the different scaffolds fabricated (rod 
diameter, spacing between rods, etc.) were determined as the average of minimum 25 
direct measurements performed on SEM images, using the ImageJ Software. These 
dimensions were then used to estimate the macroscopic, pre-designed porosity from 
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geometrical considerations assuming an ideal network of interpenetrating cylinders 
[32]: 
P = 1− !! !! !!!!!!! ! ! !! ≅ 1− !! ! ! !!      (2) 
where d, h, and s are the scaffold dimensions as defined in Fig. 1a and vi is the 
volume of the cylinders' intersection that can be neglected for small (≤ 20%) layer 
overlaps since it is well below 1% of the total volume of the scaffold. 
The compressive strength of the sintered scaffolds was determined by performing 
uniaxial tests on approximately cubic blocks of 3 mm side (Fig. 1c). The tests were 
carried out in air on a universal testing machine (AG-IS10kN, Shimadzu, Kyoto, 
Japan) at a constant crosshead speed of 0.6 mm⋅min–1. Tests were performed in the 
direction perpendicular to the printing plane. The load–displacement curves were 
registered during the tests. The compressive strength of the structure was calculated as 
the maximum applied load divided by the measured square section of the sample. A 
minimum of 25 samples were tested in each testing condition in order to get 
statistically reliable values. Weibull statistics [33] was used for the analysis of the 
resulting strength data, where failure probability, P, is given by  
P = 1 – exp [- (σ /σ0)m]                                                             (3) 
where m is the Weibull modulus, which is a measure of sample reliability, and σ0  is 
the central value of the strength distribution.  
 
2.5. Antimicrobial activity assay of powders 
An antimicrobial activity assay was carried out using pure culture colonies of two 
bacterial strains - E. coli (ATCC 25922) and S. aureus (ATCC 25923) – using an agar 
diffusion method on sterile Mueller-Hinton agar (MHA) plates (BioMerieux, France). 
The strains were grown overnight in PVX plates (BioMerieux, France), and a 
suspension of 0.5 MacFarland was achieved using 0.9% NaCl saline solution. The 
suspension was transferred to the surface of the plate using a sterile swab, and all the 
surface was swabbed. The compacted powders (0.12 g of sample, 10 mm in diameter, 
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pressed by 1200 kg for 20 s) (60Pa.s) were placed on the agar surface and incubated 
for 24 h at 37 ºC. Antimicrobial activity was determined by measuring the width of 
the zone of inhibition (mm).  
  
2.6. Osteoblast-like cytotoxicity and cell proliferation assay  
2.6.1. MG-63 cell culture 
The human osteosarcoma derived MG-63 cell line (ATCC CRL-1427) was 
maintained at 37ºC in a humidified atmosphere of 5% CO2 in air, in Eagle’s 
Minimum Medium in EBSS (Eagle’s Balanced Salt Solution) supplemented with 1% 
NEAA and 2 mM L-Glutamine (Gibco BRL, Invitrogen), 10% (v/v) fetal bovine 
serum (FBS, Gibco BRL, Invitrogen), 1% (v/v) of a 100 U⋅mL−1 penicillin and 100 
mg⋅mL−1 streptomycin solution (Gibco BRL, Invitrogen), and 2.2 g⋅L−1 NaHCO3. Sub-
confluent cultures (at 80−90% confluency) were split 1:5 using a 0.05% 
trypsin/EDTA solution (Gibco BRL, Invitrogen) at 5% CO2, 37ºC. 
 
2.6.2. Powders preparation and sterilization  
Each powder formulation (BCP and BCP-7Sr3Ag) was weighted (≈800 µg) and 
sterilized by autoclave before dissolution in 500 µL MG-63 cell culture medium. 
Solutions of cell culture media supplemented with powder at 1.6 mg⋅mL−1 were in this 
way prepared for each condition. 
 
2.6.3. Cytotoxicity and cell proliferation assays  
The resazurin metabolic and colorimetric assay was used to determine the powder’s 
cytotoxicity and their effect on MG-63 osteoblast-like cells proliferation. Cells were 
seeded at 2x104 cells⋅cm−2 in 24-well plates containing the medium with powders, and 
kept at 37ºC in a humidified 5% CO2 and 95% air atmosphere for 14 days. At the 
indicated time points (days in vitro, DIV), cells were incubated for 4 h with fresh 
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medium containing 10% of a resazurin solution [0.1 mg⋅mL−1 resazurin (Sigma 
Aldrich) in phosphate-buffered saline (PBS; Pierce, Perbio)]. Following, resazurin 
reduction to resofurin was spectrophotometrically measured (Infinite M200 PRO, 
Tecan) at 570 and 600 nm. For each time period, the resazurin conversion rate was 
calculated as the O.D. 570/O.D. 600 nm ratio minus the O.D. 570/O.D. 600 nm ratio 
of a negative control (resazurin media incubated for 4 h in the absence of cells). The 
resazurin/resofurin ratio was plotted against time of incubation. The experiments were 
carried out in triplicate and data expressed as mean ± standard error.  
 
2.6.4. Statistical analysis 
The SPSS package v22 (IBM SPSS Statistics) was used to conduct all statistical 
analyses. All data is expressed as mean ± standard error of the mean (SEM). Mixed 
design factorial ANOVA was used to compare variability between and within (along 
3DIV, 7DIV and 14DIV) groups in the metabolic activity assay. Post-hoc analysis 
(Bonferroni) was subsequently performed to compare differences between groups. All 
the requirements were previously verified using the following tests: Kolmogorov-
Smirnov (KS) test and Shapiro-Wilk (SW) test for normal distribution assessment; 
Levene’s test and Sphericity analysis to assess homogeneity of variances and/or 
covariances. Partial Eta squared (ƞ2p) is described as a measure of effect size. 
 
2.6.5. Morphological analysis of MG-63 cells cultured in the 
presence of powders  
At the end of the viability assay (14th day), cells were washed with PBS, fixed in a 4% 
paraformaldehyde PBS solution and further washed three times with PBS.  
Afterwards, cells morphology was evaluated by phase contrast (PhC) microscopy in 
an inverted Olympus (Hamburg, Germany) IX81 epifluorescence microscope, as 
before [34].  
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3. Results and discussion  
3.1. Powders characterization 
Ceramics scaffolds based on biphasic calcium phosphate have a greater potential for 
bone tissue since they have the ability to improve the formation of new bone inside 
the implanted scaffolds. Doping biphasic calcium phosphate with Sr and Ag ions is 
expected to further enhance the physico-chemical and particularly the biological 
properties of the resulting materials [35-37]. 
The crystalline phase assemblages of powders calcined at 1100ºC are presented in 
Fig. 2. The X-ray diffraction patterns confirm the formation of the HA phase (ICDD 
# 01-079-5683) [30] with the most intense XRD peaks in the diffraction planes (211), 
(112) and (300), and of the β-TCP phase (ICDD # 04-014-2292) [31] with the most 
intense XRD peaks in the diffraction planes (217), (214) and (220). Both powder 
compositions exhibit similar XRD patterns, but the peaks of the BCP-7Sr3Ag 
composition appear slightly shifted to lower 2θ angles in comparison to the control 
sample (BCP) ones. This is a clear indication that the larger size dopant ions 
(Sr2+ 1.20 Å, Ag+ 1.26 Å, in comparison to Ca2+ 0.99 Å) have been incorporated into 
the Ca2+ sites of the HA and β-TCP lattice structures replacing calcium. The relative 
percentages of crystalline phases presented in each composition after calcination at 
1100ºC, as estimated by HighScorePlus software for the both BCP and BCP-7Sr3Ag 
compositions, were: 80% HA + 20% β−TCP and 60% HA+ 40% β−TCP, 
respectively. 
The results of the particle/agglomerate size (PS) and size distributions (PSD) of BCP 
and BCP-7Sr3Ag compositions calcined at 1100ºC, used for inks preparation are 
shown in Fig. 3. Both samples presented similar size distribution curves, with main 
populations centred at sizes <1 µm and a coarser population corresponding to particle 
agglomerates. The measured average particle/agglomerate sizes are ~0.9 µm and 
~1.03 µm for BCP and BCP-7Sr3Ag powders, respectively. PS and PSD are 
parameters of crucial importance for the preparation of robocasting inks. Small size 
particles expose higher surface areas and are more prone to form agglomerates that 
might obstruct the extrusion nozzle during printing. On the other hand, a PSD with a 
suitable packing behaviour is likely to allow the preparation of suspensions with high 
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solid loading [38], with the finer ones occupying the interstitial spaces left by the 
coarser ones [39].  
 
Fig. 2. XRD patterns of the BCP and BCP-7Sr3Ag powders calcined at 1100 ºC. The 
standard ICDD PDF # 01-079-5683 and # 04-014-2292 of pure HA and β-TCP, respectively, 
are also presented for comparison. 
 
 
Fig. 3. Particle size distributions of the BCP and BCP-7Sr3Ag powders calcined at 1100 ºC 
and dry milled for 30 min. D50 is the diameter where half of the population lies below this 
value.  
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3.2. Optimization of robocasting ink formulation  
Starting from suspensions with maximized solids loading in the presence of the 
dispersant is of paramount importance when preparing extrudable pastes for 
robocasting, as a certain degree of dilution occurs upon adding the other processing 
additives as aqueous solutions. From the non-doped BCP powder, a suspension with 
solid loadings up to 55 vol.% could be prepared in the presence of Targon 1128 as 
dispersant. Fig. 4a compares the apparent viscosity versus shear rate curves for BCP 
suspensions containing: (i) 55 vol.% and 50% vol.% solids without any processing 
additive other than Targon 1128; (ii) 50% vol.% solids with further added different 
amounts of HPMC (1 and 2 wt.% relative to the dry mass of solids) to the most 
concentrated suspension; (iii) the final ink containing 2 wt.% of HPMC and the 
gelling agent (PEI). In this last case, the solids loading was decreased to 48 vol.% due 
to the diluting effect of adding PEI solution. It can be seen that all these suspensions 
exhibit a shear-thinning behaviour, characteristic of homogeneous and well dispersed 
suspensions. As expected, for suspensions with only added dispersant, the apparent 
viscosity curve of the most concentrated one (55% vol.%) is above that of 50% vol.% 
one. The addition of increasing amounts of HPMC to this last suspension caused 
noticeable gradual upshifts of the apparent viscosity curves in good agreement with 
the expected thickening role for this additive. With further addition of flocculating 
agent (PEI), the suspension viscosity increased significantly while the solids loading 
was consequently decreased to 48 vol.%. The BCP-7Sr3Ag composition allowed the 
preparation of a higher initial solids loading (60 vol.%) suspension (Fig. 4b). Even 
though, the apparent viscosity was somewhat lower in comparison to that of BCP 
suspension containing 55 vol.% solids.  
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Fig. 4. Rheological behaviour of BCP (a) and BCP-7Sr3Ag (b) composition viscosity as a 
function of shear rate for suspension with different loading percentage of solids, with 
increasing amounts of HPMC (1 and 2 wt.% for solids), and with 0.3 wt.% PEI. Effects of the 
PEI in inks were measurement in oscillatory amplitude sweep BCP (c) and BCP-7Sr3Ag (d). 
 
The suspensions exhibit overall shear-thinning behaviours, especially when derived 
from the BCP powder. This trend is less clear for suspensions prepared from the BCP-
7Sr3Ag powder, especially within the higher shear rate range. The main reasons may 
relay on their higher solids loading, an efficient destruction of particle agglomerates, 
and a suitable particle/agglomerate size distribution, as all these factors play a role 
here. Starting from high concentrated suspensions is always desirable in order to 
easily accommodate the unavoidable dilution effect upon adding the aqueous 
solutions of the other processing additives (HPMC, PEI). Accordingly, the highest 
solids loading suspension for each powder system was used as the starting point to 
prepare the inks. This enabled obtaining extrudable pastes from BCP and BCP-
7Sr3Ag powders with final solid loadings of 48 vol.% and 53 vol.%, respectively.  
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The shape stability of the extruded filaments can be inferred from the results of the 
stress sweep tests. The dynamic mechanical spectra and limit of linear viscoelasticity 
of the BCP and BCP-7Sr3Ag inks are presented in Fig. 4c-d, respectively. As can be 
observed, the addition of PEI significantly increased the elastic modulus (G´) and 
enlarged the limit of linear viscoelasticity region (LVR) for both ink compositions 
tested, in comparison to the systems in the previous condition (only with Targon 1128 
and HPMC). Final inks stay stable along all the shear stress range tested, suggesting 
that the deposited filaments will be mechanically stable and capable of fully 
supporting their own weight during the assembly. These results confirm that the 
powders and the processing additives have been suitably combined to obtain network 
structures with predicted good extrusion behaviours during printing in robocasting.  
In order to obtain information about the specific effects exerted by the processing 
additives [dispersant (Targon 1128), thickening agent (HPMC) and jellifying agent 
(PEI)] at the solid/liquid interface, zeta potential (ZP) measurements were performed 
for both powder particles (BCP and BCP-7Sr3Ag) as a function of pH in the presence 
and absence of each processing additive tested. The results are presented in Fig. 5a 
and Fig. 5b, for BCP and BCP-7Sr3Ag, respectively. In the absence of any additive 
the zeta potential curves of both powders particles show a continuous decreasing 
trend with increasing pH, with apparent isolectric points (IPE) around 5 (Fig. 5a) and 
4 (Fig. 5b). Accordingly, the addition of the processing additives also caused similar 
effects at the solid/liquid interface of both powders. The dispersing agent caused 
significant shifts of the entire electrophoresis curves towards the acidic region and 
more negative ZP values in good agreement with the anionic nature of this 
polyelectrolyte, confirming the occurrence of specific adsorption at the surface of 
calcium phosphate powders. These data confirm that Targon 1128 has a strong ability 
to act as a surface charge modifier of the dispersed calcium phosphate powders, 
explaining its ability to promote the dispersion of high concentrated suspensions. The 
addition of HPMC did not cause any noticeable shift in the IEP, but the ZP values 
became less negative. This effect can be attributed to a reduction of the 
electrophoretic mobility caused by the adsorbed HPMC chains protruding to the 
solution. On the other hand, adding PEI caused noticeable shifts of the entire 
electrophoresis curves upwards and towards the basic region, with IEPs within the 
range of 9.4−9.7. Such shifts are in good agreement with the cationic nature of PEI 
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and prove that the resulting cationic species specifically adsorb at the surface of the 
calcium phosphate powders.  
 
 
Fig. 5. Zeta-potential versus pH of BCP (a) and BCP-7Sr3Ag (b) powders in the absence and 
in the presence of the optimal amounts of processing additives for robocasting.   
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3.3. Scaffolds microstructural characterization 
Scaffolds with different pore sizes were prepared using the previously optimized inks. 
The porosity fraction was controlled by varying the gap between the rods in the x-y 
plane during the printing process (initial gap from 120 to 500 µm). The macroporosity 
of the scaffolds was assessed through SEM observations. The images of BCP and 
BCP-7Sr3Ag scaffolds are shown in Fig. 6a-g. The salient features include a good 
regularity of the structure, the straight geometry of the rods and their mutual extensive 
adhesion, predicting a reasonable mechanical strength for tissue engineering 
applications. All these features confirm the quality of the inks derived from both 
powder compositions. Only for the scaffolds with 500 µm pore size, (Fig. 6f) it is 
possible to observe slight deformations of the rods caused by the gravity during 
printing. The SEM micrographs presented in Fig. 6g1-g2 show high resolution images 
of the microstructure of the sintered rods of BCP and BCP-7Sr3Ag scaffolds, 
respectively. They confirm that both compositions sintered well, but the BCP-7Sr3Ag 
sample exhibits somewhat lower in-rod microporosity.  
Comparing the pore sizes designed on the CAD software, ranged from 120 to 500 µm 
to the real scaffolds after sintering, is possible to verify that pores in sintered scaffolds 
are slightly smaller for the BCP composition due to the different shrinkage extents, 
being ~11% and ~7% for BCP and BCP-7Sr3Ag, respectively. The smaller shrinkage 
of BCP-7Sr3Ag scaffolds can be attributed to the higher solids loading achieved for 
the starting suspension, resulting in better particle packing in green state. The 
obtained pore dimensions may promote cell seeding, proliferation, and 
vascularization, and bone formation inside the scaffold as literature indicates that 
pores in the range of 100–400 µm are optimal for the bone ingrowth [40-44]. This 
macroporosity must also provide transport pathways for nutrients, oxygen, and wastes 
necessary to maintain living cells within the scaffold.  
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Fig. 6. SEM micrographs comparing the internal microstructure of the BCP (left side) and 
BCP-7Sr3Ag (right side) scaffolds fabricated by robocasting and sintered at 1100 ºC with 
different pore size, (a) 120; (b) 180; (c) 220; (d) 300; (e) 350; (f) 500 µm (g) rods 
microstructure. 
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The evolution of total porosity, microporosity and macroporosity for sintered 
scaffolds of both compositions with initial macropore/gap size is shown in Fig. 7. As 
expected, the macroporosity, and thus the total porosity, increases with the gap 
between the rods (pore size). The aforementioned slightly smaller shrinkage observed 
in BCP-7Sr3Ag is evidenced here as a slightly increased macroporosity at each initial 
gap size. Also included in this figure are the evaluated in-rod microporosity, which is 
intrinsic to each material and independent of the distance between rods, and results 
from both the burnout of the organics present in the initial inks and sintering 
conditions, as well as from the particle packing achieved in the green structures. 
Averaging the experimental data for all gap sizes it is found that microporosity in 
BCP-7Sr3Ag is substantially lower than in BCP (27.7 ± 0.5 % vs. 39.6 ± 0.4 %). This 
difference is consistent with the higher particle packing achieved in the former 
system, which enabled starting solid loadings as high as 60 vol.% and with the lower 
extent of shrinkage during the drying and sintering steps.  
 
Fig. 7. Evolution of porosity (total, macroporosity and microporosity) for scaffolds fabricated 
by robocasting and sintered at 1100 ºC as a function of the macropore size, solid black lines 
correspond to BCP and dashed grey lines to BCP-7Sr3Ag. Data represent mean values with 
standard derivations as error bars. 
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3.4. Mechanical response of sintered scaffolds  
The size and fraction of macroporosity are important factors for bone ingrowth into 
the scaffolds [40-44], but has also obvious implications in their mechanical 
performance. Because of that, it is important knowing the interdependence of 
compressive strength and density of sintered scaffolds fabricated by robocasting as a 
function of macroporosity. Gibson and Ashby describe the interdependence of 
compressive strength,  𝛔, and macroporosity (represented by ratio d/s) for porous 
structures by the equation [46]  
𝛔 = 𝐂𝛔𝟎 ∙ 𝒅 𝒔 𝟑     (4) 
where 𝛔𝟎 is the intrinsic compressive strength. 
The compressive strength results obtained for robocast scaffolds of BCP and 
BCP-7Sr3Ag compositions are displayed in Fig. 8. For both compositions, the 
compressive strength gradually increases as ratio d/s increases, and macroporosity 
reduces, as expected. The best-fits of Eq. (4) to the experimental data are shown as 
solid lines within the plot, exhibiting a very good agreement for both materials. From 
the analysis of the fitting parameters it can be easily calculated that the intrinsic 
compressive strength is 22 % higher for the BCP-7Sr3Ag samples, in comparison to 
BCP ones, in good agreement with their lower in-rod microporosity (Fig. 8). 
Consequently, the better mechanical performance of BCP-7Sr3Ag samples can again 
be attributed to the higher solids loading in the final ink (53 vol.%), thanks to the 
enhanced packing efficiency of the respective powder particles in suspension and in 
green bodies, which, in turn, led to a higher final density of the rods. For both powder 
compositions, the compressive strength of scaffolds with macroporosity values below 
~48% are higher than that of cancellous bone (2 − 12 MPa [45]), falling within that 
range for larger fractions of macroporosity. Moreover, even the compressive strength 
values measured for the scaffolds made from the weaker composition (BCP) are 
similar to those reported in the literature for calcium phosphates with similar levels of 
porosity [47-49]. These results make the scaffolds interesting candidate materials for 
in vitro or in vivo experiments.  
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Fig. 8. Evolution of the compressive strength of BCP and BCP-7Sr3Ag robocast scaffolds 
sintered at 1100 ºC with the d/s. Cancellous bone strength (shaded band) is included for 
comparison [45]. Data represent mean values with standard derivations as error bars. 
 
Besides the average compressive strength values, evaluating their scattering is also 
essential to predict the mechanical reliability.  The probability of failure as a function 
of applied compressive stress was evaluated using the Weibull statistics. Fig. 9 
presents the Weibull plots of the compressive strength data obtained for BCP and 
BCP-7Sr3Ag for all planned pore sizes. Each point corresponds to a single test and 
the straight lines are the best data fits using the Weibull probability function. 
Obviously, for both compositions, strength gradually decreases with increasing pore 
size, in good agreement with the results discussed above (Fig. 8). The Weibull 
modulus data for BCP and BCP-7Sr3Ag scaffolds are also reported in the table 
included as Fig. 9c. From these data it can be concluded that samples of both 
compositions exhibit high Weibull modulus, which tend to decline with increasing 
pore size. This must be related to the decreasing volume of material in samples of 
constant size and to the increasing number of printing defects as the gap to span by 
the filaments increases, with BCP scaffolds being more reliable in comparison to the 
BCP-7Sr3Ag ones. This might be attributed to the higher fraction of microporosity in 
Chapter 4 
 
 
132 
BCP scaffolds and its uniform distribution in the structure, with micropores acting as 
structural defects of similar size. The distribution of micropores is expected to be less 
uniform in the denser BCP-7Sr3Ag samples, being the source of the slightly higher 
variability of the measured compressive strength.  
 
Fig. 9. Weibull plots of the compressive strength stress data for (a) BCP and (b) BCP-7Sr3Ag 
with different pore sizes. Straight lines are best fits to data using the Weibull probability 
function. Weibull modulus of the BCP and BCP-7Sr3Ag with different pore sizes (c). 
 
3.5. In vitro prokaryotic and eukaryotic cells-powders interactions 
The prokaryotic antimicrobial inhibitory effect of the powder compositions was 
manifested by the formation of circular clear zones of inhibition around the disks, as 
shown in Fig. 10. The sample co-doped with strontium and silver (BCP-7Sr3Ag) 
showed inhibitory effects on S. aureus (ATCC 29213) and E. coli (ATCC 25922). 
The diameters of the inhibition zones were measured, being 1.5 mm for S. aureus and 
1 mm for E. coli. These results suggest that this composition can be considered an 
antibacterial material to be used in implants for bone tissue engineering. The 
mechanisms of action of silver ions on microorganisms’ cells are very complex, but 
several hypotheses have been advanced to explain their antimicrobial effects. Firstly, 
silver ions bind to the prokaryotic cell envelope, thereby causing a change in their 
structure and permeability, and inactivate proteins [50,51]. Finally, the silver ions 
penetrate into the cell and inhibit various proteins in the cytoplasm and ribosome; 
inside cells, silver ions can interact with nucleic acids preventing replication and 
translation processes, ultimately causing cell death [52,53].  
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Fig. 10. Photographs of antimicrobial test results of BCP-7Sr3Ag samples against 
(a) S. aureus (ATCC 29213) and (b) E. coli (ATCC 25922). 
 
An ideal material for bone tissue engineering should promote an osteoblastic 
phenotype. The human osteoblast-like MG-63 cells adopted in this study are typically 
used to assess biomaterials’ effects on bone growth metabolism and cell-biomaterial 
interactions in bone tissue engineering [54-57]. Although Ag+ has been extensively 
used as an antimicrobial agent in clinical setting, there are still concerns about its 
cytocompatibility with eukaryotic cells. MG-63 cells typically display rapid cell 
growth and comprise an “immature” phenotype of primary osteoblasts [58]. Fig. 11 
‘control’ depicts the normal exponential growth of MG-63 cells during 14 days. 
Regarding the BCP-7Sr3Ag sample, this did not exhibit any significant negative 
effect on cellular proliferation after 3 and 7 DIV, in comparison to control cells 
(grown in the absence of any powder) or to undoped BCP. Oppositely, over time in 
culture, the BCP-7Sr3Ag powder was more efficient in inducing pre-osteoblastic 
proliferation (Fig. 11, 14 DIV). Phase contrast morphological analysis at this time 
point (14 DIV) also reveal the typical oval to spindle-shape of MG-63 cells in all 
groups (Fig. 12) [59]. Hence, cells cultured with BCP-7Sr3Ag doped-culture medium 
are able to proliferate and maintain their normal morphology. These results point to a 
non-toxic effect of silver ions on osteoblastic cells, and to a proliferative effect 
induced by Sr that is well reported in the literature [54, 57, 58]. 
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Fig. 11. Influence of BCP and BCP-7Sr3Ag on the viability of osteoblastic-like cells. MG-63 
osteoblastic-like cells were seeded at 2x104 cells.cm−2 and exposed to both powders 
composition (BCP and BCP-7Sr3Ag) for 14 days. The number of viable cells was indirectly 
accessed by the metabolic reversible resazurin assays at the indicated days in vitro (DIV). 
Results are depicted as fold increase of mean final optical density (O.D.f) over control ± SE 
(n=4-8). Statistically significant differences of metabolic activity were found between groups 
throughout cell culture (mixed design factorial ANOVA) (FGreenhouseGeisser(2.036, 5.089)=6.442; 
p=0.04 ƞ2p=0.720; Bonferroni post-hoc analysis (14DIV: Control vs SrAg p=0.025; BCP vs 
SrAg p=0.006).           
 
 
Fig. 12. Microphotographs of MG-63 cells cultured for 14 days on BCP and BCP-7Sr3Ag 
powders doped- culture medium. Full arrows highlight the presence of MG-63 cells on the 
presence of doped culture medium.  
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4. Conclusions 
The results presented and discussed along this report demonstrate the successful 
production of 3-D structures by robocasting from BCP and BCP-7Sr3Ag powders, 
suitable for bone tissue engineering. This additive manufacturing technique provides 
great design flexibility and offers the possibility of manipulating the interconnected 
macroporosity of the scaffolds. The powders of two compositions exhibited different 
packing efficiencies in the slurry state, determining distinct maximum achievable 
solids loadings either in suspensions and in the inks prepared thereof, with impacts on 
the shrinkage, porosity fraction and distribution, and mechanical performance. Denser 
BCP-7Sr3Ag scaffolds exhibited higher mechanical strength ranging from ~7 to ~40 
MPa with total porosity varying from ~70 to ~50%, respectively, although being 
slightly less reliable. In terms of mechanical behaviour, the scaffolds derived from 
both compositions present compressive strength values equal or even higher than the 
human cancellous bone, qualifying them for potential tissue engineering applications. 
Preliminary in vitro data indicates that BCP-7Sr3Ag powders can be cytotoxic to 
prokaryotes while stimulating osteoblasts. Future in vivo studies will hopefully 
confirm the good osteocompatibility of the BCP-7Sr3Ag scaffolds. 
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Abstract 
One strategy to induce bone regeneration includes the use of gridded structures able to 
allow migration and proliferation of osteoblasts and mesenchymal stem cells, matrix 
deposition in the empty spaces, as well as neo-vascularization. In the present study, 
several macroporous scaffolds were prepared by robocasting to evaluate the impact of 
the macropore size on the in vitro osteogenic differentiation of human mesenchymal 
stem cells (hMSCs) in vitro. Many ions have been described as adjuvants on hMSCs 
differentiation onto the osteogenic lineage and in this work we used biphasic calcium 
phosphate (HA/β-TCP) powders doped with strontium and zinc ions to produce the 
scaffolds. 
After ink parameters optimization we were able to successfully print scaffolds with a 
range of lattice pores size’s (120 - 500 µm) by robocasting. Doped biphasic calcium 
phosphate based scaffolds revealed to be appropriate matrices for long term in vitro 
cell culture. The obtained results demonstrate that hMSCs are able, not only to 
survive, proliferate and produce extracellular matrix components but also to 
differentiate onto the osteogenic lineage upon induction, in fact the ion-doped 
scaffolds displayed higher increased levels of ALP after 14 days even without the 
addition of external differentiation inductive factor (basal conditions) thus indicating 
that these scaffolds are able to induce osteogenic differentiation per se. For all 
scaffolds the mechanical properties (compressive strength) were comparable to or 
even higher than that of cancellous bone. The results suggest that these newly 
developed scaffolds can be used as matrices for bone regeneration with a potential for 
promoting the differentiation of hMSCs into osteoblasts. 
 
 
 
 
 
 
Keywords: calcium phosphate, porosity, mesenchymal stem cells, osteogenic 
differentiation. 
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1. Introduction 
Bone is the second most common transplanted tissue and although natural bone 
substitutes such as autografts and allografts have been used in the regeneration of 
damaged bone, they exhibit limitations such as donor-to-recipient infection, disease 
transmission, and induction of host immune responses [1]. Calcium phosphates 
(CaPs) have been widely studied as bioactive synthetic bone grafts mainly because 
their chemical composition resembles that of bone mineral and they exhibit excellent 
biocompatibility and bioactivity [2,3]. The most commonly employed CaPs are 
hydroxyapatite (HA) [Ca10(PO4)6(OH)2] and tricalcium phosphate in both of its 
polymorphs (α- and β-TCP) [Ca3(PO4)2] [4]. The solubilities and in vivo behaviours 
of HA and TCP are very different, and several studies suggest that an ideal CaP 
scaffold should be a mixture of both phases (biphasic calcium phosphates) [5,6]. In 
recent years, ionic substitutions have been broadly explored as a way for improving 
the physicochemical properties of CaPs. Ionic substitutions may enhance the 
biocompatibility of CaP based scaffolds, playing critical roles in the biological 
process after implantation. For instance, strontium (Sr2+) has demonstrated the 
capability to support osteoblastic differentiation while simultaneously inhibiting 
osteoclastogenesis [7]; consequently, it decreases bone resorption, while maintaining 
bone formation. Yang et al. showed that in vitro osteogenic differentiation 
enhancement was observed in human mesenchymal stem cells (hMSCs) cultured in 
presence of increased Sr2+ concentrations through Wnt/β-catenin signaling [8]. In 
addition of Sr2+, it has been shown that zinc can influence the behaviour of 
(pre)osteoblast and osteoclast and influence the differentiation of osteogenic cells [9]. 
Zinc also exerts a stimulatory effect on bone formation and mineralization in vivo and 
in vitro. Implants incorporating Zn promote bone formation around the material, 
improve biological properties, decrease the inflammatory response, and exhibit 
bactericidal properties [10-12].  
The strategies to regenerate bone include the use of scaffolds with suitable 3D porous 
structures to act as temporary templates for the biological processes leading to new 
bone formation, which should exhibit mechanical properties comparable to the host 
tissue [13-15]. The porosity of such scaffolds plays a significant role in tissue 
regeneration and should allow migration and proliferation of osteoblasts and 
mesenchymal stem cells, matrix deposition in the empty spaces, as well as 
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vascularization, promoting the bone tissue ingrowth and remodelling. Hierarchical 3D 
porous architectures at scales ranging from 10 to 1000 µm are essential, and each pore 
size plays a different role [16]. The macro pores (greater than 100 µm) allow cell 
ingrowth. The micro- (1–30 µm), and submicron (less than 1 µm) pores enable to 
establish a sufficiently high specific surface area for efficient binding of a critical 
number of cells to the scaffolds [17].  
Attempting to overcome the difficulties of conventional manufacturing techniques, 
porous structures with suitable characteristics for bone tissue engineering (geometry 
and size of pores, their spatial distribution, etc.), direct write assembly, also frequently 
called robocasting, has been often used for the fabrication of scaffolds. This layer-by-
layer additive manufacturing technique involves the extrusion of a ink/paste through 
fine nozzles and the deposition of filaments according to a computer-aid design 
(CAD) model to create complex 3D porous structures [18-21]. Highly uniform 
macropores can be obtained by varying the rod spacing and size to build the 3D lattice 
patterns [22]. This ability of robocasting to provide by a fully controlled reproducible 
and customizable architecture has been recently combined with the excellent 
biological properties of bioceramics [21,23-26]. However, the extensive materials 
characterization performed so far has been mostly intended to elucidate the 
dependence of mechanical properties of robocast scaffolds on the processing 
variables. There is few biological information available supporting the expected 
applicability of these architecturally well-defined porous ceramics on the in vitro 
behaviour to help predicting the new bone tissue formation after implantation. In this 
study, macroporous scaffolds with different macropore sizes were prepared by 
robocasting from biphasic calcium phosphate doped with strontium and zinc. The aim 
was to correlate pore size with in vitro osteogenic potential of human mesenchymal 
stem cells (hMSCs) by evaluating different cell parameters such as morphology, 
viability, adhesion and proliferation.   
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2. Materials and Methods  
 2.1. Synthesis and characterization of calcium phosphate powder 
Calcium nitrate tetrahydrate [Ca(NO3)2.4H2O, Panreac], strontium nitrate [Sr(NO3)2, 
Sigma-Aldrich] and zinc nitrate hexahydrate [Zn(NO3)2.6H2O, Sigma-Aldrich] were 
used as cationic precursors for Ca, Sr and Zn, respectively. Diammonium hydrogen 
phosphate solution [(NH4)2HPO4, Panreac] was used as phosphate source. 
Biphasic calcium phosphate powders with a planned total cationic/anionic molar ratio 
of 1.62 were envisaged in this work. The precursor of calcium was partially replaced 
by co-doping with 7 mol% Sr2+ and 3 mol% Zn+. The nomenclature used for this 
powder was BCP-7Sr3Zn. Two stock solutions of P and cationic precursors were 
firstly prepared with molar concentrations of 1.2 M and 1.94 M, respectively. The 
precipitation was carried out by slowly adding the required volume of P solution to a 
given volume of each continuously stirred (1000 rpm) cationic solution. The pH of 
the mixed system was increased to 9 and maintained at this value by adding the 
required amounts of 8 M ammonium hydroxide [NH4OH, Sigma-Aldrich, Germany] 
solution. The reaction was performed at 90 ºC for 2 h under constant stirring 
conditions (1000 rpm). 
The suspensions were poured out from the reactor and the precipitates separated 
through vacuum filtration and dried at 100 ºC overnight. The prepared powders were 
calcined at 1100 ºC in a Thermolab furnace (Pt30%Rh/Pt6%Rh thermocouple) using 
a heating rate of 5 ºC min–1 followed by a dwelling time of 2 h at that temperature, 
and then cooled to room temperature (RT). The calcined powders were then dry 
milled for 45 min in a high energetic ball milling up to achieving mean particle sizes 
of ~1 µm.  
Particle size distributions of the powders were determined using a light scattering 
instrument (Coulter LS 230, UK, Fraunhofer optical model).  The morphology and 
microstructure of the particles was observed by scanning electron microscopy (SEM, 
Hitachi S4100, Tokyo, Japan). The specific surface areas of the powders were 
measured by the Brunauer–Emmett–Teller method (BET) using a Micromeritics 
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Gemini 2370 V5.00 (Norcross, USA) through the gas adsorption after degassing the 
powders in a Micromeritics Flow Prep 060 (Norcross, USA). 
Qualitative crystalline phase analysis of calcined powders was performed using a 
high-resolution Bruker D8 Advance DaVinci diffractometer with Cu Kα radiation (λ 
= 1.5406 Å) produced at 40 kV and 40 mA. Data sets were recorded in the 2θ range 
of 20–80º with a step size of 0.015º 2θ s−1. Collection of XRD pattern data for 
Rietveld refinement studies was performed using a conventional Bragg–Brentano 
diffractometer (Bruker D8 Advance DaVinci, Karlsruhe, Germany) with Ni-filtered 
Cu-Kα radiation by recording X-ray diffraction data within the 2θ range = 20−80º 
(step size 0.015º and 0.5 s for each step). The software TOPAS version 4.2 (Bruker 
AXS, Karlsruhe, Germany) with the fundamental parameter approach, and the ICDD 
card numbers of # 04-015-7245 for HA [27] and # 04-006-9376 for β-TCP [28] were 
used for Rietveld refinements.  
 
2.2. Printing 3D porous scaffolds by robocasting 
A BCP-7Sr3Zn ceramic ink for robocasting with a final solid content of 53 vol.% was 
prepared following a previous work [23]. Briefly, a stable suspension was initially 
prepared by adding 0.4 wt.% (relative to the dry mass of solids) of ammonium 
polycarbonate dispersant (Targon 1128, BK Laden-burg, Germany) in distilled water, 
with a gradual addition of powders to reach up to 60 vol.% solids. Different amounts 
(1–2 wt.% based on mass of solids) of hydroxypropyl methylcellulose (HPMC, 
average Mn <10,000, Sigma-Aldrich) were also added to increase the intrinsic 
viscosity of the liquid. The as obtained suspension was subsequently turned into a 
jellylike ink by adding 0.3 wt.% (based on mass of solids) of polyethylenimine (PEI, 
50% w/v in water, Sigma-Aldrich) as flocculant. After each component addition, the 
system was placed in a planetary centrifugal mixer (ARE-250, ThinkyCorp., Tokyo, 
Japan) for a few minutes to improve the homogeneity of the mixture. 
Rheological measurements were made after each incremental amount of the 
processing additives using a Kinexus Pro+Rheometer (Malvern, USA). The apparent 
viscosity of the ink was measured in viscometry mode using a cone and plate sensor 
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system (4º/40 mm) and 150 µm gap size. The viscoelastic properties were assessed 
using the same rheometer equipped with plate and plate sensor (20 mm) with 1 mm 
gap size in the oscillatory mode. A solvent trap (a metal ring with di-ionized water) 
was used in all the rheological measurements to prevent water evaporation from the 
samples during the tests. 
3D scaffolds were constructed via direct-write assembly the extruded ink filaments 
layer-by-layer, using a robotic deposition device (3-D Inks, Stillwater, OK) as 
illustrated in Fig. 1. Cylindrical metallic deposition nozzles (EFD Inc., East 
Providence, RI) with a diameter d = 410 µm and a printing speed of 10 mm s–1 were 
adopted (Fig. 1a-c). The external dimensions of the scaffolds were about 9×9×3 in a 
total of 12 layers. Each structure consisted of 9 individual scaffolds of 3×3×3 mm 
(Fig. 1d-e), which were produced with six different pore sizes of 120, 180, 220, 300, 
350 and 500 µm. The deposition was performed into a paraffin oil bath to ensure 
uniform drying during assembly. The samples were removed from the bath and dried 
in air at RT for 24 h, heat treated at the heating rate of 1 ºC min–1 up to 400 ºC, and 
held at this temperature for 1 h to burnout the organics. The samples were 
subsequently sintered at 1100 ºC for 2 h using a heating rate of 5 ºC min–1.  
 
 
Fig. 1. The robocasting fabrication process: the ceramic scaffold is built layer-by-layer from a 
computer design (a-c). The dimensions of individual scaffolds were 3 × 3 × 3 mm (d) and (e) 
with a total of 12 layers. 
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2.3. Microstructural and mechanical characterization  
The density of the scaffolds, ρs, was determined from the mass and external 
dimensions of the structures of at least 25 samples with regular shape. The porosity, 
P, was then calculated according to equation 1:  
                                         P = 1 – (ρs /ρth) = 1 − ρrel                                                    (1) 
   
where ρth is the theoretical density (3.1 g⋅cm−3) given by the Rietveld refinement 
taking into account the percentage of each phase (HA and β−TCP) in the doped 
powder.  
The morphological features and the microstructure of the sintered scaffolds were 
analysed by scanning electron microscopy (SEM, Hitachi SU-70, Hitachi High-
Technologies Europe, GmbH, Germany), under an acceleration voltage of 25 kV and 
a beam current of 10 µA. Internal dimensions of the different scaffolds (rod diameter, 
spacing between rods, etc.) were determined as the average of minimum 25 direct 
measurements performed on SEM images, using the ImageJ Software. These 
dimensions were then used to estimate the macroscopic, pre-designed porosity from 
geometrical considerations assuming an ideal network of interpenetrating cylinders 
[29]: 
𝑃 = 1− !! !! !!!!!!! ! ! !! ≅ 1− !! ! ! !!      (2) 
where d, h, and s are the scaffold dimensions as defined in Fig. 1c and vi is the 
volume of the cylinders' intersection that can be neglected for small (≤ 20%) layer 
overlaps since it is below 1% of the total volume of the scaffold. 
The compressive strength of the sintered scaffolds was determined by performing 
uniaxial tests on approximately cubic blocks of 3 mm side (Fig. 1d-e). The tests were 
carried out in air on a universal testing machine (AG-IS10kN, Shimadzu, Kyoto, 
Japan) at a constant crosshead speed of 0.6 mm min–1. Tests were performed in the 
direction perpendicular to the printing plane. The load–displacement curves were 
registered during the tests. The compressive strength of the structure was calculated as 
the maximum applied load divided by the measured square section of the sample, and 
a minimum of 25 samples were tested. 
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2.4. In vitro studies  
2.4.1. hMSCs culture and seeding on the scaffolds 
Human mesenchymal stem cells (hMSCs, Lonza) were cultured, expanded, and 
maintained at 37 ºC in a humidified atmosphere of 5% CO2 in α-MEM (α-MEM, 
Gibco), supplemented with 10% v/v inactivated foetal bovine serum (FBS, Gibco), 
and 1% v/v penicillin/streptomycin (P/S, Biowest). The culture medium was refreshed 
every 2–3 days. hMSCs were harvested at pre-confluence using TrypLE™  
(TrypLE™) solution. Cells were used between 6 and 8 passages.  
The calcium phosphate scaffolds were sterilized by autoclave (121 ºC, 20 min) and 
placed in uncoated 48-well cell culture plates (Cellstar®) to avoid cell adhesion to the 
bottom of the wells. Non-doped biphasic calcium phosphate (BCP) scaffolds, 
containing approximately 50% of HA and 50% of β-TCP were also studied for 
comparison. Before cell seeding the scaffolds were pre-incubated in medium for 1 h, 
followed by seeding with cells at a density of 3x104 cells per scaffold. hMSCs were 
allowed to adhere for 20 min and 500 µl of the fresh medium was added to each well. 
hMSCs were cultured on calcium phosphate scaffolds for 14 days. After 1, 7 and 
14 days of culture, samples were evaluated for cell metabolic activity and 
morphology.  
One day after seeding, and in order to induce the hMSCs differentiation into the 
osteoblastic lineage, cells were also cultured with osteogenic medium: basal medium 
supplemented with 10 mM glycerophosphate (Sigma–Aldrich), 100 nM 
dexamethasone (Sigma–Aldrich), and 0.05 mM ascorbic acid (Fluka). At time-points 
7 and 14 days of culture osteogenic differentiation was evaluated.  
 
2.4.2. Cell metabolic activity 
Metabolic activity was measured using a resazurin assay at days 1, 7 and 14. 
Resazurin (Sigma) was added to fresh medium at a final concentration of 20% (v/v). 
The scaffolds with cells were incubated in this solution at 37 ºC for 3 h, after which 
100 µL per well was transferred to a 96-well black plate and fluorescence was 
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measured (Ex 530 nm/Em 590 nm) using a micro plate reader spectrophotometer 
(Bioteck Plate Reader, Synergy MX). 
The dsDNA quantification was performed using the Quant-iT PicoGreen dsDNA kit 
(Molecular Probes, Invitrogen), according to the manufacturer's instructions. Briefly, 
the frozen samples were thawed and lysed in 1% v/v Triton X-100 (in PBS) for 1 h at 
250 rpm and 4 ºC. Then, they were transferred to a black 96-well plate with clear 
bottom (Greiner) and diluted in TE buffer (200 mM Tris–HCl, 20 mM EDTA, pH 
7.5). After adding the Quant-iT PicoGreen dsDNA reagent, samples were incubated 
for 5 min at RT in the dark, and fluorescence was measured using a microplate reader 
(Ex 480/ Em 520 nm) (Bioteck Plate Reader, Synergy MX).  
 
2.4.3. Cell Morphology 
At different time points (1, 7 and 14 days after in vitro culture initiation), samples of 
each pore size were processed for cell morphology and cell distribution analysis by 
scanning electron microscopy (SEM). The scaffolds were washed in PBS and fixed in 
4% w/v paraformaldehyde in PBS for 20 min at room temperature, followed by 
dehydration with graded ethanol series (60%, 70%, 80%, 90%, and 99%) for 10 min 
in each solution and overnight in hexamethyldisilazane (Sigma-Aldrich). They were 
sputter-coated with carbon and observed using a Hitachi S-4100. 
At days 7 and 14 an immunocytochemical staining of actin filaments (F-actin) and 
nuclei was used to assess cytoskeleton organization of hMSCs. In order to evaluate 
the differentiation of the hMSCs the ALP was also stained. Briefly, cultured scaffolds 
were rinsed with PBS and fixed in 4% w/v paraformaldehyde in PBS and 
permeabilization with 0.1% v/v Triton X-100 for 5 min, then samples were incubated 
for 30 min with 1 wt.% bovine serum albumin (BSA, Merck) in PBS to block any 
non-specific staining.     
For alkaline phosphatase (ALP) staining, scaffolds were incubated overnight at 4 ºC 
with ALP antibody, monoclonal mousse IgG1 (Bio-Techne 3:100) and then with the 
goat anti-mousse secondary antibody Alexa Fluor® 594 (Molecular Probes-
Invitrogen, 1:1000, 45 min at RT). For F-action staining samples were incubated with 
the conjugated probe phalloidin/Alexa Fluor® 488 (Molecular Probes-Invitrogen, 
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1:40 in 1% BSA, 45 min at RT). Finally, samples were washed three times with PBS, 
and just before confocal visualization the nuclei were counterstained with 4’,6-
diamidino-2-phenylindole dihydrochloride (DAPI, H-1200, Vector). Samples were 
immunostained immediately before confocal visualization as described in the section 
above (CLSM, Leica SP5AOBS, Leica Microsystems) and acquired using LCS 
software (Leica Microsystems). The scanned Z-series were projected onto a single 
plane and pseudo-coloured using ImageJ and final panels were obtained using 
Photoshop CC 2017 vs 2017.1.1.  
 
2.4.4. ALP mean pixel intensity quantification  
 
Samples were imaged on MatTek glass bottom dishes (MatTek Corporation) using 
Vectashield containing DAPI (Vector Laboratories) for observation in a Leica 
SP5AOBS SE scanning confocal microscope (Leica Microsystems). Fluorescence 
intensity profiles were traced using an RGB profiler plugin of ImageJ1.45h Software 
(NIH). The relative intensities of ALP fluorescence were determined on maximum 
projected images acquired with fixed exposure acquisition settings; DAPI staining 
was used to define a selected area, and mean pixel intensities were determined 
(ImageJ).  
 
2.5. Statistical analyses 
 
Statistical analyses were performed using GraphPad Prism 7.0 software (version 
7.0a). For both the metabolic activity measurements normalized for the DNA content 
and ALP mean pixel intensity data comparison the non-parametric Mann-Whitney 
test was used. All tests were performed using a 95% confidence interval and 
statistically significant differences are marked with * (p < 0.05), ** (p < 0.01) , *** (p 
< 0.001) or **** (p < 0.0001). For the sake of graph clarity, specific p values are 
depicted in the supplementary table (Table 1) for Fig. 7. 
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3. Results and Discussion  
3.1. Characterization of BCP-7Sr3Zn powders 
CaP based biomaterials are well known for their bioactivity and similarity to the 
mineral phase of bone in terms of composition and structure. Biphasic calcium 
phosphate ceramics consisting of β-TCP and HA blends present excellent 
bioresorbability and bioactivity and proper osteoconductive properties resultant from 
the different performance of both phases [30,31]. The dissociation of β-TCP from 
BCP induces local super-saturation of calcium and phosphate ions, increasing the 
degradability and the nucleation of biological apatite. In addition, HA provides a 
bone-like environment with good osteoconductive and/or osteoinductive properties 
[32]. 
Strontium and zinc ions are presented in trace concentrations in natural bone [33] and 
have been demonstrated to significantly improve osteoblastic response on calcium 
phosphate bioceramics when added individually [34,35]. In the present study, the 
behaviour of BCP powders doped with both ions has been evaluated.  
Fig. 1 shows the physical-chemical characterization of BCP-7Sr3Zn powders after 
calcination at 1100 ºC. The XRD patterns present sharp and well defined diffraction 
peaks of the two phases, HA and β-TCP, as expected. The XRD data was refined 
assuming, for HA, the space group P63/m and the unit cell and structural parameters 
reported by Arcos et al. [27], and for β-TCP, the space group R3c and the parameters 
reported by Nicolopoulos et al. [28]. The quantitative phase analysis obtained by 
Rietveld refinement (wt.%) indicate the presence of 45.77% of HA and 54.23% of 
β−TCP. The refined cell parameters were a = b = 9.430664 Å, c = 6.907843, α = β = 
90º and γ = 120º in HA phase and a= b = 10.44789, c = 37.49057, α = β = 90º, and γ = 
120º in β-TCP phase.  
Morphological features of calcined powders observed by SEM show small and tightly 
agglomerated particles with regular shape and non-uniform size. Particle size 
distribution parameters including D50, average, as well as BET specific surface area 
are also detailed in Fig. 2 (b). BCP-7Sr3Zn powders present a bimodal distribution 
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with a measured average particle/agglomerates size of 1.02 µm.  
 
Fig. 2. Physical-chemical characterization of BCP-7Sr3Zn powder after calcination at 
1100 ºC: (a) X-ray diffraction pattern showing two phases, HA and β-TCP; (b) particle size 
distribution and specific surface area after dry milling for 30 min (D50 is the diameter where 
half of the population lies below this value); (c) SEM micrographs (bar: 6 µm). 
 
These particles size distributions are likely to allow the preparation of suspensions 
with high solid loading [36], important factor to avoid high shrinkage levels and 
improve the mechanical integrity of the final scaffolds.  
 
3.2. Optimization of scaffolds processing 
Specific effects exerted by the processing additives [dispersant (Targon 1128), 
thickening agent (HPMC) and jellifying agent (PEI)] at the solid/liquid interface of 
BCP-7Sr3Zn particles were evaluated by zeta potential (ZP) measurements in 
presence and absence of each processing additive, which results are presented in 
Fig. 3.  
In the absence of processing additives, zeta potential curve for BCP-7Sr3Zn powder 
shows a continuous decreasing trend as pH increases and an isolectric point (IEP) 
around pH 4. Measurements below ~pH 4 are not reliable for CaPs due to their 
enhanced solubility and the consequent increase in ionic strength under stronger 
acidic conditions. The dispersing agent promoted a significant shift of the 
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electrophoretic curve towards more negative ZP values, confirming its anionic nature 
and specific adsorption at the surface of BCP-7SrZn powder. This is in good 
agreement with previous findings that pointing out Targon 1128 as a very efficient 
surface charge modifier for calcium phosphate powders, enabling the preparation of 
high concentrated suspensions [23,37]. The IEP did not change with the further 
addition of HPMC, but ZP values became noticeably less negative. However, such 
noticeably decrease of absolute ZP values occurred without negatively affecting the 
apparent colloidal stability of the system. This can be explained either by an airy-like 
configuration adopted by the HPMC molecules adsorbed at the surface of BCP 
particles, slowdown their electrophoretic mobility, or by shifting of the shear plan to 
larger distances from the particle surface, or both. Adding PEI shifted the entire 
electrophoresis curve upwards and towards the basic region, with IEP at pH 10. Such 
shift is in good agreement with the cationic nature of PEI, attesting the specific 
adsorption of cationic species at the surface of the calcium phosphate based powders.   
 
Fig. 3. Zeta-potential versus pH of BCP-7Sr3Zn powders in absence and in presence of the 
optimal amounts of processing additives for robocasting ink.   
 
Colloidal inks for printing by robocasting process should have a high solid volume 
concentration to minimize shrinkage during drying and sintering. Exhibiting proper 
viscoelastic properties to flow through the fine deposition nozzle and then set to keep 
filament shape and support their own weigh layer by layer is another important 
requirement. A suspension with solid loadings up to 60 vol.% could be prepared from 
the BCP-7Sr3Zn powder in presence of Targon 1128 as dispersant. It is worthy to 
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underline that the addition of processing additives as aqueous solutions imply a 
certain diluting effect. Fig. 4(a) compares the apparent viscosity versus shear rate 
curves for suspensions containing: (i) 60 vol.% and 55% vol.% solids with added 
Targon 1128 as the only processing additive; (ii) 55% vol.% solids with further added 
different amounts of HPMC (1 and 2 wt.% relative to the dry mass of solids) to the 
most concentrated suspension; (iii) the final ink containing 2 wt.% of HPMC and the 
gelling agent (PEI), the addition of which justified a further decrease in solids loading 
to 53 vol.%.  
 
 
Fig. 4. Rheological behaviour of BCP-7Sr3Zn suspension/ink: (a) viscosity versus shear rate 
for suspensions with different solids loading in the absence (55 and 60 vol.%) or in the 
presence of HPMC (55 vol.% + 1 and 2 wt.% for solids), and with 53 vol.% in the presence of 
all processing additives (53 vol.% + 2 wt.% HPMC + 0.3 wt.% PEI). (b) Oscillatory 
amplitude sweep of final inks in the absence (55 vol.% + 2 wt.% HMPC) and in the presence 
of PEI (53 vol.% + 2 wt.% HPMC + PEI).  
 
The apparent viscosity of the most concentrated suspension (60% vol.%) is above that 
of 55% vol.%, as expected. In the presence of dispersant only, both systems exhibit 
slightly shear thickening behaviour. This can be attributed to the high solids loading 
and to the low intrinsic viscosity of the dispersing solution. But all the other 
suspensions with added HPMC exhibit shear-thinning behaviours, more accentuated 
with increasing the content of this processing additive, in good agreement with its 
thickening role. HPMC enhances the intrinsic viscosity of the dispersing liquid and 
Chapter 5 
 
 
159 
smooths the collisions between particles under flow, while confers a certain internal 
structure to the system that is gradually broken down as shear rate increases. The 
further addition of flocculating agent (PEI) has significantly increased the viscosity of 
the system, turning it into an extrudable ink in good agreement with ZP results 
(Fig. 3).  
The viscoelastic properties of the inks can be inferred from the results of the stress 
sweep tests. The dynamic mechanical spectra and limit of linear viscoelasticity of the 
BCP-7Sr3Zn inks are presented in Fig. 4(b). As can be observed, the addition of PEI 
significantly increased the elastic modulus (G´) and enlarged the limit of linear 
viscoelasticity region (LVR) in comparison to the systems without PEI (with only 
with Targon 1128 and HPMC). The final ink with all the ingredients remained stable 
along all the shear stress range tested. Such viscoelastic behaviour suggests that the 
extruded filaments will be mechanically stable and capable of keep their shape after 
the printing step. These results confirm that the powders and the processing additives 
have been suitably combined to obtain pastes with predicted good extrusion 
behaviours during printing in robocasting.  
 
3.3. 3D porous scaffolds characterization 
It has been shown that pore size in scaffolds with approximately 100 µm diameter is 
required for ingrowth of bone cells, and that sizes in the range of 100−600 µm 
facilitates osteoconductivity [38].  Although several strategies can be used to obtain a 
scaffold with different porosity, the control of pore size, geometry and 
interconnectivity of pores, essential to nutrients diffusion, is difficult in most of the 
common techniques (as for example polymeric sponge replication). Robocasting 
emerges as a 3D printing technique capable to fabricate scaffolds with a precise 
macroporosity and controlled geometry.  
Scaffolds with different pore sizes were prepared using the previously optimized inks. 
The macroporosity of the scaffolds was assessed through SEM observations and the 
images are presented in Fig. 5A (a-f). The porosity fraction was controlled by varying 
the gap between the rods in the x-y plane during the printing process (initial gap from 
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120 to 500 µm). The prominent features include a good regularity of the structure, the 
straight geometry of the rods and their mutual extensive adhesion, predicting a 
reasonable mechanical strength for tissue engineering applications. Fig. 5B shows the 
geometrical parameters of scaffolds measured from the SEM images. All these 
features confirm the suitable viscoelastic properties of the inks (Fig. 4). Comparing 
the distance dxy to the original CAD model, a slightly shrinkage (5%) in the scaffolds 
after sintering can be detected, thanks to the high percentage of solids in the ink. 
Concerning the distance dz, the scaffolds with larger pore size (500 µm) present 
higher deformation due to gravity phenomenon, as expected. 
 
 
Fig. 5. 3D porous scaffolds characterization. (A) SEM micrographs of the cross-sections of 
the BCP-7Sr3Zn scaffolds with different pore sizes [(a) 120; (b) 180; (c) 220; (d) 300; (e) 
350; (f) 500 µm, (bar: 750 µm)], fabricated by robocasting and sintered at 1100 ºC. (B) 
Measurements of the rod distances in the scaffolds. The dashed lines on graphs refer to the 
CAD design model.   
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Fig. 6 (a) shows the evolution of total porosity, microporosity and macroporosity for 
sintered scaffolds with initial macropore/gap size. The geometrical properties of the 
scaffolds were measured from SEM images and used for the calculation of the total 
porosity, which ranged from ~50% and ~70%. The macroporosity, increases as gap 
between rods increases, as expected, varying between 26.6% and 50.8% for pore size 
of 120 µm and 500 µm, respectively. Concerning the microporosity, which is intrinsic 
to each material and result from both the burnout of the organics presented in the 
initial ink and sintering conditions, was around 26%. The compressive strength results 
obtained for robocast scaffolds are displayed in Fig. 6 (b). As expected, the 
compressive strength gradually decreases as pore size increases. Nevertheless, even 
the lower compressive strength values obtained for scaffolds with 500 µm pore size, 
are in the range of the cancellous bone (2−12 MPa [39]).   
From the mechanical view point, it can be concluded that all the scaffolds present 
satisfactory mechanical properties for being used as bone substitutes, justifying their 
further use in in vitro studies aiming at evaluating their biological performance. 
 
 
Fig. 6. Evolution of structural and mechanical features of robocast scaffolds sintered at 
1100 ºC with macropore size: (a) porosity (total, macroporosity and microporosity); and (b) 
compressive strength. For comparison, a shaded band representing the cancellous bone 
strength is also included [39]. Data represent mean values with standard derivations as error 
bars. 
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3.4. hMSCs activity on the scaffolds 
The metabolic activity of hMSCs culture on scaffolds with different pore size (lowest 
(120 µm), intermediate (300 µm) and highest (500 µm)) was measured using the 
resazurin-based method after 1, 7 and 14 days and normalized with DNA content for 
each time point (Fig. 7A). The hMSCs remained viable and metabolically active 
throughout the 14 days of culture in all scaffolds, with a continuous increase in cells 
metabolic activity for all macropore sizes. Comparing the BCP-7Sr3Zn with the non-
doped scaffolds (used as control), the doped composition scaffolds showed higher 
metabolic activity values for all pore sizes. Analysing the values normalized with 
DNA content, an increase in the values displayed in the Fig. 7A indicates an increase 
on the metabolic activity of the individual cell, showing that the doped scaffolds 
could enhance cell metabolism. Studies of Pina et al. [40] have shown that β-TCP 
bone cement doped with strontium and zinc ions improved the metabolic activity in 
vitro of MC3T3- E1 cells. Furthermore, J. Caverzasio showed that Sr may directly 
interact with the calcium sensing receptor in osteoblast cells (MC3T3- E1) to trigger 
mitogenic signals in the protein kinase c/d signalling pathways, resulting in increased 
cell division [41]. Though no proliferation marker was used in this study, it can 
clearly be observed the difference on the number of cells throughout time in culture 
(Figs. 7, 8 and 9) justifying the increase of the scaffold occupancy by the hMSCs. 
Cells attach and spread when in contact with an adequate surface through adhesion 
proteins-dependent processes. The quality of cell attachment affects the cell 
morphology as well as their proliferation and differentiation ability [42]. Microscopic 
analyses were used to evaluate the distribution of hMSCs on the BCP-7Sr3Zn 
scaffolds after 1, 7 and 14 days in culture (Fig. 7B) and revealed that cells were well 
were able to adhere to the scaffold surfaces. An increase on cell density from day 1 to 
day 14 can be observed since After 14 days the side of scaffolds was completely 
covered with cells, indicating their survival, regardless of pore size. Moreover, seeing 
in detail the morphology of the cells 24 h after the seeding, it is possible to observe 
that cells exhibit a nearly polygonal shape with a multiple filopodia attached to the 
scaffolds (Fig. 7C (a)). The absorption of proteins integrins (major cell receptors 
involved in the cell-binding-to-matrix) from culture mediums determines the early 
non-specific stage of cell adhesion, enabling cell spreading on the scaffolds through 
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the formation of a conditioning protein layer that promotes this adhesion  [43, 44]. 
Moreover, the surface area (total of porosity in range of ~50% and ~70%) and 
microporosity (Fig. 6) facilitate the wettability of the scaffolds and provide much 
more contact points for protein anchorage.  By day 7, in some areas of the scaffolds, 
cells were already disposed in a monolayer with cell-to-cell contact, partially coating 
the materials surface (Fig. 7C (b)). After 14 days in culture, hMSCs were visible on 
the top surface of the 500µm pore size scaffold, linking the structure´s filaments (Fig. 
7C (c)).   
The morphology of the hMSCs on the scaffolds is shown in CLSM images of Figs. 8 
and 9 for BCP and BCP-7Sr3Zn, respectively, assessed by labelling f-actin filaments 
(green) and nuclei (blue), in basal and osteogenic medium (where no osteoinductive 
agents were provided to the cells), after 7 and 14 days in culture. The cells were well 
spread under all pore size in both compositions (BCP and BCP-7Sr3Zn) but when 
comparing basal and osteogenic conditions, it seems obvious, that the cells occupied 
the surface of the scaffold filaments differently. After 7days in culture, the cell 
number was higher in the basal medium. In the presence of differentiation inductors, 
there is a metabolism-shift on hMSCs and it is already reported that cells proliferate 
less on osteogenic inductive medium when compared with basal medium [45].  
hMSCs are promising cell sources for bone engineering because of its osteogenic 
capacity under certain conditions [46]. Previous studies demonstrate the osteogenic 
capability of MSCs cultured on calcium phosphate ceramics (CaPs), as well as 
showing that adhesion, localization, ECM deposition and cell differentiation is 
affected by design and pore geometry of the scaffolds [47]. 
ALP is a functional enzyme, which plays a key role in bone formation and 
mineralization and has always been related to osteoblast differentiation [48]. In order 
to evaluate the effect of macropore size on osteogenic differentiation we quantified 
the signal intensity of ALP (a marker of early osteogenesis) produced from hMSCs on 
culture after 7 and 14 days (Fig. 10).  
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Fig. 7. (A) Metabolic activity normalized for DNA content of hMSCs on BCP and 
BCP-7Sr3Zn, with different pore size (120, 300 500 µm), after 1, 7 and 14 days of culture. 
Statistical analysis results can be found on supplementary Table 1.  (B) SEM images of 
hMSCs on BCP-7Sr3Zn after 1, 7 and 14 days in culture in basal medium (bar: 750 µm); (C) 
seeded hMSCs adhered on the 500 µm pore size scaffolds after 24h (a) and 7 days (b); 
(c) Top-view of the 500 µm pore size scaffold after 14 days in culture.  
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Fig. 8. Immunocytochemistry of ALP protein (red), nuclei (blue) and actin filaments (green) 
of hMSCs on BCP scaffolds, with different porosity, after 7 and 14 days in basal and 
osteogenic medium (scale bar = 100 µm) 
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Fig. 9. Immunocytochemistry of ALP protein (red), nuclei (blue) and actin filaments (green) 
of hMSCs on BCP-7Sr3Zn scaffolds, with different porosity, after 7 and 14 days in basal and 
osteogenic medium (scale bar = 100 µm).   
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In order to evaluate the macropore size effect on the osteogenic differentiation we 
quantified the mean pixel intensity of ALP by standard procedures (described in 
section 2.4.4). Fig. 10A and Fig. 10B show that when comparing the range of pore 
size in basal conditions, higher levels of ALP (in the individual cells) were detected in 
the higher pore sized scaffolds (500 µm), proving higher osteogenic differentiation of 
hMSCs on these scaffolds, when compared with smaller pore sized ones. For BCP 
scaffolds, when comparing 7 days data with 14 days data under basal conditions, the 
highest statistical significance detected was in the 500 µm pore size with a p < 0.0001 
thus indicating that this increase in ALP staining is proof of osteoinduction without 
the addition of osteoinductive exogenous factors, thus representing a key advantage 
on the future application of these biofabricated scaffolds. A possible explanation 
could be related to the small pore size closing faster, causing a deficiency of nutrient 
and oxygen for the cells located in that zone in comparison to the cells in the larger 
pores. The same tendency is observed on the basal medium cultured ion-doped 
scaffolds with the higher ALP intensity values being detected on the bigger pore sized 
scaffolds. 
 
 
 
Fig. 10. Quantification of immunostained ALP using the a confocal images of hMSCs in 
culture in basal medium in BCP (A) and BCP-7Sr3Zn (B) scaffolds with different pore sizes, 
after 7 and 14 days.  Statistically significant difference are marked as * (p < 0.05), ** (p < 
0.01) and **** (p < 0.0001). 
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ALP staining was also quantified for both BCP and BCP-7Sr3Zn 500 µm pore 
scaffolds and the results shown in Fig. 11 display the same tendency on osteogenic 
differentiation for both scaffold formulations. Upon exposure to the osteoinductive 
factors added to the basal culture media, hMSCs undergo a rapid differentiation event 
onto the osteogenic lineage as assessed by ALP mean pixel intensity. After 7 days, the 
highest values for ALP can be detected for both types of scaffolds but the continuous 
supply of such factors seems to traduce in the stabilization of such levels since no 
significant differences are observed when comparing 7 days post-induction with 14 
days for both scaffolds. 
When we analyse the difference between the BCP and the ion-doped scaffolds, higher 
absolute levels of ALP are quantified for the ion-doped formulation indicating a 
beneficial effect of the presence of Sr and Zn regarding the osteogenic differentiation. 
These findings are in line with the results describing the influence of such ions in 
osteoinduction [49,50]. 
 
 
 
Fig. 11. Quantification of immunostained ALP using the a confocal images of hMSCs in 
culture in osteogenic medium in BCP (A) and BCP-7Sr3Zn (B) scaffolds with 500 µm after 7 
and 14 days Statistically significant difference are marked as **** (p < 0.0001), n.s. means 
not statistically significant. 
 
Chapter 5 
 
 
169 
4. Conclusions 
Biphasic calcium phosphate scaffolds doped with strontium and zinc ions with pore 
sizes in the range of 120-500 µm were successfully printed by robocasting. Inks with 
suitable viscoelastic behaviour for printing process were obtained from aqueous 
starting suspensions containing 60 vol.% of solids with subsequent addition of 2 wt.% 
of thickening agent (HPMC) and 0.3 wt.% of flocculating agent (PEI). All porous 
scaffolds presented compressive strength values equal or even higher than the human 
cancellous bone. In vitro studies performed in hMSCs culture presented a positive 
response towards the investigated compositions. hMSCs differentiation analysed by 
the ALP activity showed that the BCP-7Sr3Zn induce osteogenic differentiation per 
se with better results for the scaffolds with 500 µm pore size. These results suggest a 
better tissue response for this last pore size scaffolds, predicting an enhanced bone 
formation after in vivo implantation. 
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Supplementary Tables  
Table 1. Statistical analysis of data from Fig. 8, metabolic activities of hMSCs on BCP and 
BCP-7Sr3Zn. Statistically significant differences are marked with * (p < 0.05), ** (p < 0.01), 
*** (p < 0.001) or **** (p < 0.0001), n.s. means not statistically significant. 
 
BCP_120 _day1 Vs BCP_300 _day 1 n.s. 0.1145 
BCP_120 _day1 Vs BCP_500 _day 1 ** 0.0046 
BCP_120 _day1 Vs BCP_120 _day 7 * 0.0239 
BCP_120 _day1 Vs BCP_120 _day 14 *** 0.0007 
BCP_120 _day1 Vs BCP-7Sr3Zn_120 _day 1 <0.0001 
BCP_300 _day1 Vs BCP_500 _day 1 ** 0.0016 
BCP_300 _day1 Vs BCP_120 _day 7 <0.0001 
BCP_300 _day1 Vs BCP_300 _day 7 <0.0001 
BCP_300 _day1 Vs BCP_300 _day 14 <0.0001 
BCP_300 _day1 Vs BCP-7Sr3Zn_300 _day 1 *** 0.0002 
BCP_500 _day1 Vs BCP_500 _day 7 *** 0.0009 
BCP_500 _day1 Vs BCP_500 _day 14 <0.0001 
BCP_500 _day1 Vs BCP-7Sr3Zn_500 _day 1 <0.0001 
BCP_120 _day7 Vs BCP_300 _day 7 <0.0001 
BCP_120 _day7 Vs BCP_500 _day 7 <0.0001 
BCP_120 _day7 Vs BCP_120 _day 14 ** 0.0010 
BCP_120 _day7 Vs BCP-7Sr3Zn_120 _day 7 *** 0.0002 
BCP_300 _day7 Vs BCP_500 _day 7 n.s. 0.8503 
BCP_300 _day7 Vs BCP_300 _day 7 <0.0001 
BCP_300 _day7 Vs BCP-7Sr3Zn_300 _day 7 ** 0.0056 
BCP_500 _day 7 Vs BCP_300 _day 14 * 0.0356 
BCP_500 _day 7 Vs BCP-7Sr3Zn_500 _day 7 <0.0001 
BCP_120 _day14 Vs BCP_300 _day 14 ** 0.007 
BCP_120 _day14 Vs BCP_500 _day 14 *** 0.0001 
BCP_120 _day14 Vs BCP-7Sr3Zn _120 _day 14 <0.0001 
BCP_300 _day14 Vs BCP_500 _day 14 n.s. 0.1362 
BCP_300 _day14 Vs BCP-7Sr3Zn _300 _day 14 n.s. 0.149 
BCP_500 _day14 Vs BCP-7Sr3Zn_500 _day 1 <0.0001 
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BCP-7Sr3Zn _120 _day1 Vs BCP-7Sr3Zn _300 _day 1 n.s. 0.7575 
BCP-7Sr3Zn _120 _day1 Vs BCP-7Sr3Zn _500 _day 1 <0.0001 
BCP-7Sr3Zn _120 _day1 Vs BCP-7Sr3Zn _120 _day 7 <0.0001 
BCP-7Sr3Zn _120 _day1 Vs BCP-7Sr3Zn _120 _day 14 <0.0001 
BCP-7Sr3Zn _300 _day1 Vs BCP-7Sr3Zn _500 _day 1 <0.0001 
BCP-7Sr3Zn _300 _day1 Vs BCP-7Sr3Zn _300 _day 7 <0.0001 
BCP-7Sr3Zn _300 _day1 Vs BCP-7Sr3Zn _300 _day 14 <0.0001 
BCP-7Sr3Zn _500 _day1 Vs BCP-7Sr3Zn _500 _day 7 <0.0001 
BCP-7Sr3Zn _500 _day1 Vs BCP-7Sr3Zn _500 _day 14 <0.0001 
BCP-7Sr3Zn _120 _day7 Vs BCP-7Sr3Zn _300 _day 7 <0.0001 
BCP-7Sr3Zn _120 _day7 Vs BCP-7Sr3Zn _500 _day 7 <0.0001 
BCP-7Sr3Zn _120 _day7 Vs BCP-7Sr3Zn _120 _day 14 <0.0001 
BCP-7Sr3Zn _300 _day7 Vs BCP-7Sr3Zn _500 _day 7 <0.0001 
BCP-7Sr3Zn _300 _day7 Vs BCP-7Sr3Zn _300 _day 14 <0.0001 
BCP-7Sr3Zn _500 _day7 Vs BCP-7Sr3Zn _500 _day 14 <0.0001 
BCP-7Sr3Zn _120 _day14 Vs BCP-7Sr3Zn _300 _day 14 <0.0001 
BCP-7Sr3Zn _120 _day14 Vs BCP-7Sr3Zn _500 _day 14 <0.0001 
BCP-7Sr3Zn _300 _day14 Vs BCP-7Sr3Zn _500 _day 14 <0.0001 
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Abstract 
The present work reports on the fabrication of biphasic calcium phosphate/chitosan 
composite scaffolds using robocasting as additive manufacturing technique. Taking 
advantage of sintering step elimination, the possibility to obtain drug loaded scaffolds 
was also explored by adding levofloxacin to the extrudable inks. High amounts of 
solids (biphasic calcium phosphate powders, BCP) in inks and chitosan crosslinking 
by added genipin are the main factors responsible for the mechanical properties of the 
scaffolds after printing. 
Three BCP powders containing different HA/β−TCP ratios were used. High 
percentage of solids (45 vol.%) in the final inks were attained, allowing successful 
extrusion behaviours during 3D porous structures printing.  Adding levofloxacin 
induced slightly changes on the rheological behaviour of the inks and consequently, 
on the microstructure and on the mechanical properties of the final scaffolds. Drug 
delivery studies revealed a fast release of levofloxacin with a high burst of drug 
within the first 30 min. Levofloxacin loaded samples also presented bacteria growth 
inhibition ability, proving that antibiotic was not degraded during the fabrication 
process and its bactericidal efficacy was preserved.  
The composite scaffolds fabricated constitute a promising approach joining both local 
bone regeneration and infection control.  
 
 
 
 
 
Keywords: Sintering-free, composite scaffolds, robocasting, Biphasic CaP, bone 
regeneration, local-drug-delivery.  
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1. Introduction 
Bone defects caused by several ways, such us traumatic accidents, tumour resection 
or osteoporosis, demand major health care challenges to biomedical science and 
repairing technologies. Also, therapies for bone associated infections often require the 
removal of infected bone, treating the infection around and filling the left bone space 
with a bio-regenerative material [1]. Combined efforts of medical practitioners and 
material scientists have been undertaken in enable fabrication of bone-regenerative 
scaffolds incorporating biomolecules with clinically important functionalities as 
reported in several recent works [2-9]. For instance, addition of antibiotics or 
chemotherapeutic drugs in the scaffolds could prevent bacterial infection and prevent 
cancer recurrence, respectively [2-9]. Therefore, as mentioned by Fernandes et al. 
[10], finding an implanted biomaterial that smartly combines both therapy functions 
of drug-eluting and regeneration will bring lots of benefits not offered by the 
conventional medical practice. This challenging approach is likely to become a 
compulsory target in the near future [10].  
A number of biopolymers, such as polycaprolactone (PCL) and poly (lactic-co-
glycolic acid, PLGA) have been studied for this purpose [11,12]. However, the 
exclusive use of polymer scaffolds has shown limited success because of their 
hydrophobicity, difficulty to control drug release, and low osteoconductivity [2]. 
Calcium phosphate (CaP) based materials are still the best choice to repair damaged 
bones [13]. CaP are osteoconductive, might acquire osteoinductive properties [14,15], 
being the most adequate type of material for controlled drug delivery. The trend is 
therefore finding an optimal combination of biomaterials to obtain tunable drug-
delivery bone scaffolds with proper mechanical strength [1,2,12,16]. Biphasic calcium 
phosphates (BCP) have been widely investigated for several purposes [17]. As the 
name suggests, BCP consists of two calcium phosphate phases, commonly a more 
stable phase (HA) and a more soluble one (β-TCP), assorted in different proportions. 
This phase’s combination offers some advantages over the pure phases, enabling a 
better control of bioactivity and biodegradation, and assuring the stability of the 
biomaterial while promoting bone ingrowth.  
Besides based material, scaffold’s architecture on the macro-, micro- and nanoscale is 
crucial for proper nutrient and waste transport, cellular interactions, mechanical 
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stability, drug delivery and ultimately functional tissue formation [1,11]. Additive 
manufacturing (AM) appears as an emergent and promising technique in regenerative 
medicine, essentially for bone substitute’s fabrication, where a precise control of pore 
shape and size is possible, among other advantages [18-22]. Robocasting, also called 
direct write assembling (DWA) was developed for ceramics and uses extrudable 
aqueous ceramic inks at room temperature that are commonly obtained by mixing 
ceramic powders in water with few amounts of organic additives [19,21,22]. 
However, after printing, all green CaPs based scaffolds are commonly submitted to a 
sintering step at high temperatures (1100-1200 ºC) to obtain suitable mechanical 
properties. This hinders the incorporation of temperature sensitive bioactive 
molecules in the extrudable ink before sintering. Because of that, bioactive molecules 
for different therapeutic applications can only be added after sintering by soaking the 
scaffolds in suspensions with suitable concentrations of the desired biomolecules or 
drugs [3-5,7,8]. This means that impregnation process limits the amount of 
biomolecules incorporation to the absorption capacity of the scaffolds, as well as to 
their surface properties. However, the loading output of the process is very low, since 
a highly concentrated solution must be prepared in order to incorporate a small 
amount of drug in the scaffold, and hence the process is neither very well controlled 
and nor cost-effective. To overcome these difficulties, sintering-free scaffolds 
fabrication could be the ground-breaking solution. Martínez-Vázquez et. al. [16] 
published the first results related to the sintering-free drug-loaded Si-doped HA 
composite scaffolds fabricated by robocasting. The biological behaviour and 
biodegradabilty of these hybrid (Si-doped HA + gelatin) scaffolds was greater than 
that of sintered inorganic Si-doped HA scaffolds, but the overall targets are still far 
from being satisfactorily accomplished. The main drawback was related to the low 
inorganic contents of inks that strongly limited the filaments strength during printing 
process and the final mechanical properties of the scaffolds. Optimizing the 
rheological properties of the inks to obtain appropriate extruded filaments is a key 
step to fabricate scaffolds by robocasting. 
Considering all the constraints stated in literature review and having ahead the future 
requirements to improve life quality of patients with bone diseases, the main goal of 
the present work is to develop calcium phosphate based scaffolds, with simultaneous 
activity on infection and regenerative therapies. This target will be achieved by 
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combining pioneering manufacture specifications, including: (1) preparation of drug-
loaded high concentrated calcium phosphate based inks with proper rheological 
performance, (2) 3D-printing by robocasting technique and (3) sintering stage 
elimination. The model drug selected for this study was levofloxacin, an antibiotic 
successfully used in the treatment of bone infection, due to its ability to penetrate into 
trabecular and cortical bone minimizing the risk of resistance selection [23,24]. The 
drug delivery behaviour and the antibacterial activity of the resultant 3D scaffolds 
were also evaluated.  
 
2. Experimental Procedure 
2.1 Synthesis and characterization of biphasic calcium phosphate 
powders 
The synthesis of CaP-based powders by aqueous precipitation requires a close control 
of many parameters such as, reaction pH, ripening time, temperature and 
stoichiometry of the raw materials [25]. Since the first step of this work was obtaining 
biphasic calcium phosphate powders (BCP) with different proportions of HA and β-
TCP phases, and considering that higher Ca/P ratios and pH values promote the 
formation of HA phase [26,27], the initial Ca/P ratios and pH values were accordingly 
varied.  
BCP powders with Ca/P ratios of 1.50, 1.59 and 1.65 were obtained via aqueous 
precipitation, according to a procedure described in a previous work [21]. Briefly, 1.2 
M di-ammonium hydrogen phosphate solution [(NH4)2HPO4, Panreac, Spain] was 
added to a calcium nitrate tetrahydrate [Ca(NO3)2.4H2O, Panreac, Spain] solution 
with the concentration required for the planned Ca/P ratio. The reaction occurred at 
90 ºC for 2 h under constant stirring conditions (1000 rpm) at pH 8, 8.5 and 9, for 
synthesis of BCP 1.50, 1.59 and 1.65, respectively. These pH values were maintained 
by adding the required amounts of 8 M ammonium hydroxide solution [NH4OH, 
Sigma-Aldrich, Germany]. After the synthesis, the precipitates were separated 
through vacuum filtration and dried at 100 ºC overnight. The prepared powders were 
calcined at 1100 ºC in a Thermolab furnace (Pt30%Rh/Pt6%Rh thermocouple) using 
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a heating rate of 5 ºC min−1 and 2 h dwelling time at the maximum temperature, 
followed by cooling to room temperature (RT). The calcined powders were then dry 
milled for 45 min in a high energetic ball milling up to achieving a mean particle 
size ~1 µm.  
The collection of XRD data for Rietveld refinement studies was performed using 
High Resolution X-ray Diffractometer (PANalytical X'Pert PRO) with Cu Kα 
radiation (λ = 1.5406 Å) produced at 45 kV and 40 mA, between 20º and 80º 
diffraction angles (2θ) with a step size of 0.013º and 200 s time per step. The software 
TOPAS version 4.2 (Bruker AXS, Karlsruhe, Germany) with the fundamental 
parameter approach, and the ICDD card numbers of # 04-015-7245 for HA [28] and 
# 04-006-9376 for β-TCP [29] were used for Rietveld refinements.  
The particle size and particle size distributions of all powders were measured using a 
particle size analyser (COULTER LS230, UK) with Fraunhofer optical model. The 
specific surface area of the powders were measured by the Brunauer–Emmett–Teller 
(BET) method using a Micromeritics Gemini 2370 V5.00 (Norcross, USA) through 
the nitrogen gas adsorption after degassing the samples in a Micromeritics Flow Prep 
060 (Norcross, USA). Powder morphology was also observed by Scanning Electron 
Microscopy (SEM, Hitachi S4100, Hitachi High-Technologies Europe, 
GmbH,Germany). 
2.2 Inks preparation and characterization 
The first step of ink preparation started with fine tuning the temperature and time 
dependent gelling/reticulation behaviour of the BCP/chitosan solution system in 
presence of the crosslinking agent genipin (Challenge Bioproducts, Taiwan) by 
rheological measurements. A chitosan (low molecular weight, Sigma-Aldrich, 
Germany) 3 wt.% solution was prepared in 0.5 vol.% of acetic acid glacial (Pronalab, 
Portugal) solution at room temperature (RT) overnight under constant stirring. Since 
cross-linking of chitosan can also occur in presence of only CaP powders [30], the 
inorganic component in these preliminary studies was fixed at 20 vol.% to assess the 
effects of the other variables. BCP-1.65 powder was selected for these experiments. 
The test methods employed included temperature, time, stress, and frequency sweeps 
in oscillatory mode at a constant temperature of 37 ºC, except for the temperature 
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sweep experiments that cover the temperature range from 20 to 90 ºC. The rheometer 
used is a Kinexus Pro+ instrument (Malvern, USA) coupled with plate and plate (20 
mm diameter) as measuring system and 1000 µm gap. A solvent trap was used to 
prevent drying of the samples during experiments.  
To select the most appropriate amount of crosslinking agent (wt.% genipin) for 3 
wt.% chitosan solution, temperature sweep measurements of chitosan solution in 
presence of  0, 0.5, 1 and 2.5 wt.% of genipin, in absence and in presence of BCP-
1.65 powder, was evaluated. In all measurements, 1 Hz frequency and shear stress 
values within the linear viscoelastic region (LVR) were selected. The dynamics of 
both viscoelastic characteristic functions (elastic storage modulus, G’, and viscous 
loss modulus, G’’) were employed to determine the gelation temperature, the instant 
at which G’ intersects G’’. The gel strength of resultant composite systems (80 vol.% 
chitosan solution + 20 vol.% BCP powder) in presence of different amounts of 
genipin (0, 0.5, 1 and 2.5 wt.%) was assessed by frequency sweeps at 37 ºC after 12 h 
maturation at a constant stress selected from LVR profiles. The reticulation ability of 
chitosan by the three as-synthetized BCP powders (without genipin) was analysed by 
measuring the time evolution of the viscoelastic (G´ and G´´) parameters. The results 
of these preliminary studies revealed that chitosan was rapidly reticulated by BCP-1.5 
even at this low concentration, hindering the preparation of the inks. Therefore, only 
the BCP-1.59 and BCP-1.65 powders have been used for further studies.    
Inks for robocasting containing 45 vol.% of inorganic components were prepared by 
mixing the powders (BCP-1.59, or BCP-1.65) with 3 wt.% chitosan solution. The 
powders were gradually added to chitosan solution using a planetary centrifugal mixer 
(ARE-250, Thinky Corp., Tokyo, Japan) to guarantee homogeneity of all components. 
The final ink preparation stage consisted of adding 1 wt.% of genipin (based on the 
mass of chitosan) followed by homogenization for further 2 min. Levofloxacin-loaded 
scaffolds were prepared using a similar procedure by adding 2 wt.% of levofloxacin 
(based on the mass of inorganic component) to the 3 wt.% chitosan solution just 
before mixing it with BCP powders. The final inks with 45 vol.% of solids without 
and with levofloxacin were characterized by amplitude sweep and frequency sweep 
modes.  
Chapter 6 
 
 
187 
For an easier identification, final inks were nominated as: Ink1.65 and Ink1.59; 
Ink1.65-LEV and Ink1.59-LEV, for inks prepared from BCP-1.65 and BCP-1.59 
powders in absence and in presence of levofloxacin, respectively.   
2.3 Scaffolds fabrication by robocasting 
3D BCP scaffolds consisting of a mesh of ceramic rods were constructed layer-by-
layer via direct write assembly of the ink using a robotic deposition device (3-D Inks, 
Stillwater, OK). The ink was deposited through cylindrical deposition nozzles (EFD 
Inc., East Providence, RI) with 410 µm diameter, at a printing speed of 10 mm s –1. 
The external dimensions of the scaffolds were set at about 3×3×3 mm, being a total of 
12 layers with 500 µm pore size. The deposition was at environment temperature and 
humidity. After printing, samples were placed at 37 ºC overnight with controlled 
humidity (80%) to promote chitosan crosslinking by genipin. Then, scaffolds were 
frozen at −80ºC and subsequently lyophilized (Telstar lyoQuest HT-40, Beijer 
Electronics Products AB, Malmoe, Sweden) at −80 ºC, keeping a sublimation 
pressure of 0.025 mbar to remove water.  
Final scaffolds were nominated as: S1.65 and S1.59; S1.65-LEV and S1.59-LEV for 
scaffolds prepared from Ink1.65 and Ink1.59 in absence and in presence of 
levofloxacin, respectively.   
2.4 Scaffolds characterization 
2.4.1 In vitro cytotoxicity assessment  
The cytotoxicity of the scaffolds was assessed according to ISO 10993-5 standard 
practices [31]. The hDNFs (human dermal neonatal fibroblasts) were routinely 
cultured in DMEM supplemented with 10% v/v FBS (Gibco), 1% v/v P/S (Biowest) 
and 1% v/v amphotericin B (Capricorn Scientific) and kept at 37 ºC in a humidified 
atmosphere of 5% CO2. hDNFs were used up until passage 8. For cytotoxicity assays, 
hDNFs were seeded at a density of 1×104/well into 48-well plates and incubated in 
500 µL of complete DMEM and allowed to reach full confluence. Sterilized scaffolds 
(S1.65 and S1.59) were incubated under the same conditions and after 24 h incubation 
time direct and indirect contact test were performed. For the direct contact assay 
samples were directly put into the wells containing fibroblasts and the medium was 
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refreshed. For the indirect contact assay the medium was replaced by the medium that 
had been incubated with the scaffolds to test the leachable substances thereof. All 
experiments were carried out in triplicate and cells that were not in contact with the 
materials were used as control. The resazurin-based assay was used to assess 
cytotoxicity after 24 h. Briefly, culture medium was removed and replaced with 
complete medium with 20% v/v resazurin (Sigma-Aldrich, Germany) and incubated 
at 37ºC in a humidified incubator with 5% CO2 for 2 h, after which 100 µL per well 
was transferred to a 96-well black plate and fluorescence was measured (Ex 530 
nm/Em 590 nm) using a micro plate reader spectrophotometer (Bioteck Plate Reader, 
Synergy MX).  
2.4.1.1 Statistical analysis 
Statistical significance analysis was conducted using analysis of variance (ANOVA), 
followed by the Greenhouse-Geisser test. Differences with p value <0.05 were 
considered significant. 
2.4.2 Structural features  
Morphological features and microstructure of the scaffolds were analysed by scanning 
electron microscopy (SEM, Hitachi S4100, Hitachi High-Technologies Europe, 
GmbH, Germany) and MetrologyCT system (µCT, Phoenix V|TOME|X, GE). µCT 
performs non-destructive imaging and allows the quantification of 3D micro 
architectural morphology of each scaffold. For that, samples were imaged with an X-
ray tube voltage of 80 kV and a current of 80 mA. The scanning angular increment 
was 0.15 degrees and the voxel resolution 6.7 microns. Data sets were reconstructed 
and segmented into binary images (16-bit BMP images) for the subsequent image 
processing, namely dimensional measurements and 3D surface reconstructions using 
Volume Graphics 3.04 software (Volume Graphics).  
The compressive strength of scaffolds was determined by uniaxial tests on cubic 
blocks of 3 mm per side cut from the 3D printed lyophilized scaffolds. Tests were 
carried out in air using a universal testing machine (AG-IS 5 kN, Shimadzu Corpor., 
Kyoto, Japan) in the perpendicular direction to the printing plane at a constant speed 
of 0.5 mm min−1. Compressive strength was calculated as the maximum applied load 
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divided by the measured square section of the sample. A minimum of 15 samples was 
tested for each composition to obtain statistically reliable values. The apparent density 
values of scaffolds (g.cm−3) were calculated based on their weights and geometrical 
volumes.  
 
2.4.3 Evaluation of levofloxacin distribution 
Levofloxacin distribution, throughout 3D scaffolds obtained from Ink1.65-LEV and 
Ink1.59-LEV, was evaluated by Raman Imaging using a confocal Raman microscope 
(WITec alpha300 RAS+ (WITec, Ulm, Germany). An Nd:YAG laser operating at 532 
nm were used as excitation source, with the power set at 8.5 mW (150 x 150 points 
per grid in a 50 x 50 µm area, 0.05 s). Raman images were produced by raster 
scanning the laser beam over the samples and by accumulating a full Raman spectrum 
at each pixel (in total 22500 spectra), with a spatial resolution of approximately 0.33 
µm. The WITec software, WITec Project 4.0 (WITec, Ulm, Germany), was used to 
create the Raman images. The Raman images were generated using band integrals, in 
which the value of the absolute area underneath a band (e.g. at 1620 cm-1) 
corresponds to a colour intensity in the scale, shown in the image at the respective 
pixels. 
2.5 In vitro drug release and antimicrobial susceptibility testing 
Levofloxacin (LEV) release from the different scaffolds was determined according to 
previously described methods [32,33]. Briefly, scaffolds accurately weighted (50 mg) 
were immersed in 25 mL of PBS (Phosphate Buffer Saline, Sigma-Aldrich) buffer 
(pH 7.4) in propylene tubes. Tubes were placed in a water bath at 37 ºC and shaken 
horizontally (30 strokes min−1). At pre-determined time points (10 min, 30 min, 1 h, 2 
h, 6 h, 8 h, 24 h) samples were collected and analysed for LEV content by UV-
spectrophotometry  (288 nm) (BMG Labtech FLUOstar Omega). 
Agar disk diffusion tests (Kirby-Bauer test) were conducted to examine the 
antibacterial effect of levofloxacin-loaded materials [34]. For this, inks without and 
with 2% of levofloxacin (w/w) were prepared (as previously described in section 2.2) 
and used to obtain 8 mm diameter disks (1 mm height). Hereafter, these disks were 
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submitted to the same process as the scaffolds, i.e., placed at 37 ºC overnight under 
controlled humidity, frozen at −80 ºC and subsequently lyophilized.  A methicillin 
susceptible S. aureus ATCC®25923 (MSSA) strain obtained from American Type 
Culture Collection (ATCC) and one clinical isolate methicillin resistant (MRSA) were 
used. Aliquots from frozen stocks at -80ªC were used to culture microorganisms on 
Tryptic Soy Agar (Biokar Diagnostics, France) plates for 24h. S. aureus inoculum of 
both strains (1×108 CFU mL−1) was prepared by direct colony suspension in Mueller-
Hinton Broth (Biokar Diagnostics, France) and swabbed uniformly across Mueller-
Hinton Agar (Biokar Diagnostics, France) plates. The disks with and without 
levofloxacin and filter-paper disks with 5 mg of levofloxacin (control) were placed on 
the agar surface. Plates were incubated at 37 ºC for 20 h and the inhibition zone 
diameter was measured using a Vernier calliper. Three independent experiments were 
conducted. 
 
3. Results and Discussion 
3.1 Powders characterization 
Particle size, size distributions and crystalline phase contents (HA and β-TCP in the 
BCP powders) are important factors determining the rheological behaviour of the inks 
and consequently the structural properties of scaffolds fabricated thereof. The 
mechanical integrity of the scaffolds depends essentially on a well-balanced 
formulation of the ink containing optimized proportions of gelling components and 
BCP powders with suitable particle size distributions. Hence, having BCP powders 
with similar particle size distributions will facilitate investigating the specific 
interactions between the different powders and the gelling system (chitosan/genipin). 
Data on specific surface area (SSA), particle size distribution (Dmean, D10, D50 and 
D90) and crystalline phase assemblage of the three different BCP powders are 
presented in Fig. 1 (A). All powders presented similar particle size distribution 
parameters with mean particle sizes around 1.5 µm for BCP-1.65 and BCP-1.5 and 
slightly lower (1.4 µm) for BCP-1.59, with the same trend observed for D50 and D90. 
Comparing the size data (Fig.1 A) with SEM micrographs in Fig. 1 (B) reveals that 
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individual particles are actually smaller than 1.5 µm. The high degree of particles 
agglomeration could be responsible for the higher values of mean particle size 
obtained by Coulter analysis.  
 
Fig. 1. Physical, chemical and morphological features of BCP powders heat-treated at 
1100 ºC: (A) specific surface area, particle size distribution parameters and phase (HA+β-
TCP) contents determined by Rietveld refinement (95% repeatability limits of the phase 
quantification should be considered to be close to ±1% [35]); (B) SEM micrographs of the 
BCP-1.65 (a), BCP-1.59  (b) and BCP-1.5  (c) powders (bar: 1.5 µm); (C) XRD patterns.  
 
The biphasic nature (HA + β-TCP) of the powders is confirmed and, as expected, the 
amount of HA increased with increasing Ca/P ratios from 1.5 (~23%) to 1.59 (~46%) 
and 1.65 (87%). These results are in good agreement with XRD diffraction patterns of 
BCP powders displayed in Fig. 1 (C), showing clear intensity differences in the peaks 
of both HA and β-TCP phases according to the starting composition. 
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3.2 Inks characterisation 
Colloidal inks for direct write assembly must satisfy two important criteria: (i) be able 
to flow through the fine deposition nozzle and then “set” immediately to facilitate 
shape retention of the extruded filaments even as they span gaps in the underlying 
layer(s); (ii) have a high solid volume fraction to minimize shrinkage during drying 
and assure mechanical integrity of the final scaffolds. In sintering-free scaffolds the 
viscoelasticity of the pastes and the structural reliability of the constructs will be 
assured by the gelling capacity of chitosan/BCP composite with genipin as 
crosslinking agent, as well as, the amount of inorganic components. Chitosan, a 
natural polymer obtained from the alkaline deacetylation of the chitin, is insoluble in 
aqueous solutions above pH 5.7. In dilute acids (pH <6) the free amino groups are 
protonated and the molecule becomes soluble, resulting in a relatively high viscosity 
solution. The reticulation of chitosan requires the addition of a crosslinking agent. 
Genipin is a natural crosslinking agent for chitosan, often preferred to several 
synthetic compounds as widely reported in literature [36]. It is also known that the 
polymerization/gelling process is somewhat faster in presence of CaPs due to the 
synergetic effect between the functional amine groups from chitosan and the 
phosphate groups of CaP powders [30]. Therefore, the first step of preliminary 
viscoelastic measurements aimed at establishing the maximum solids loading that 
could be used to investigate the effects of the other experimental variables. Fig. 2 
plots the dynamic modulus (G´, G´´) as a function of temperature for BCP-1.65 
system with 20 and 25 vol.% solids. It can be seen that G´ predominates over G´´ for 
the most concentrated system in BCP powder, contrarily to what is observed for the 
more diluted one. The higher stiffness of the paste containing 25 vol.% of BCP-1.65 
is likely to derive from its higher solids loading, but an eventual more active 
contribution of the surface of the CaP particles and phosphorous leached ions towards 
chitosan reticulation cannot be discarded. Therefore, 20 vol.% of BCP  (80 vol.% of 
chitosan) was the solids loading adopted for further studies involving temperature 
sweep measurements. 
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Fig. 2. Evolution of elastic modulus (G´) and viscous modulus (G´´) with temperature for 
BCP-1.65 suspensions with different solid loadings (20 and 25 vol.%) in the absence of 
genipin. The gelation temperature is defined as the temperature at which G´ and G´´ curves 
intersect each other.   
 
The effects of the different added amounts of genipin on gelation behaviours of 
chitosan solutions in the absence and in the presence of BCP-1.65 powder, were 
investigated under temperature ramping. The results presented in Fig. 3 (a) and (b), 
respectively, indicate that gelation temperature decreases as the added amount of 
cross-linking agent increases. As expected, gelation process is faster in the presence 
of BCP-1.65 powders (Fig. 3b), with a significant decrease of gelation temperature for 
a given amount of genipin when compared to the chitosan solution in absence of BCP 
(Fig. 3a). In absence of genipin, gelation temperature decrease from 79ºC (only 
chitosan, Fig. 3a) to 42 ºC (chitosan + BCP-1.65, Fig. 3b) demonstrating the 
polymerization potential of BCP powder for chitosan chains. Surprisingly, for the 
composite systems the polymerization temperature apparently increases again for 
genipin additions >1 wt.% (Fig. 3b), oppositely to the behaviours observed in the 
absence of BCP-1.65 (Fig. 3a). In fact, the presence of BCP particles would cause 
local disruptions of the gel structure while reducing the freedom of polymeric chains 
of chitosan for searching an ordered binding with genipin. These unexpected 
behaviours are likely derived from the competition between the two polymerization 
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mechanisms, i.e., covalent crosslinking by genipin and ionic crosslinking by BCP 
powders [37].  
 
 
Fig. 3. Evolution of elastic modulus (G´) and viscous modulus (G´´) with temperature for: (a) 
100 vol.% chitosan solution (3 wt.%); (b) 80 vol.% chitosan solution (3 wt.%) + 20 vol.% 
BCP-1.65) for different added amounts of genipin (0, 0.5, 1, 2.5 wt.%). The gelation 
temperature is defined as the temperature at which G´ and G´´ curves intersect each other. 
Zoomed areas of the plots in (a) and (b) are inserted for an easier observation of the gelation 
temperatures, also indicated by the vertical coloured dashed lines. The shear stress value used 
in each test was selected from linear viscoelastic region at RT.  
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These results allow concluding that a temperature in the range of 35−40 ºC could be 
adequate for BCP scaffolds reticulation in presence of genipin. To shed further light 
on the gelation kinetics and gel properties after BCP/chitosan composite maturation, a 
frequency sweep was carried out at 37 ºC. Fig. 4 presents the mechanical spectra of 
resultant gels. Due to the great differences in magnitude between G´ and G´´, the 
dynamic analysis was restricted to the elastic component (G´). In fact, measuring G´´ 
values under these conditions was no longer reliable as it depends on the instrumental 
resolution of the lag phase between sinusoidal stress and strain. Fig. 4 shows that all 
curves run almost parallel to the x-axis until 10 Hz, a characteristic behaviour of 
strong gels [38]. 
 
 
 
Fig. 4. Evolution of elastic modulus (G´) as a function of frequency at constant temperature 
(37 ºC) for the system containing 20 vol.% BCP-1.65 dispersed in 3 wt.% chitosan solution in 
the presence of different added amounts of genipin (wt.%) after 12 h of maturation. The shear 
stress value used in each test was selected from linear viscoelastic region.  
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Additions of 0.5 and 1 wt.% of genipin to BCP/chitosan suspensions enhanced G´ 
over the entire frequency range tested. This increase in G´ can be attributed to 
chitosan crosslinking with genipin/BCP, besides the particle-polymer network 
formation already present in the absence of crosslinking agent. Further increasing the 
added amount of genipin to 2.5 wt.% decreased gel strength, in good agreement with 
results presented in Fig. 3. This might be attributed to the saturation of free amine 
groups of chitosan molecules that could bond with genipin as proposed elsewhere 
[39]. The added amount of genipin also influences the swelling behaviour and pore 
size and size distribution of chitosan [40,41]. Increasing genipin concentration 
increased the total porosity and decreased pore size. A higher crosslinked density of 
chitosan gels is alleged to result in limited hydration, lower swelling and consequently 
smaller pore sizes [40]. All these trends could be slightly changed when BCP particles 
are presented as fillers, explaining the selection of 1 wt.% of genipin for the 
subsequent inks preparation for 3D printing.  
The next step aimed to maximise the solid loadings while ensuring a suitable 
extrusion behaviour. This target was achieved for 45 vol.% solids for both BCP-1.59 
and BCP-1.65 powders. Oppositely, increasing the volume fraction of BCP-1.5 to 45 
vol.% turned the resulting ink too stiff and useless for printing as guessed from the 
results reported in Fig. 5. It can be seen from these time sweep results that the BCP-
1.5 paste began turning into a gel-like system (G´>G´´) after 20 min, attributed to the 
crosslinking of chitosan promoted especially by this BCP powder. This stronger 
network formation effect of BCP-1.5 (richer in β-TCP, ~77 %) is likely related to the 
higher solubility of this phase and the resulting higher concentrations of Ca and P ions 
in solution for chitosan polymerisation. Accordingly, the BCP-1.5 powder was not 
further considered for the fabrication of scaffolds.  
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Fig. 5. Evolution of elastic modulus (G´) and viscous modulus (G´´) with time for pastes 
containing 20 vol.% of the different BCP powders dispersed in 3 wt.% chitosan solution. 
Time sweep was conducted at constant values of temperature (25 ºC), frequency (1 Hz) and 
shear stress selected from linear viscoelastic region.  
 
 
Fig. 6 presents the elastic modulus (G´) versus complex shear stress (amplitude 
sweep) for both extrudable final inks, Ink1.65 and Ink1.59. They exhibit high elastic 
modules (G´ ~105 Pa) and remain stable along the entire shear stress range tested, 
suggesting that the deposited filaments will be mechanically stable and capable of 
fully support their own weight during assembling. 
The mechanical spectra of Ink1.65 and Ink1.59 over the frequency range of 1−100 Hz 
in the absence and in the presence of levofloxacin are presented in Fig. 7. Within the 
lower frequency range up to ~0.2 Hz, G´ slightly increases with frequency, suggesting 
the occurrence of some structural relaxation. This is followed by trend to a plateau 
indicative of stable inks. The addition of LEV did not apparently disturb the structure 
of inks prepared from the BCP-1.65 powder for frequencies >0.2 Hz, but slightly 
decreased the elastic modulus of the inks derived from the BCP-1.59 powder, 
especially in the lower frequency range in which LEV seems to exert opposite effects 
on G’.  
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Fig. 6. Oscillatory amplitude sweep of final inks, Ink1.65 and Ink1.59. 
 
 
 
Fig. 7. Oscillatory frequency sweep of final inks without (Ink1.65 and Ink1.59) and with 
levofloxacin (Ink1.65-LEV and Ink1.59-LEV).   
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3.3. Scaffolds characterization  
3.3.1 Cytotoxicity 
Since acetic acid was used as solvent for chitosan and the final scaffolds were not 
submitted to any leaching procedure, assessing their cytotoxicity is essential. For that, 
direct and indirect contact tests were performed according to the ISO 10993-5 
standard practice. Fig. 8 presents the metabolic activity normalized for cell number 
for scaffolds S1.65 and S1.59. The constructs proved to be non-cytotoxic as both 
direct and indirect contact assays showed cell metabolic activity values above the 
required 70% of the control’s measured value. Moreover, the metabolic activity for 
direct contact with S1.65 was 60% higher than that of the control. These positive 
results seem promising for further future biological studies. 
 
 
 
Fig. 8. Metabolic cell activity normalized for cell number for each assay (S1.65 and S1.59) of 
the cytotoxicity test. *statistically significant (p<0.05). 
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3.3.2 Structural 
Scanning electron micrographs of scaffolds S1.65, S1.59, S1.65-LEV and S1.59-LEV 
are presented in Fig. 9. All constructs maintained their shapes after robotic deposition 
and no filament collapsing could be observed (Fig. 9 a-h). Keeping the structure (3D 
dimensions and pores grid) after printing is only possible for sintered-free scaffolds 
thanks to the high percentage of solids in the inks. High solid loading inks are also 
advantageous in decreasing shrinkage levels during drying avoiding shape distortions. 
In presence of levofloxacin, both scaffolds (S1.65-LEV and S1.59-LEV) showed an 
elliptical pore shape (Fig. 9 c,d,g,h), considerably more accentuated for S1.59-LEV, 
instead of squared shape visible in S1.65 and S1.59 (Fig. 9 a,b, e, f) as planed in CAD 
model. These results are in agreement with rheological properties of final inks (Fig. 7), 
being the less dominant elastic features of inks in presence of levofloxacin responsible for 
the interpenetration of filaments from consecutive layers and for the elliptical shape of 
macropores, more pronounced for Ink1.59-LEV (Fig. 9 g,h). According to mechanical 
spectra (Fig. 7), the inks exhibit a solid-like behaviour under high deformation rates 
during printing process.  At low mechanical vibrations, upon depositing the subsequent 
layers, Ink1.59-LEV presents a weak gel-like structure where some structural relaxation 
occurs, explaining the partial collapsing of the macropores. The incorporation of 
levofloxacin seems also to affect the homogeneity of the pastes as deduced from the 
morphological features of rods, internal (Fig. 9 k, l) and surface (Fig. 9. o, p). The 
LEV containing scaffolds show higher microporosity when compared with respective 
scaffolds without drug (Fig. 9. i, j, m, n).  
SEM observations were complemented by Metrology CT system (µCT) images shown in 
Fig. 10. The 2D and 3D µCT reconstructed structures of all sintering-free scaffolds (Fig. 
10A) confirm the interconnected macro pore grids, as planned in CAD model. The size 
and fraction of micro pores in the filaments with added antibiotic increased (Fig. 10B) are 
in good agreement with SEM results. The drug effects on porous structure (pore amounts 
and size) are also more noticeable in S1.59-LEV as expected from the previous results. 
The overlapping of both 3D µCT reconstructed structures of S1.65 and S1.65-LEV (Fig. 
10C) shows that they could not be totally superimposed due to the slightly different 
viscoelastic properties of the starting inks (Fig. 7). The more extensive structural 
relaxation of filaments extruded from Ink1.65-LEV induces small dimensional 
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variations upon depositing the subsequent layers and during the drying process. 
Accordingly, the percentages of macroporosity determined from µCT images 
presented in Fig. 10D reveal that scaffolds with added LEV are somewhat less porous 
in comparison to the ones without drug. This is in good agreement with the ellipsoidal 
shape of the pores visible in SEM (Fig. 9) and µCT pictures (Fig. 10A). 
 
 
Fig. 9. SEM micrographs showing morphological aspects of S1.65 and S1.59 scaffolds with 
and without levofloxacin: (a, b, c, d) lateral views; (e, f) top-views; (g) rod detail, (h) pore 
detail; (i, j, k, l) rods’ surface; (m,n,o,p) rods’ inner fractured cross sections.  
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The compressive strength values of scaffolds  (Fig. 10E) also concur to the 
consistency of the overall results discussed so far. The values appear in the following 
decreasing order: S1.65-LEV > S.165 > S1.59 > S1.59-LEV, which coincides with 
that of G´ in Fig. 7 under or near rest conditions. The lower compressive strength 
value of S1.59-LEV is also consistent with larger size (red colour in Fig. 10B) and 
fraction of micro pores (red and green colours) clearly noticeable from µCT images. 
Fig. 10E also replots the compressive strength values reported by Martínez-Vázquez 
et al. [16] for sintered-free composite (Si-doped HA + gelatin) scaffolds prepared 
from inks with only about 20 vol.% of the inorganic component, which seem 
analogous at a first glance. However, the extensive collapse of their scaffolds clearly 
evidenced by SEM lateral views.  
Such extensive collapse is probably due to unsatisfactory rheological properties of the 
inks (not presented) that reduce the size of macropores, increases scaffolds density 
and consequently enhanced the apparent mechanical properties [16]. Moreover, the 
reported density values for composite scaffolds were already underestimated by the 
low density assumed for Si-doped HA (2.91 g cm−3). The replacement of ~4.2 mol% P 
by Si is not expected to induce such significant changes in density of the Si-doped HA 
[42] in comparison to the theoretical value for pure HA (3.16 g cm−3). The high solids 
loading of inks (45 vol.% BCP) used in the present study conferred to the extruded 
filaments enough stiffness for shape retention enabling to obtain almost perfect 3D 
porous scaffolds. The strains up to the maximum load are close to 10% and tend to be 
slight higher for the less rigid S1.59-LEV structure. Such relatively high strains 
demonstrate that the crosslinking of chitosan matrix by genipin was effective, 
conferring to scaffolds a considerable level of toughness. 
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Fig. 10. (A) 2D (top plane and cross-section views) and 3D images of S1.65 and S1.59 
scaffolds with and without levofloxacin obtained through Metrology CT. (B) 3D 
reconstruction of the scaffolds mapped with colour-coded for the internal porosity of rods. (C) 
3D and 2D views of overlapped S1.65 and S1.65-LEV mapped with colour-coded. (D) 
Macroporosity (%) of the scaffolds determined from 3D µCT images in A; (E) compressive 
strength as a function of apparent density for S.165, S1.59 and S1.65-LEV, S1.59-LEV. 
*compressive strength values of composite scaffolds reported without drug by Martínez-
Vázquez et al. [16], where the percentage of macroporosity is unknown. Graph illustration 
adapted from [16].  
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3.4. Levofloxacin release and in vitro bactericidal efficacy  
The levofloxacin releasing profiles in PBS solution from S1.65-LEV and S1.59-LEV 
scaffolds along an immersion period of 24 h are shown in Fig. 11. The curves exhibit 
an initial burst release (at 10 min) more pronounced for S1.65-LEV (∼75 % of total 
drug amount released, when compared with only ∼27 % for S1.59-LEV), followed by 
more gradual increases towards plateaux trends. After 30 min, the percentages of 
LEV released were ∼83% and ∼62% for S1.65-LEV and S1.59-LEV, respectively, 
further increasing to ~88% and ∼71% at 24 h time point, proving that antibiotic 
release is faster from S1.65-LEV scaffolds. 
 
 
 
 
 
 
 
Fig. 11. Percentage of levofloxacin released in PBS solution from S1.65-LEV and S1.59-LEV 
scaffolds at 37 ºC throughout a period of 24 h. The data was obtained by UV 
spectrophotometry at 288 nm. Data is expressed as mean ± SD of at least three independent 
experiments. 
 
The initial fast release of levofloxacin from both scaffold compositions could be 
explained due to the high surface area of the 3D structures, resulting not only from the 
macroporosity (~50 %), but also from the porosity on the rods themselves. In 
addition, it´s known that fluoroquinolones, namely levofloxacin, can interact with 
multivalent cations (Al3+, Mg2+, Fe2+, Fe3+, Ca2+), forming ion-quinolone chelates 
[43]. Considering that S1.59-LEV is richer in the most soluble β-TCP phase than 
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S1.65-LEV, higher amounts of calcium ions will be available in solution to form 
chelates with levofloxacin, promoting the initial release of S.59-LEV three times 
lower than S1.65-LEV (Fig. 11). The Ca2+−levofloxacin interactions could also help 
explaining the less predominating elastic character observed in rheological behaviour 
of I1.59-LEV (Fig. 7) and the consequent more extensive microstructural relaxation 
of the scaffolds. 
The spatial distributions of levofloxacin molecules within the filaments of S1.65-LEV 
and S1.59-LEV evaluated by confocal Raman microscope are presented in Fig. 12. 
The integration of the absolute area underneath the calcium phosphate band at 964 
cm−1 assigned to the symmetric stretching of the P–O bond [44] and of the 
levofloxacin band at 1620 cm−1 assigned to the C=C vibration of quinolone ring [45] 
were used to determine the colour intensity of the image pixels and create the Raman 
maps. Thus, the brighter colours in the images presented in Fig. 12A and Fig. 12B 
indicate regions with stronger Raman signals of BCP and antibiotic molecules, 
respectively. A well homogeneous spatial distribution of BCP can be inferred from 
Fig. 12A, while an overall fair distribution with some small aggregates is apparent for 
levofloxacin molecules in Fig.12B. 
Strong differences can be observed when comparing the single Raman spectra 
obtained in the higher Raman levofloxacin signal spot on each S1.65-LEV and S1.59-
LEV sample (Fig. 12C). The Raman spectrum of S1.65-LEV is equal to that of pure 
antibiotic, while the intensity of Raman peaks in the S1.59-LEV spectrum is much 
lower and similar to that found for a solution of levofloxacin in water or ethanol 
[45,46]. These results support the hypothesis of levofloxacin complexation with the 
more abundant Ca2+ cations suggested above (Fig. 11) due to the higher solubility of 
β-TCP phase in the case of S1.59-LEV. This is likely to induce polarization changes 
in the LEV molecule. These changes in the molecular structure of the antibiotic can 
induce chemisorption interactions with other components in the scaffold such as 
chitosan via a cleavable amide bond [47] or ion-quinolone chelates formation [43], 
leading to a slow release profile of the drug. Oppositely, levofloxacin is likely to be in 
its molecular solid state in the case of S1.65-LEV scaffold [48].  
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Fig. 12. Raman images were obtained using the integrated intensity of the bands at (A) 964 
cm−1 and (B) 1620 cm−1 for the S1.65-LEV and S1.59-LEV scaffolds (excitation at 523 nm, 
8.5 mW laser power, 150 points per line x 150 lines per image, 0.02 s). The coloured vertical 
bar represents the relative intensity scale. (C) Single Raman spectra (0.05 s and 1 acquisition).  
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Fig. 13 presents the results of bacterial growth inhibition, using the agar disk-
diffusion test with two bacterial strains, S. aureus ATCC25923 and S. aureus clinic. 
Disks derived from Ink1.65-LEV and Ink1.59-LEV effectively inhibited bacterial 
growth, being the inhibition zone diameters of ∼45 mm and ∼36 mm against MSSA 
and MRSA, respectively. On the other hand, disks without antibiotic failed to inhibit 
bacterial growth, except for the Ink1.65 that presented an inhibition zone of ∼24 mm 
against MSSA. This inhibition could be attributed to a smaller ionic contribution of 
chitosan reticulation by the less soluble BCP-1.65, leaving more chitosan available to 
play its antimicrobial role [49]. These results indicate that levofloxacin did not lose its 
bactericidal efficacy during the fabrication process. Moreover, the inhibition zone 
observed for the antibiotic control (5 µg of levofloxacin) was in accordance with the 
expected results for S. aureus ATCC 25923 (25–30 mm) and the MRSA (< 15 mm) 
(CLSI, 2014 [50])  
 
 
Fig. 13. Agar disk-diffusion test showing bacterial inhibition against two S. aureus strains 
(ATCC25923 and a clinic isolate). 
 
The high initial burst and suitable porous structure of S1.65-LEV and S1.59-LEV 
scaffolds makes them very interesting and promising multifunctional devices for bone 
regeneration and in situ drug delivery to prevent local infections. They appear as a 
good alternative to systemic administration of antibiotic. As a matter of fact, 
achieving an effective antimicrobial concentration using intravenous antibiotics is 
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difficult, while systemic antibiotic treatment can lead to systemic toxicity. 
Furthermore, the on-site drug release can reduce the dose required to achieve a 
pharmacological response, when compared to the systemic delivery route. Moreover, 
a faster release rate after implantation could be desired in the case of scaffolds 
endowed with antimicrobial activity in order to respond to the elevated risk of 
infection from bacteria introduced during the surgical treatment [51,52]. 
 
 
5. Conclusions  
The processing conditions to fabricate sintering-free composite scaffolds 
(BCP/Chitosan), containing high solids loading in the absence of any other processing 
additives (dispersant and binders) were established. Inks with proper rheological 
properties were successfully obtained and subsequently used for robocasting 
deposition.  
The percentage of β-TCP in BCP powders (more soluble phase than HA) strongly 
influences the gelation behaviour of chitosan, being impossible to prepare extrudable 
inks for β-TCP contents >50 wt.%. The addition of levofloxacin modifies the 
viscoelastic behaviour of the inks, especially in the presence of BCP with higher 
amounts of β-TCP (I1.59-LEV, with ~50 wt.% β-TCP). Accordingly, the more 
extensive interactions between dissolved ions and levofloxacin induce rheological, 
morphological and structural changes along the fabrication process, with 
consequences in the mechanical performance of the final scaffolds. The obtained 3D 
LEV-loaded scaffolds exhibiting an early and fast drug release, opens a new path for 
local bone regeneration and infection treatments, since a more direct administration of 
drug might be a better solution than the conventional treatment strategies. 
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GENERAL CONCLUSIONS 
The main goal of this PhD thesis was to develop novel 3D porous scaffolds similar to 
the human cancelous bone for bone regeneration using robocasting technique. Their 
porosity was tailor-made in order to evaluate the influence of porous structure on the 
formation of bone tissue in a cellular environment thus enabling the prediction of 
scaffolds’ behaviour after implantation. Thereby, all the relevant properties (chemical, 
structural, mechanical and biological) were considered and balanced in order to obain 
the best compromise for the proposed aim.   
Biphasic calcium phosphates (BCP) both undoped and co-substituted with different 
ions (shown to have important roles in biological processes) were successfully 
synthesized by precipitation. The crystalline phase assemblages and the biological 
performances were strongly dependent on the specific dopant ions as all the used ions 
present a tendency for preferentially entering into the β–TCP’s lattice rather than into 
the HA’s one, increasing the percentages of β–TCP phase in the resulting BCP. Sr2+ 
was the only one capable of totally enter the lattice structures of both HA and β–TCP 
phases, replacing calcium ions. The in vitro biocompatibility with pre-osteoblasic 
cells was proven for all synthesized powders, while only the silver-doped powders 
exhibited antimicrobial activity.  
The prepared BCP powders have shown proper behaviour for colloidal processing 
enabling the preparation of suspensions with very high solids concentrations, around 
50 vol.% for all compositions. The rheological properties of the suspensions were 
properly adjusted to enable the successful production of 3D structures appropriate for 
bone tissue engineering by robocasting. The size and morphology of the powder 
particles and the concentrations of the processing additives were shown to play major 
roles in inks performance during extrusion process by robocasting. Scaffolds with 
different pore sizes and a rod diameter of 410 µm were fabricated and sintered at 
1100 ºC and, finally, characterised in terms of their physical and mechanical 
properties. For all pore sizes tested, compressive strength of scaffolds was comparable 
to or even higher than that of cancellous bone, and mechanical data could be 
systematically correlated with the porosity fraction. Since scaffolds for bone tissue 
engineering must have sufficient mechanical properties that match those of the host 
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tissue, it could be concluded that BCP scaffolds developed under this PhD thesis 
present the required properties for the target application.  
It is known that the microstructural characteristics, i.e., porosity, pore size, pore 
shape, and interconnectivity of the pores can influence the performance of a tissue 
engineering scaffold. To study the effect of a single parameter such as pore size, other 
parameters should be identical in all scaffold designs. Biphasic calcium phosphate 
(HA/β-TCP) based scaffolds revealed to be appropriate matrices for in vitro cell 
culture. Furthermore, it could be demonstrated that hMSCs are capable not only to 
survive, proliferate and produce extracellular matrix components but also to 
differentiate into the osteogenic lineage upon induction. The behaviour of the cells on 
the scaffolds with pore size between rods around 500 µm demonstrates the positive 
effect of a bigger pore size on cell differentiation.  
Avoiding sintering step allowed the introduction of drug molecules during ink 
preparation step for fabricating biphasic calcium phosphate/chitosan composite 
scaffolds by robocasting. The 3D scaffolds obtained exhibited an early and fast 
release of levofloxacin, opening a new strategy for local bone regeneration and 
infection treatments, since a more direct administration of drug might be a better 
solution than the conventional treatment of systemic administration. 
The results presented and discussed along this PhD Thesis demonstrated this direct 
write assembling technique (robocasting) is a particularly suitable alternative to the 
currently used production methods, showing an extraordinary potential for creating 
adequate support structures for new bone tissue engineering strategies. The attractive 
advantages of this technique for fabricating 3D porous scaffolds include: (i) the 
ability to fabricate devices with complex shapes providing great design flexibility and 
the possibility to manipulate the macroporosity of the scaffolds; (ii) the technique is 
rapid, simple, repeatable and versatile.   
Giving all the above mentioned findings, it is possible to conclude that the tissue 
engineering strategy proposed in this thesis allowed to obtain a bone substitute with 
osteogenic potential and opening new possibilities for the development of antibiotic-
releasing tissue engineering scaffolds with the potential of a single stage surgical 
treatment of bone infection treatment. 
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FUTURE WORK  
Although the present work has contributed to progresses in the state-of-the art by 
disclosing new biphasic calcium phosphate compositions and devices to mimic the 
structure, the mineral composition and the properties of bone, additional work still 
needs to be done. Concerning calcium phosphate powders composition, testing doped 
powders with new ions and/or different ions combinations and select the best quantity 
of each phase in the perspective of bone regeneration is still desirable. 
Additionally, to achieve a material that might be qualified for bone tissue engineering 
applications and since the scaffolds manufacturing by robocasting allows great level 
of accuracy in tailoring the pore size/porosity, different architectures should be 
designed and fabricated in an attempt to devise an “ideal scaffold”. Moreover, it 
would be important to investigate the degradation rate of scaffolds in vitro and how 
that affects its mechanical properties.  
In vivo studies will be required in order to evaluate the biological performance of 
scaffolds manufactured under this PhD thesis, testing the materials in animal models 
to confirm their suitability for intended applications in bone regeneration. 
Degradation study should be carried out to determine the period of time that scaffolds 
continue to maintain its biomechanical properties upon implantation. 
Printing composite scaffolds without sintering offers new opportunities to design 
biomaterials with new functionalities, which can act as synthetic bone substitutes and 
as drug delivery systems. However, plenty of future work needs to be carried out to 
study the release kinetics. Since the addition of organic molecules such as 
levofloxacin in aqueous CaP pastes changes viscoelastic properties of the inks, drug 
encapsulation before its addition to the paste system would be a good approach to 
overcome this problem.  
 
